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Viral hepatitis
Viral hepatitis is a group of  infectious diseases that primarily affect the liver and 
cause serious illness and death to hundreds of  millions of  people worldwide. To 
date, there are five distinct hepatitis viruses, referred to as types A, B, C, D, and E 
around the globe. The history of  modern study on viral hepatitis was dating back 
to the year 1963 when Nobel Prize winner Baruch Blumberg (1925-2011) and his 
team identified an unusual antigen from an Australian Aborigine blood, which 
they named the Australian antigen 1. Some years later this was recognized to be 
the hepatitis B virus surface antigen (HBsAg), the first specific marker of  viral 
hepatitis 2. Thereafter, hepatitis B virus became a driving force for the discovery 
of  hepatitis A and D in the 1970s, hepatitis C in 1989 3, and hepatitis E in 1990 
4. Except for their liver tissue tropism, all the five viral hepatitis are unrelated 
viruses belonging to different families, have different epidemiological profiles and 
vary in terms of  their impact. Hepatitis B is a DNA virus whereas A, C, D, and 
E are RNA virus. Hepatitis A and E typically cause acute infections (although 
hepatitis E virus can be chronic in immunocompromised patients), usually 
obtained by fecal-oral transmission (including food and waterborne spread), while 
hepatitis B, C, and D are blood-borne viruses that are transmitted by parenteral or 
mucosal contact with infected blood or other body fluids, and cause both acute 
and chronic infections 5. Infections with viral hepatitis remain major global health 
problems for decades and the morbidity and mortality because of  viral hepatitis 
is increasing. In 2013 alone, viral hepatitis caused 1.45 million deaths, making it 
the seventh most important cause of  death worldwide 6. Together hepatitis B 
and C accounted for 96% of  viral hepatitis-related mortality and 91% of  viral 
hepatitis-related disability life-years. Hence, this thesis focuses exclusively on 
hepatitis B and C viruses, a leading cause of  infectious disease-related morbidity 
and mortality, particularly in low-income countries.
HePatitis b VirUs
Epidemiology
Hepatitis B virus (HBV) infection is a serious global public health problem 
causing significant morbidity and mortality. It is estimated that 2 billion people, 
one-third of  the world’s population, have been infected with HBV and more 
than 250 million are chronic carriers 7,8. The largest number of  chronic carriers 
live in the Western Pacific region (> 95 million, prevalence estimate 5.26%) and 
sub-Saharan Africa (> 75 million, prevalence estimate 8.83%), which together 
account for 70% of  the global HBV burden 8. Despite the availability of  vaccine 
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 1and antiviral treatment, HBV still remains among the top 10 global leading 
causes of  mortality and morbidity 9. Each year approximately 1 million people 
die from chronic HBV-related consequences, including liver cirrhosis, end-stage 
liver disease, and hepatocellular carcinoma (HCC) 10. HBV ranks tenth among all 
causes of  mortality and HBV- related HCC is the sixth most common and second 
deadliest cancer worldwide 11-13. Moreover, 30% of  liver cirrhosis and 53% of  
HCC cases globally are attributed to HBV infection 14
HBV prevalence (as measured by serology) and mode of  transmission vary 
markedly worldwide, and the epidemiology of  HBV changes over time. It is 
highly endemic (≥ 8% seroprevalence) in sub-Sharan Africa, South-East Asia, 
China, most Pacific Islands, and the Amazon basin, where ~45% of  HBV-infected 
individuals live. The Middle East, Mediterranean region, Eastern Europe, and 
South America are considered areas of  intermediate prevalence (2-7%) while the 
United States, Western and Northern Europe, and Australia are regions of  low 
prevalence (< 2%) 7,15. Roughly, 43% of  infected individuals live in intermediate 
prevalence areas and 12% live in low prevalence areas 7. HBV is transmitted 
by percutaneous and mucosal exposure to blood or body fluids from infected 
persons. The common routes of  transmission related to this exposure are vertical 
transmission (defined as transmission during or immediately after pregnancy), or 
transmission through unsafe injection practices, sexual intercourse, and blood 
transfusions. In high prevalence areas, perinatal or household transmission during 
early childhood are the major modes of  infection 7,15. However, in sub-Saharan 
Africa, perinatal transmission is less common since most women of  fertile age are 
HBeAg negative and early childhood horizontal transmission is the main route of  
HBV infection. In addition, transfusion-transmission is substantial in this region 
because of  the frequent use of  paid or replacement donors and incomplete donor 
screening coverage 16,17. In intermediate prevalence areas, multiple modes of  
transmission like perinatal, household, sexual, and injection drug use contribute 
to the infection burden, while sexual and injection drug use in adults are the 
major routes of  spread in low prevalence areas 15. Overall, the risk of  developing 
chronic HBV infection is 90% when infected perinatal, 20 to 30% when infected 
at childhood, and less than 1% when first infected as adults18.
Basic virology
Hepatitis B virus is the prototype member of  the family hepadnaviridae, a group 
of  small, hepatotropic, DNA viruses that share similar genomic organization 
and replication strategy. The family Hepadnaviridae contains two genera; the 
Orthohepadnaviruses that infect mammals (human, woodchucks, ground squirrel 
and bats HBV), and the Avihepadnaviruses that infect birds (ducks, goose, and 
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herons HBV) 9,19. Human HBV shares 70% nucleotide sequence homology with 
other mammalian hepadnaviruses and around 40% sequence homology with 
avian hepadnaviruses 20,21. The human HBV is morphologically diverse and 
exists in human blood in three different viral structures: as infectious virions 
(Dane particles), and as noninfectious subviral particles that are either spherical 
(particles of  20 nm diameter) or filamentous (particles of  22 nm diameter but of  
variable length). The noninfectious subviral particles are composed of  hepatitis 
B surface antigen (HBsAg) and host-derived lipids but lack genomic DNA. The 
infectious virion is a 42 nm double-shelled sphere and consists of  an outer lipid 
envelope and an inner icosahedral nucleocapsid 9,22. The envelope is composed of  
a double lipid layer and three envelope proteins, while the nucleocapsid is a 27 nm 
particle assembled from 240 viral capsid proteins that enclose the viral genome 12. 
The viral genome is a relaxed, circular, partially double-stranded DNA (rcDNA) 
of  approximately 3.2 kb and organized into four open-reading frames (ORFs) 
(Figure 1). The largest ORF (P) encodes the viral polymerase, which is functionally 
divided into four domains — the terminal protein, a spacer region, the reverse 
transcriptase (RT), and the ribonuclease H domain 22. The polymerase enzyme 
catalyzes many functions during HBV replication, including viral RNA binding, 
RNA packaging, protein priming, template switching, DNA synthesis and RNA 
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Figure 1. HBV genome organization. The genome nucleotide numbering is based on the unique 
EcoRI restriction enzyme site. The four different open reading frames encoded by the genome, the S, 
core, polymerase, and X, are indicated by gray color palette.
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 1degradation 
23. The second largest ORF (S) encodes three viral envelope proteins 
— large (L), middle (M) and small surface antigen (HBsAg) protein — that are 
encoded by three in-frame genes (the pre-S1, pre-S2 and S gene, respectively). 
HBsAg is the serological marker for current HBV infection and the main antigenic 
determinant for serotyping and diagnosis 9. The antigenic determinant referred 
as the “a” determinant is located between amino acid positions 124 and 147 of  
HBsAg and plays an important role in diagnosis and immunoprophylaxis. The 
pre-S1 domain is a key determinant in hepatocyte receptor binding (residue 21-
47) and initiation of  viral infection 24. The preS2 region contains only 165 nt and 
shows the highest nucleotide polymorphism among the S regions. The third ORF 
(C) encodes the precore, also known as HBV E antigen (HBeAg), and the core 
protein (HBcAg), which makes up the viral capsid. HBeAg is a non-structural 
protein secreted by infected cells into the blood and serves as a surrogate marker 
for active high-level viral replication 12. The core protein contains numerous T 
and B-cell immune recognition epitopes and plays a critical role in the interactions 
between HBV and the host immune response, which in turn shapes the course of  
the disease 25. The fourth ORF (X) encodes the HBV X protein (HBx), a small 
regulatory protein (154 amino acids) with multiple functions, including signal 
transduction, cell cycle progress and viral replication 13. 
In addition to the four ORFs, there are other elements that are important 
components of  the HBV genome. The short RNA-primer is used for the DNA 
positive strand synthesis during rcDNA repair to form a covalently closed circular 
DNA. The DR1 and DR2 represent 11 base pair direct repeats that play a pivotal 
role in template switches during viral replication.
The HBV replication cycle is complex and unique because it replicates via 
reverse transcription of  an RNA intermediate like retroviruses. The initial step 
in HBV replication involves the attachment and entry of  mature virions to host 
hepatocytes through the sodium taurocholate cotransporting polypeptide (NTCP) 
receptor on the cell membrane 24. Once in the cytoplasm, the nucleocapsid is 
released from the viral envelope and transported to the nucleus where the rcDNA 
is repaired by host and viral polymerase to form a covalently closed circular DNA 
(cccDNA). The cccDNA, which forms a minichromosome, is a template for 
the transcription of  all viral RNAs including the pregenomic RNA (pgRNA, a 
3.5 kb RNA intermediate, which serves as a translation template for HBV core 
and polymerase proteins and is also the template for reverse transcription to 
viral DNA) (Figure 2). These transcripts are then exported into the cytoplasm 
where they are translated to form the viral proteins. In the cytosol, RT binds 
to pgRNA and triggers assembly of  the core proteins into immature RNA-
containing nucleocapsids. The immature nucleocapsids then undergo a process 
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of  maturation whereby pgRNA is reversed transcribed by RT to make the viral 
rcDNA genome. The newly formed nucleocapsids are either re-imported to the 
nucleus to replenish the cccDNA pool or enveloped and secreted as mature 
virions 12,22,26. A schematic overview of  HBV replication cycle is shown in Figure 
2.
HBV genetic diversity 
Similar to other viruses, genetic variability and genome evolution are common 
features of  the HBV life cycle. HBV is unique among DNA viruses because its 
polymerase lacks proof-reading activity and uses an RNA (pgRNA) intermediate 
during its replication. These features increase the probability of  random errors 
during genomic replication, leading to change in genome sequence over time 9. 
It has been estimated that HBV genome evolves at an error rate of  ~ 10 –3 to 
10 –6 nucleotide substitutions/site/year, which is approximately 100 times higher 
than that of  other DNA viruses 27. The accumulation of  these mutations over 
a long period of  time results in a large amount of  genetic diversity in the form 
of  genotypes, subgenotypes, serotypes, and mutants. In addition, HBV genomes 
evolve by recombination 28. Prior to the defi nition of  genotypes, HBV was 
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Figure 2. Hepatitis B virus replication cycle. Enveloped virion enters hepatocytes through NTCP, 
followed by uncoating, and nuclear transport of  the rcDNA. The rcDNA is repaired to yield cccDNA, 
which serves as template for transcription of  pgRNA & mRNAs. These RNAs are exported to 
cytoplasm for protein translation.
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 1classified by serotyping, which discriminates HBV strains into nine serotypes, 
ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq+ and adrq-, based on the main 
antigenic determinant ‘a’ and two mutually exclusive determinant pairs (d/y and 
w/r) in the HBsAg protein. The molecular bases for both the d/y and w/r changes 
were mediated through a shift from Lysine to Arginine at positions 122 and 160, 
respectively 29,30. The advent of  molecular biology later enables classification of  
HBV strains by genomic sequences rather than by serotyping. Okamoto et al 31 first 
analyzed 18 full-length HBV genome sequences and classified them into 4 distinct 
genotypes, A to D, based on greater than 8% divergence between genotypes. Since 
then, six additional genotypes, E to J, have been identified 30,32-36. HBV genotypes 
are further divided into subgenotypes based on nucleotide divergence of  more 
than 4% but less than 8% over the complete genome 30,37. By this criteria, different 
studies worldwide have identified several subgenotypes within genotypes, A (A1-
A7), B (B1-B9), C (C1-C16), D (D1-D9), F (F1-F4) and I (I1 and I2) 30,35,38-41. It is 
noteworthy to mention that genotype C has 16 subgenotypes and is probably the 
oldest genotype while genotypes E, G, and H have no subgenotypes, suggesting 
their recent origin 42. There is a significant association between HBV serotypes 
and genotypes: adw is associated with genotypes A, B, F, G, and H, adr with C and 
ayw with D & E 37 although many exceptions exist (Table 1). 
Besides differences in genome sequences, genotypes also differ in their genome 
length, the size of  open reading frames, and the proteins decoded (Table 1). 
Genotypes B, C and I have a genome size of  3215 nucleotides whereas genotypes 
A, E, and G have a genome size of  3221, 3212, and 3248 nucleotides, respectively. 
Genotypes D and J have the smallest genome size of  3182 nucleotides 43. The 
differences in genome size are due to in-frame insertions or deletions. For 
instance, genotypes A and G are characterized by 6 and 36 nucleotides insertion 
in the core gene, respectively while genotype D and J have 33 nucleotides deletion 
at the N-terminus of  the preS1 region 27,35. As shown in both in vitro and in vivo 
study, these virological features have marked genotype-dependent differences 
in the expression of  HBV DNA levels (viral replication) and antigens (HBeAg, 
HBsAg) 44. These, in turn, may have contributed to differences among genotypes 
in clinical and epidemiological settings. 
chapter 1
14
Table 1. Characterstic of  HBV genotypes and their correletion with serotypes 
Genotype Genome 
length (nt)
Differentiating 
features
Protein Subgenotypes Serotypes
preS1 Pol Core
A 3221 6 nt insertion near 
the 3′ end of core 
gene
119 845 185 A1, A2
A3 - A6
A7 
adw2
ayw1
ayw1/adw2
B 3215 119 843 183 B1- B3, B5 - B9
B4
adw2 
ayw1/ dw2
C 3215 119 843 183 C1-C3, C6 -15
C4
C5
C16
adr
ayw2/ayw3
adw2
ayr
D 3182 33 nt deletion at 
the 5′ end of the 
preS1 region
108 832 183 D1, D4, D7
D2
D3, D5
ayw2
ayw3
ayw2/ayw3
E 3212 3 nt deletion at the 
5′ end of the preS1 
region
118 842 183 - ayw4
F 3215 119 843 183 F1
F2 - F4
adw4/ayw4
adw4
G 3248 36 nt insertion 
at the 5′ end of 
core gene and a 3 
nt deletion at the 
5′ end of preS1 
region; stop codons 
at positions 2 & 28 
in precore 
108 842 195 - adw2
H 3215 119 843 183 - adw4
I 3215 119 843 183 I1
I2
adw2
ayw2
J 3182 33 nt deletion at 
the N-terminus of 
the preS1 region
108 832 183 - ayw3
It is increasingly evident that recombination is a very important source of  HBV 
genetic variability and evolution, with possible clinical implications 21,45. HBV 
intergenotypic recombinants are generated either from two or more genotypes. 
As most recently reviewed by Araujo 43, nearly 60% of  the recombinants detected 
were either B/C or C/D hybrids. Other recombinants identified included A/D, 
D/E, A/B/C, A/C, A/C/G, A/E, A/G, B/C/U (U = unknown genotype), 
15
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 1C/F, C/G, C/J, D/F, and F/G hybrids. In addition, a large-scale phylogenetic 
analysis by Shi and colleagues 46 showed that only genotypes H and J showed 
no recombination, whereas genotype I was composed entirely of  recombinants 
(A/C/G) and 93% (803/860) of  genotype B were recombinants (mainly with 
C in Asia where both genotypes are prevalent). Recombination may provide a 
selective advantage to the viral strains, and the recombinants over time become 
the dominant strains of  HBV and persist in a population in respective geographic 
areas. Generally, HBV recombinants were reported in almost all regions of  the 
world with similar circulation patterns as their original genotypes 38,40,41,43,47-50. 
The B/C recombinants are most prevalent in East and Southeast Asia, A/D and 
A/E recombinants in Africa and C/D recombinant in Tibet (96% of  the isolates 
sequenced were C/D recombinants) 51. Although not commonly reported, 
Simmonds and Midgley showed the evidence of  frequent intragenotypic 
recombination between members of  genotypes A, D, and F/H variants, but not 
in B and C, in HBV strains of  Southeast Asia 45.
Geographical distribution of  HBV genotypes and subgenotypes 
HBV genotypes and subgenotypes have a distinct ethno-geographic distribution 
worldwide 30,52 (Figure 3). Genotype A is widespread around the world but is most 
prevalent in sub-Saharan Africa, Europe, and North America 27. Genotypes B and 
C are most common in Asia and Oceania 30. Genotype D is predominant in the 
Mediterranean areas, the Middle East, and India, while genotype E is endemic to 
western and central Africa 52. Genotype F is most frequent in South and Central 
America whereas genotype H is endemic to Central America. Little is known 
about the distribution of  genotype G although sporadic cases have been reported 
in Europe, USA, and Japan chiefly among homosexual men 53. Genotype I has 
been reported in Vietnam and Laos and genotype J in a Japanese patient 53.
Like genotypes, HBV subgenotypes also display distinct geographical 
distributions. Subgenotype A1 is dominant in Southern and Eastern Africa, A3 
to A7 are common in Central and Western Africa, and A2 is dominant in Europe 
and North America 54. Subgenotype B1 is common in Japan, B2 to B5 in East and 
Southeast Asia 30 whereas B6 is found in indigenous populations living in Arctic 
regions, including Alaska, Northern Canada, and Greenland. Subgenotypes B7, 
B8, and B9 are mainly found in Southeast Asia islands 55. While subgenotype 
C4 is restricted to Australian Aborigines, C1 is widespread in East Asia, C2 in 
China and Southeast Asia, and C3 in Oceania 30. The geographical distributions 
of  subgenotypes D1-D4 are less defined than those for genotypes A, B, C and F 
30. Subgenotype D1 dominates in the Middle East and Asia, D2 in Europe, D3 in 
South Africa, Asia and Europe, D4 in Oceania, D5and D9 in India, D7 in North 
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Africa, and D8 in Niger 53,56. Having a knowledge of  the prevailing genotype 
and subgenotype in a given geographic region is important as these genotypes 
and subgenotypes differ in disease progression, clinical outcomes, prognosis 
and response to antiviral therapies 54,57,58. For instance, in Africa, genotype A1 is 
associated with HCC in young men who are usually HBeAg-negative and without 
underling cirrhosis 59. Most studies (mainly in Asia) showed that patients infected 
with genotype C have more severe liver disease, including cirrhosis and HCC, 
than those with genotype B 54,60. Similarly, antiviral treatment response to standard 
or pegylated interferon is more favorable in patients infected with genotype A 
than D and in B than those with genotype C 61,62. It is important to note that 
the rates of  disease progression, clinical and treatment outcomes for each HBV 
genotype are also infl uenced by environmental, host and other viral factors.
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Figure 3. Global distribution of  HBV genotypes and subgenotypes. In Africa, genotypes A, D 
and E predominant.
HBV quasispecies variants 
HBV quasispecies variants — defi ned as a population of  genetically distinct but 
closely related variants — emerge in response to external selective pressures such 
as host immune responses, prophylactic or therapeutic responses (vaccination, 
antiviral treatments) 21. They are generally less fi t than the normal genotypic 
variants (wild type) and do not emerge as dominant viral populations in patients in 
the absence of  selective pressures. However, under the external selective pressure, 
the minor mutants can be selected and become the dominant variants 28. Some of  
these quasispecies variants include the preS1 and S2 mutants, the HBsAg vaccine 
escape mutants, the core, precore (PC) and basal core promoter (BCP) mutants, 
and the polymerase drug-resistant mutants 21. 
17
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 1Many of  the mutations affecting the preS1 and preS2 domains of  the envelope 
proteins are deletions 28. Some of  these deletions are harmful to the virus while 
others are beneficial for its survival 63. For instance, a mutation in the N-terminus 
of  the preS1 affects the virus as this domain is a key determinant for virus receptor 
binding and entry 24. In addition, some preS1mutations can result in intracellular 
retention of  the preS1 protein, which inhibits virion secretion. As a result, most of  
such mutants are usually found as minor viral populations 21. In contrast, deletion 
in the preS2 and in the C-terminus of  preS1 result in reduced expression of  HBV 
surface proteins and help viral persistence by eliminating HLA-restricted B-cell 
and T-cell epitopes 63. Many of  such mutants have clinical importance, including 
influencing the risk of  HCC, fulminant hepatitis, and cirrhosis 63-65. The HBsAg, 
in particular the major hydrophilic region (MHR; amino-acids 99-169), is the main 
target for viral neutralization 28. Mutation in the MHR can lead to immune and 
vaccine escape mutants that exist as minor/dominant viral populations depending 
on selective pressure. Several immune- and vaccine escape variants of  clinical 
importance have been identified worldwide, but G145R is by far the most common 
vaccine escape variant, and the most studied 28,63. Further, variants within MHR 
region have been shown to be associated with the occurrence of  HBsAg escape 
mutants that are undetectable by current commercial diagnostic assays 66,67.
Various naturally occurring mutants have been described in the BCP (nt1814-
1900) and PC (nt1742–1849) regions, some of  which are defective variants 
and require helper virus while others are competent stable variants 21,65. The 
most common PC mutation is a G to A transition at nucleotide position 1896 
(G1896A), which creates a premature stop codon at codon 28 that completely 
abolishes HBeAg synthesis but increase viral replication 21. The most frequent 
BCP mutation is the double A1762T and G1764A nucleotide substitution, which 
decreases HBeAg production by up to 70% through suppressing the transcription 
of  precore mRNA, but enhances viral replication 28,65. The consequent decrease 
or abolishment of  the HBeAg production lead to selection of  anti-HBe antibody 
escape mutants and subsequently favoring the persistence of  HBV infection 68. 
Several studies have shown that the persistent BCP and PC mutants are clinically 
important because they increase the risk of  HCC, cirrhosis, fulminant hepatitis, 
and because they are difficult to treat 64,69-71.
The RT domain which is the main catalytic center of  the polymerase enzyme 
is the main target for most antiviral drugs, particularly the nucleos(t)ide analogs. 
Mutations within RT may affect the replication capacity of  the viruses, leading to 
the emergence of  drug-resistant mutants that can exist as minor or major variants 
28,72. For example, rtM204I/V, rtL180M and rtA181T/V mutants confer resistance 
to lamivudine and telbivudine whilst rtA181T/V and rtN236T mutants confer 
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resistance to adefovir and tenofovir 28,65,73. HBV harboring I169T and M250V, 
or T184G and S202I variants have been associated with entecavir resistance 
74. In addition, drug-resistance mutations in the polymerase may result in the 
production of  mutations and stop codons in the HBsAg envelope and lead to 
altered viral secretion, infectivity, antigenicity, and vaccine escape mutants because 
of  the overlap between the two genes 73. For instance, A181T/V mutations in the 
RT region can cause W172* (stop codon), W172L and L173F mutations while 
M204V/I mutations result in I195M, W196*, W196S and W196L mutations in 
the HBsAg 28,73.
HePatitis c VirUs
Epidemiology 
Hepatitis C virus (HCV) is a global health problem that causes substantial 
morbidity and mortality. It is estimated that more than 185 million people are 
chronically infected with HCV worldwide and at great risk of  developing liver 
disease 75. Each year, 3 to 4 million people are newly infected 76 and around 
700,000 people die from HCV-related liver diseases 77. HCV is a major global 
health burden because it accounts for 20%-30% of  acute hepatitis, 70%-80% 
chronic hepatitis that subsequently leading to 20-40% cirrhosis, 25% HCC, and 
30-40% liver transplants worldwide 78,79. Moreover, HCV is one of  the most 
common causes of  death in HIV-positive patients on highly active antiretroviral 
therapy 80. Furthermore, the most recent estimation of  disease burden shows an 
increase in global HCV seroprevalence over the last 15 years from 2.3% to 2.8%, 
with great variation in different geographic areas. Africa has the highest HCV 
burden with an overall prevalence of  5.3% or an estimated 32 million chronic 
carriers 75. Within Africa, Central Africa has the highest estimate prevalence at 
6%, followed by Western Africa 2.4% while Southern and Eastern Africa have 
the lowest estimated at 1.6% 5. Most of  the European countries, America, and 
Southeast Asia have a prevalence < 2.5% 78, whereas in the Western Pacific region 
the prevalence is 3.9% 78. The prevalence of  HCV in the Middle East and Central 
Asia countries varies between 1 and 12% with an overall prevalence rate of  4.7% 
81. Worldwide, Egypt has the highest HCV prevalence (>15%) and the United 
Kingdom and Scandinavia countries have the lowest prevalence (0.01-0.1%) 82.
Basic virology
Hepatitis C virus is a single-stranded positive-sense RNA virus classified in the 
Hepacivirus genus within the Flaviviridae family 83. It was discovered in 1989 by 
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 1the joint efforts of  researchers at the centers for disease control and prevention 
(CDC) and Chiron Cooperation 84. Until recent time it has been considered the 
sole species within the genus Hepacivirus. However, most recently numerous 
genetically diverse hepaciviruses have been identified in bats, dogs, cows, horses, 
primates and rodents 85, which now classify the genus into 14 recognized species 
(Hepacivirus A–N) 86. Humans are the only natural host and apparent reservoir 
of  HCV although it can be transmitted experimentally to non-human primates 83. 
HCV is spherical in shape, 40–100 nm in diameter 87 and consists of  a single RNA 
genome encapsidates in core proteins, which in turn enclosed by the envelope 
glycoproteins, E1 and E2 88. The HCV genome interacts with the capsid protein 
to form the nucleocapsid that is surrounded by a lipid membrane in which the 
envelope glycoproteins are anchored.
The HCV genome is a linear, non-segmented, single-stranded RNA of  ~ 9.6 kb 
in length (Figure 4). It encompasses a single open reading frame encoding a long 
polyprotein of  3000 amino acids, which proteolytically cleaved by cellular and 
viral proteases into 10 proteins. These include 3 structural proteins (core, E1, and 
E2), and 7 nonstructural (NS) proteins ( p7, NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B) 89,90. These proteins have different functions and are encoded in the gene 
order of  5′-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3′ (Figure 4). The 
ORF is flanked in 5′ and 3′ by two highly conserved untranslated regions (UTRs) 
of  341 and 230 nucleotides, respectively 81 that are essential for viral replication 
and translation. The core protein is a highly basic multifunctional protein, which 
is responsible for packaging viral RNA to form a viral nucleocapsid 81,88. The 
viral envelope, E1 (33–35 kDa) and E2 (70–72 kDa) are type I transmembrane 
glycoproteins that mediate viral entry and fusion 88,91. In addition, the E2 gene 
constitutes the hypervariable region 1 (HVR1), which is the most variable 
region of  the genome and appears to be involved in immune escape and disease 
progression. p7, an integral membrane protein, is a member of  the viroporin 
family which plays a critical role in capsid assembly and envelopment. NS2 (21–23 
kD) is a non-glycosylated transmembrane protein that together with NS3 forms a 
metalloproteinase which cleaves the site between NS2 and NS3 and contributes to 
virus particle assembly 81,91. NS3 is a 67 kDa multifunctional protein with a serine 
protease, viral helicase and NTPase activities that antagonize the host innate 
immune response 88,92. The NS4A (8 kDa) is a cofactor of  NS3 91 while NS4B is 
a membrane-associated protein that serves as an anchor for the viral replication 
complex 88. NS5A is a 58 kDa phosphoprotein that appears to play a vital role in 
RNA replication and regulation of  cellular pathways. The NS5B protein (68 kDa) 
is the viral RNA-dependent RNA polymerase (RdRp), an enzyme that catalyzes 
viral replication 88.
chapter 1
20
HCV genetic diversity 
Genetic variability is a distinctive characteristic of  HCV and exists at several 
levels throughout the genome. This high genetic diversity is primarily caused by 
the error-prone nature of  the RdRp that lacks proofreading ability, combined 
with the high viral replication rate (1010- 1012 virions per day) 83,93. The resulting 
genetic heterogeneity is reflected by the high mutation rates, 1.5–2.0 x10-3 
nucleotide substitutions per site per year 90, which led to the classification of  
HCV into different groups. Through phylogenetic and sequence analyses of  the 
entire genome, HCV has been classified into seven confirmed genotypes, 1-7 94. 
These genotypes differ from each other by 30–35% at the nucleotide level 95. 
All genotypes except 5 and 7 are further divided into multiple epidemiologically 
distinct subtypes, denoted by lower-case letters 1a, 2c, 3d, 6f, etc., that differ 
at least by 15 % at nucleotide level 94,96. At present, there are 67 confirmed, 20 
provisional, and 21 unassigned subtypes in HCV 94. While genotypes are easy to 
discrete genetically, subtypes discrimination is less clear, particularly in areas of  
high HCV genetic diversity such as sub-Saharan Africa and Southeast Asia. This 
highlights that much of  genetic characterization is needed in this part of  the 
world. 
In addition to genotypes and subtypes, HCV circulates in infected individuals as 
a complex mixture of  genetically distinct but closely related variants referred to as 
quasispecies, which differs by 1–3% at nucleotides level 76. This quasispecies exists 
as a continuously evolving mutant spectrum, i.e., an array of  viral variants, which 
confers the advantage of  a rapid adaptation to a changing environment, a strategy 
utilized by the virus to escape selective forces such as antiviral agents or the host 
immune system 97. Study revealed that there are 1010–1012 variants produced per 
day in each infected individual, which leads to highly individualized quasispecies 
translation
Replication complex
Nonstructural proteinsStructural proteins
Capsid Envelope
glycoproteins
Viroporin and
assembly factor
Autoprotease and
assembly factor
Serine protease
and helicase,
assembly factor
NS3 protease
co-factor
Organizer of replication
complex and membranous web
Regulator of
replication and
viral assembly
RNA-dependent
RNA polymerase
NS3
NS4A
NS4B NS5A
1 192 384 747 810 1027 1658 1712 1973
C E1 E2 NS2p7 NS5 B
2421 3011
5’ 3’
UTR UTR
9.6 kb genome
Figure 4. HCV genome organization and polyprotein. The genome is composed of  a single open 
reading frame flanked by 5’ and 3’ untranslated regions. The ~ 9.6 kb genome is translated in a single 
polypeptide of  3000 amino acids, which proteolytically cleaved by cellular and viral proteases into 10 
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 1that are unique because of  the individual’s immune response to HCV, and that 
may play a role in disease progression and treatment response 98.
Although not common like in many other RNA viruses and HBV, a few naturally 
occurring HCV recombinants have been documented worldwide 46,99. To date, 
around ten inter-genotype recombinants have been identified, of  which only one 
(2k/1b) is represented by multiple isolates originated in different countries 99,100. 
It is likely that recombination in HCV might be underestimated due to difficulties 
in detection of  recombinant HCV strains 101.
Geographical distribution of  HCV genotypes and subtypes
HCV genotypes and subtypes display distinct geographical distribution and 
prevalence worldwide 83,96 (Figure 5). HCV genotype 1 is the most prevalent 
genotype worldwide accounting for 46% of  all HCV cases. Genotype 3 is 
the second most prevalent with 22% of  all HCV cases, followed by genotype 
2 (13%), genotype 4 (13%), genotype 6 (5.4%), and genotype 5 (< 1%) 96,102. 
The global distribution of  these genotypes shows geographic variations, which 
reflect differences in transmission history and ethnicity. Overall, genotypes 1- 
3 are widely distributed across the globe, while 4 – 7 have relatively restricted 
geographic distribution (Figure 5) 96. HCV genotype 1 is the most dominant 
genotype in North America (70% of  cases), Japan (75%) and Europe (50–70%); 
although genotypes 2 and 3 are also prevalent in these regions 83,102. On the other 
hand, genotype 2 is predominant in West Africa, genotype 3 in South Asia and 
parts of  Scandinavia, genotype 4 in Central and North Africa and the Middle 
East, genotype 5 in South Africa, and genotype 6 in Southeast Asia 96, while 
genotype 7 only presents in Central Africa 103. Like genotypes, most subtypes 
also show variation in their geographic distribution. Subtypes, 1a, 1b, 2a, 2b, 2c, 
and 3a are widely distributed across the globe and account for the majority of  
HCV infections worldwide, therefore termed epidemic. They are thought to have 
spread rapidly during the twentieth century via infected blood and blood products, 
intravenous drug use, and invasive medical procedures 96,104,105. In contrast, the 
other HCV subtypes have long-term local persistence and restricted geographic 
distribution, hence endemic 106. For instance, subtypes belonging to genotypes 1, 
2, and 4 are endemic in Africa, while those belonging to genotypes 3 and 6 are 
endemic in South and South East Asia 96,107.
Africa is known for its high HCV genetic diversity pool and thought to be 
the origin of  this virus. Almost all the known HCV genotypes circulate in the 
continent and six of  them are proposed to have originated here: genotype 1 and 2 
in West Africa 106,108, 4 and 7 in Central Africa 103,105, 3 and 5 in South Africa 109,110. 
Within Africa, HCV genotype distribution exhibits two epidemiological patterns 
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— one characterized by high genetic diversity, distributed in West Africa, with 
genotypes 1 and 2 106, and the other in Central and Norther Africa, with genotype 
4 105. A single subtype, 5a, dominates in Southern Africa 102, and very little is 
known about the genotype distribution in Eastern Africa, including Ethiopia. 
Viral hepatitis B and C infection in Ethiopia
Ethiopia is a large, culturally diverse country in the Horn of  Africa located at a 
strategic geographic position between Africa and Eurasia. It shares borders with 
Eritrea to the north, Djibouti and Somalia to the east, Sudan and South Sudan to 
the west and Kenya to the south. It has a land area of  1.1 million square kilometers 
and is home to more than eighty different ethnic groups. With a population of  
nearly 100 million persons, it is the second most populous country in Africa and 
the twelfth populous in the world. Around 80% of  its population resides in rural 
areas where health infrastructures are limited, and the delivery of  essential health 
services remains challenging. As a result, little information is available on the 
public health burden due to infectious diseases in general and hepatitis viruses in 
particular. Owing to the asymptomatic nature of  HBV and HCV infections for 
decades, most people don’t know that they are infected. Also, the cause of  deaths 
usually remains undocumented in Ethiopia.
Nevertheless, a clinical study performed in the 1980s showed that liver disease 
accounted for 12% of  hospital admissions and 31% of  deaths of  hospitalized 
patients in Ethiopia 111,112. Moreover, seroepidemiological studies, although quite 
small in number, show heterogeneity in seroprevalence estimates for HBV (2.1 to 
25.0%) and HCV (0.7 to 13.3%), even within specifi c geographical areas 113. Most 
of  these reports are either from a limited number of  subjects, or are biased for 
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Figure 5. Global distribution of  HCV genotype and subtype
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 1specific groups and may not represent the true national burden of  viral hepatitis in 
the general population. As a result, the burden of  viral hepatitis in Ethiopia is not 
accurately known. Besides, there is a lack of  awareness among the general public 
concerning viral hepatitis, with underdiagnosis and therefore undertreatment. 
Moreover, HBV and HCV are blood borne pathogens, and practices contributing 
to their transmissions such as shared materials during traditional tattooing, 
scarification and body piercing, circumcision and female genital mutilation are 
common in Ethiopia. There is a continuous influx of  refugees from South Sudan 
where HBV prevalence is hyperendemic (prevalence estimate 22.38%, 95% CI 
20.10–24.83), further adding to the unknown reservoir of  carriers 8. As a result 
of  these factors, transmission of  these viruses may go unnoticed. 
It is well-known that HBV and HCV show great genetic diversity 53,94. As shown 
by many studies, this genetic diversity has an impact on clinical outcomes and 
treatment responses 28,60,98. However, there is very limited information regarding 
the genetic diversity of  these viruses in Ethiopia. To establish effective strategies 
for the control and prevention of  these viruses, knowledge of  the prevailing 
genotype and subgenotype in Ethiopia is highly important. Thus, this thesis 
focused on this and other related issues as outlined below.
Outline of  the thesis
Since HBV and HCV infections can go without clinical symptoms for decades, 
the prevalence and disease burden are generally underestimated. In addition, their 
genetic diversity is not fully studied. Therefore, this thesis in its first part, chapter 
2-5, focuses on understanding the viral diversity and seroepidemiology of  HBV 
and HCV in Ethiopia, to provide a baseline for predicting clinical outcomes, 
disease progression, and response to antiviral. Then the second part, chapter 
6 and 7, of  the thesis is focusing on a further understanding of  HBV/HCV 
quasispecies variants through in-depth molecular analyses. 
Thus, in chapter 2 of  this thesis, we describe the seroepidemiology of  HBV and 
HCV in five distinct geographic regions in Ethiopia that differ in socioeconomic, 
culture and ethnicity to gain insight into the burden of  these viruses in the general 
population. Chapter 3 focuses on the molecular epidemiology and genetic 
diversity of  HBV in Ethiopia and emphasizes the main genotypes, subgenotypes, 
serotypes and mutants that circulate, based on study conducted using S gene 
sequence of  391 sera obtained from blood donors living in five different 
geographic regions. Here we discussed differences in HBV genotype/subgenotype 
distribution among Ethiopian regions and compare those with data from other 
African countries and the world. Chapter 4 describes in-depth complete genome 
sequence analysis of  29 selected HBV strains; 10 genotypes A and 19 genotypes 
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D. These strains were selected based on their unique features in the previous 
fragment analysis including separate clusters, divergent strains and unusual strains 
(like D2 which is less common in Africa) to classify them into subgenotypes 
and to gain more insight into the molecular diversity and evolution of  HBV in 
Ethiopia. Here, a novel subgenotype D10 was identified and discussed thoroughly 
and the two genotype A1 clades and the D2 strains were further elaborated. In 
addition, mutations in the basal core promoter (BCP), precore (PC) and preS 
regions that have a role in the clinical manifestation of  disease following HBV 
infection were characterized and two natural recombinant strains noted. Then 
Chapter 5 describes HCV genetic diversity in Ethiopia; the main genotypes and 
subtypes and their implication in the future development of  treatment guidelines 
and patient management. Thereafter Chapter 6 discusses the HBV quasispecies 
variants and their association with clinical characteristics such as HBeAg and 
viral load. It further describes HBV variants variation between HBeAg positive 
and negative patients and among different genotypes. Chapter 7 investigates the 
pre-existence of  direct-acting antivirals (DAA) resistance-associated variants in 
the NS5B region of  treatment-naïve patients. Further, it assesses whether there 
is a difference in quasispecies variants distribution between plasma and liver 
compartments of  the same patient. Finally, the main findings of  this thesis are 
summarized and discussed in Chapter 8.
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abstract
This study was conducted to investigate the prevalence of  hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infections among blood donors in different 
regions in Ethiopia. A total of  56,885 sera were tested for HBsAg and anti-HCV 
antibodies. Of  these, 3.9% were found HBsAg-positive, 0.52% anti-HCV-positive 
and 0.054% dual positive. HBV prevalence was relatively higher in Adama (5.91%) 
than Gondar (4.05%), Jimma (3.87%), Addis Ababa (3.75%), and Tigray (3.7%); 
and in males (4.64%) than females (2.1%). Overall, HBV and HCV prevalence 
increased with age. In conclusion, HBV and HCV seroprevalence among blood 
donors in Ethiopia is intermediate and low, respectively.
Keywords
Ethiopia; HBV; HCV; Seroepidemiology 
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introDUction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are a major public health 
problem in all parts of  the world. Worldwide, over 240 million people are infected 
with HBV and 185 million with HCV 8,75. HBV and HCV are the leading cause of  
infectious disease-related morbidity and mortality. According to a recent study by 
Stanaway et al., the annual number of  deaths attributable to viral hepatitis rose by 
63% from 1990 to 2013 — from 0.89 million to 1.4 million. Of  these, HBV and 
HCV accounted for 96% of  hepatitis-related mortality in 2013 alone, with the 
highest mortality rates seen in Africa and Asia 6.
Although HBV and HCV infections are a global health problem, there is a 
distinct geographical variation in their prevalence, with regions having high (≥ 
8%), intermediate (2-7%) and low (< 2%) endemicity. Africa is among the highly 
endemic regions, with an HBV prevalence rate over 8%. Overall, this continent 
shares 30% of  the global HBV burden, with over 75 million chronic carriers 8. 
Moreover, Africa has the highest HCV burden with a prevalence of  5.3% and an 
estimated 32 million chronic carriers 75. Like most African countries, Ethiopia has 
been categorized among the highly endemic areas for viral hepatitis. However, 
due to the lack of  a nationwide survey and readily available routine serological 
tests for patients, the exact prevalence of  these viruses in Ethiopia remains 
unknown. Although a few studies have been performed, these were mainly either 
restricted to subjects from risk groups, HIV patients, a small sample size 114-117 or 
done several years ago 118. Hence, large-scale studies are needed to monitor the 
up-to-date prevalence of  these viruses and to implement appropriate preventive 
measures. In this multicentric cross-sectional study, we aimed to determine the 
prevalence of  HBV and HCV infections among healthy blood donors to gain 
insight into the burden of  these viruses in the general population of  Ethiopia.
materials anD metHoDs 
In a cross-sectional study, a total of  56,885 serum samples was collected from 
healthy blood donors living in five distinct geographical regions in Ethiopia. 
Between March 2013 and April 2014, 46,052 samples were collected from Addis 
Ababa, 3,488 samples from Adama, 2,986 samples from Gondar, 465 samples 
from Jimma and 3,894 samples from Tigray regions. Serum sample collections 
were carried out at laboratories in national and regional blood banks. Blood 
donors who fulfilled the national blood bank criteria to be eligible for donation 
were included. Those who did not meet the inclusion criteria: age < 18 or > 
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65 years, history of  long-term medication use, family history of  liver disease, 
surgery, repeated blood donation < 1 year and pregnant women were excluded 
from the study. A blood sample of  10 ml was collected from each donor using a 
sterile BD vacutainer, and the serum was separated by centrifugation and placed 
in sterile serum storage vials. All samples were screened for hepatitis B surface 
antigen (HBsAg) and anti-HCV antibodies by using a fourth-generation Enzyme-
linked immunosorbent assay (ELISA) kits (DIALB Diagnostics GmbH, Vienna, 
Austria), according to the manufacturer’s instructions. The study was approved 
by the National Research Ethics Review Committee at the Federal Ministry of  
Science and Technology, Ethiopia.
resUlts
Of  the 56 885 blood donors tested in this study, 40 204 (70%) were males and 
16 681 (30%) were females, aged 18-62 years. The prevalence of  HBV, HCV and 
HBV/HCV coinfection is shown in Table 1. Of  the 56 885 samples screened, 2,217 
were HBsAg positive, giving the overall nationwide HBV prevalence of  3.9%. 
When we compare each region, HBV prevalence was relatively high in Adama 
(5.91%) followed by Gondar (4.05%), Jimma (3.87%), Addis Ababa (3.75%) and 
Tigray (3.7%). With regard to gender, there was a significant difference between 
males and females in HBV seropositivity. HBsAg prevalence was roughly two 
times higher in males than females (4.64% vs. 2.1%). 
Notably, a very low prevalence of  anti-HCV antibodies was found in the 
present study. The overall prevalence of  HCV was 0.52%, corresponding to 294 
anti-HCV positive individuals out of  56,885 tested. No difference was observed 
in anti-HCV positivity between males and females. Regarding the prevalence of  
HBV/HCV coinfection, the presence of  both HBsAg and anti-HCV antibodies 
were seen in 31 out of  56,885 (0.054%) individuals. Of  these, 23 were males and 
8 were females. 
Age-related prevalence of  HBV and HCV was also assessed in this study. As 
shown in Figure 1 the prevalence of  HBV and HCV increases with age with a 
peak in the age group 40-49 (5.33% for HBV and 0.81% for HCV). This peak is 
then followed by a gradual decrease in prevalence in the older group > 50 years 
old (to 4.57% for HBV and to 0.78% for HCV). 
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Table 1. Prevalence of  HBV and HCV infection and coinfection by region and gender
No. 
Tested
HBsAg positive 
N (%)
Anti-HCV-Ab 
positivea N (%)
Coinfection N 
(%)b
Total N (%)
Region
Addis Ababa 46052 1728 (3.75) 248 (0.54) 29 (0.063) 2005 (4.35)
Adama 3488 206 (5.91) 13 (0.37) 0 219 (6.28)
Gondar 2986 121 (4.05) 15 (0.50) 1 (0.033) 137 (4.59)
Jimma 465 18 (3.87) 3 (0.65) 0 21 (4.52)
Tigray 3894 144 (3.7) 15 (0.39) 1 (0.026) 160 (4.11)
Total 56885 2217 (3.9) 294 (0.52) 31 (0.054) 2542 (4.47)
Gender
Male 40204 1866 (4.64) 196 (0.49) 23 (0.06) 2085 (5.19)
Female 16681 351 (2.1) 98 (0.59) 8 (0.05) 457 (2.74)
Total 56885 2217 (3.9) 294 (0.52) 31 (0.054) 2542 (4.47)
bPositive for both HBsAg and Anti-HCV antibody; aAb, antibody
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Figure 1. Age-specific prevalence of  HBsAg and anti-HCV antibody among blood donors
DiscUssion
Information on the epidemiology of  viral hepatitis in Ethiopia is still lacking. To 
the best of  our knowledge, this is the first large-scale nationwide epidemiological 
study of  HCV and HBV infections from Ethiopia. Herein we report the prevalence 
of  HBV and HCV in different geographical regions— Addis Ababa, Adama, 
Gondar, Jimma, and Tigray. These regions are approximately 100 to 1,500 km 
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distant from each other and differ in their socioeconomic, culture and ethnicity. 
The overall prevalence of  HBsAg was 3.9%, and anti-HCV was 0.52%. These 
prevalence rates classify the country as an intermediate (2–7%) endemic area for 
HBV infection and low (< 1.5%) for HCV 8,75. 
Region wise HBsAg positivity rates ranged from 3.7% in the northern Tigray 
region to 5.91% the eastern Adama region. The centrally located Addis Ababa 
city (capital city) had HBsAg prevalence of  3.75%, whereas the southwestern 
region Jimma had 3.87%. These results are in concurrence with previous studies 
reported from Addis Ababa and Gondar 114,115,119, but lower than those studies 
from Jijiga 120, Sekota 117, Wolaita Sodo 116 regions, and a nationwide study (10.8%) 
118. This may be attributable to the difference in the study period, study subjects, 
and sample size. For instance, the previous nationwide study was conducted three 
decades ago and the sample size was limited to 5270 young males. Whereas the 
majority of  study subjects at Jijiga blood banks were replacement donors 120 and 
those studies by Gebreegziabher et al. and Bistetegen et al. were limited to 482 
and 390 samples, respectively, included risk groups and suspected patients 117, our 
findings were drawn from a large sample size consisting of  only voluntary donors. 
The HBsAg prevalence among blood donors in this study is comparable with 
reports from neighboring countries; 4.2% in Sudan 121 and 2.58% in Eritrea 122, 
but lower than other Central and Western African countries 123. Overall, blood 
donors showed lower HBsAg prevalence compared to the general population 
124-127 might be due to exclusion of  risk groups with clinical signs and symptoms 
of  hepatitis in blood donors. 
Regarding the HCV infection, the overall prevalence in the present study 
was 0.52%, which is significantly lower than the previously estimated 2.0% 75. 
Interestingly, the prevalence rate was constantly lower than 1% across all regions. 
Our result is in line with HCV prevalence among blood donors in Southeast 
African region (0.43%) but lower than Central (2.61%) and West (3.18) Africa 
regions 128. It is noteworthy that HBV/HCV coinfection is not uncommon in 
endemic areas because of  the shared modes of  transmission. Many studies have 
reported HBV/HCV coinfection prevalence rates, ranging from 0.7 to 15%, as 
recently reviewed by Konstantinou and Deutsch 129. In our study, we found only 
31 (0.054%) coinfections out of  56, 885 samples tested, which is significantly 
lower than the aforementioned studies. This might be due to differences in 
study subjects as HBV/HCV coinfection is more frequently found in high-risk 
populations, including injecting drug users, hemodialysis patients, organ transplant 
patients, HIV-positive and β-thalassemia patients 129, whereas our study subjects 
are healthy blood donors.
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Another important observation in this study was gender-related differences 
in the prevalence of  HBV infection. The prevalence of  HBV infection was 
significantly higher in males than in females. This was comparable with findings 
reported elsewhere 115,124,125. This difference might be due to the higher exposure 
to occupational HBV risk factors in males than females, or because females are 
more likely than males to produce hepatitis B surface antibody (anti-HBs) in 
response to HBV infection 130. Nevertheless, no difference was observed in anti-
HCV positivity between males and females.
With regard to age-related analysis, the prevalence of  both HBV and HCV 
infection increased with age from 2.35% to 5.33% for HBV and from 0.34% to 
0.81% for HCV. The highest prevalence had been seen among persons 40–49 
years of  age. Whereas, in the older group over 50 years, the prevalence of  both 
viruses decreased progressively. This could be probably due to deaths caused 
by chronic hepatitis-related cirrhosis and hepatocellular carcinoma in this age 
group 131. Moreover, 25% of  people who acquire HBV as children will develop 
primary liver cancer or cirrhosis as adults. This is the case in sub-Saharan Africa, 
where transmission predominantly occurs in infants and children by perinatal and 
horizontal routes 8. Thus, it is important to note that many people are at high risk 
of  developing viral hepatitis-related chronic liver disease at the later age, due to 
the fact that antiviral therapy is currently not available in Ethiopia.
In conclusion, this study shows that the prevalence rate of  HBV is intermediate 
and that of  HCV is low in Ethiopia and their prevalence more or less similar across 
the different regions. Although these findings are useful for making estimates 
about the overall viral hepatitis burden in Ethiopia, it might underestimate the 
prevalence in the general population due to exclusion of  risk groups with clinical 
signs and symptoms of  hepatitis in blood donors. Thus, we strongly encourage a 
need for national-level surveillance and public campaigns to raise awareness. 
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abstract
Although hepatitis B virus (HBV) infection is hyperendemic in Ethiopia and 
constitutes a major public health problem, little is known about its genetic 
diversity, genotypes and circulation. The aim of  this study was to determine 
the molecular epidemiology and genetic diversity of  HBV in Ethiopia, using 
391 serum samples collected from HBsAg-positive blood donors living in five 
different geographic regions. The HBV S/pol gene was amplified, sequenced, 
and HBV genotypes, subgenotypes, serotypes and major hydrophilic region 
(MHR) variants were determined. Phylogenetic analysis of  371 samples (95%) 
revealed the distribution of  genotypes A (78%) and D (22%) in Ethiopia. Further 
phylogenetic analysis identified one subgenotype (A1) within genotype A, and 4 
subgenotypes within genotype D (D1; 1.3%, D2; 55%, D4; 2.5% and D6; 8.8%). 
Importantly, 24 isolates (30%) of  genotype D formed a novel phylogenetic 
cluster, distinct from any known D subgenotypes, and two A/D recombinants. 
Analysis of  predicted amino-acid sequences within the HBsAg revealed four 
serotypes: adw2 (79%), ayw1 (3.1%), ayw2 (7.8%), and ayw3 (11.6%). Subsequent 
examination of  sequences showed that 51 HBV isolates (14%) had mutations 
in the MHR and 8 isolates (2.2%) in the reverse transcriptase known to confer 
antiviral resistance. This study provides the first description of  HBV genetic 
diversity in Ethiopia with a predominance of  subgenotypes A1 and D2, and also 
identified HBV isolates that could represent a novel subgenotype. Furthermore, 
a significant prevalence of  HBsAg variants in Ethiopian population is revealed. 
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introDUction
Despite the availability of  vaccine and antiviral treatments, hepatitis B virus (HBV) 
infection remains a major global health problem, causing substantial mortality 
and morbidity. The World Health Organization (WHO) estimates that there are 
240 million chronic HBV carriers worldwide 132, more than 65 million of  them 
living in Africa 133. Ethiopia, a sub-Saharan African country with a population of  
~95 million, is classified by the WHO as one of  the African countries with the 
highest rate of  HBV infection 134. It is a geographically diverse nation, home to 
over eighty different ethnic groups, and bordered by six different countries. Over 
70% of  the population shows evidence of  past infection with HBV and 7–14% 
are chronic carriers 115,135. Even though a safe and effective vaccine against HBV 
has been available since 1982, Ethiopia implemented the HBV vaccine into its 
national immunization program only recently, in 2007. In general, hepatitis B is 
one of  the most neglected infectious diseases in Ethiopia, and overall awareness 
of  the population about HBV is very low. Because of  this late implementation, 
lack of  awareness, and the absence of  a national HBV control program, the 
burden of  hepatitis B likely remains substantial and molecular data on HBV 
genetic diversity is lacking. 
HBV, a member of  the family Hepadnaviridae, is a circular, partially double-
stranded DNA virus with a genome size of  3.2 kb 27. HBV shows high genetic 
diversity and has been classified into ten genotypes (A-J) 30,35,36,136, forty 
subgenotypes 20,27,30, and nine serotypes (adw2, adw4, ayw1, ayw2, ayw3, ayw4, 
adrq+, adrq– and ayr) 29,30. HBV genotypes and subgenotypes differ in clinical 
outcomes and response to antiviral therapy 54,58 and have distinct geographic 
distributions 27,52. Some genotypes and subgenotypes are restricted to particular 
geographic regions while others are distributed globally. 
Besides genotype diversity, HBV genomic variations in the hepatitis B surface 
antigen (HBsAg) which are selected during the infection course are of  clinical 
and public health importance. HBsAg contains a central region called the Major 
Hydrophilic Region (MHR; aa 100 to 170) 137. MHR is highly immunogenic and 
is one of  the main targets for neutralizing antibodies. Mutations within MHR 
have been associated with HBsAg detection failure, vaccine and immunotherapy 
escape 138,139. The epidemiology of  these mutants has been studied in many HBV 
endemic countries 140, however, not in Ethiopia.
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obJectiVes
Information about HBV genetic diversity is essential not only for epidemiological 
reasons but also to understand the routes of  HBV transmission and to establish 
efficient strategies for preventing and controlling HBV infection. Here we aimed 
to study the distribution of  HBV genotypes, subgenotypes, serotypes and HBsAg 
variants in Ethiopia, a hyper-endemic HBV region where HBV molecular data is 
lacking, to obtain more insight into the molecular epidemiology of  HBV. 
materials anD metHoDs 
Study area and sample collection 
A total of  391 serum samples were collected from HBsAg-positive blood donors 
at blood bank centers in five geographically distinct regions of  Ethiopia: Addis 
Ababa, (central), Adama (central-east), Gondar (north-west), Mekelle (north), 
and Jimma (south-west). Serum samples were collected between March 2013 
and April 2014, and stored at −80°C until use. The study was approved by the 
National Research Ethics Review Committee at the Federal Ministry of  Science 
and Technology, Ethiopia.
Serological Assays
Serological markers for HBsAg and anti-HCV antibodies were tested using 
commercially available ELISA kits (DIALB Diagnostics GmbH, Vienna, Austria). 
Blood was also screened for anti-HIV-1 and -HIV-2 antibodies by ELISA kit 
(Vironostika HIV Ag/Ab, Bio-Merieux, Boxtel, The Netherlands) and anti-
Treponema Pallidum antibodies by Rapid Plasma Reagin Test (RPR) (DIALB 
Diagnostics GmbH, Vienna, Austria). All serological tests were carried out twice 
according to the manufacturer’s instructions. HBsAg-positive serum samples 
from patients co-infected either with HCV or HIV were excluded from the 
present HBV study.
HBV DNA extraction, quantification, amplification and sequencing
Viral DNA was extracted from 200 µl serum using the QIAamp MinElute virus 
spin kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. 
Serum HBV DNA levels were quantified using an in-house quantitative real-time 
PCR (qPCR) as described previously 141,142. AcroMetrix® HBV low, medium and 
high controls (Applied Biosystems, life technology, USA) were used as standard 
reference. The HBV S-gene (nucleotides 56 to 805) was amplified by one-round 
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PCR for samples with viral loads >3.5 log (3 ×103 IU/ml) and by a nested PCR for 
those with viral loads ≤ 3.5 log with primers S01F (5’- CCTGCTGGTGGCTC-
CAGTTC-3’), S05R (5’-TGGTAACAGCGGTATAAAGGGACT-3’), S03F(5’-
GCTGGTGGCTCCAGTTCAGGAACA-3’) and S07R (5’-AAGGGACTCAA-
GATGYTGTACAGA- 3’). Amplicons were sequenced bi-directionally using 
Big Dye Terminator v3.1 kits and an ABI PRISM 3130xl sequencer (Applied 
Biosystems).
Phylogenetic analysis and HBV typing 
Sequence alignments were created with ClustalW implemented in MEGA version 
6.0 143. Phylogenetic trees were constructed using PhyML v 3.0 [http:// www.
atgc-montpellier.fr/phyml/]. Briefly, a maximum likelihood (ML) phylogenetic 
tree was inferred using the Hasegawa-Kishino-Yano (HKY85) nucleotide 
substitution model with gamma distributed rates with invariant sites (G+I). 
A tree searching operation was performed using the best of  nearest neighbor 
interchange (NNI) and subtree pruning and regrafting (SPR) branch-swapping 
algorithm. The statistical robustness and reliability of  the branching order within 
each phylogenetic tree were confirmed with a bootstrap analysis (1000 replicates). 
The obtained tree was visualized in FigTree v1.4.2 [ http://tree.bio.ed.ac.uk/
software]. The tree was rooted using a midpoint rooting. HBV recombinant 
analysis was performed by jumping profile Hidden Markov Model (jpHMM) 144. 
HBV serotypes were determined as described previously 30,145.
HBV mutations analysis in the S and RT regions
The analysis of  the amino acid substitutions within the MHR (aa 99 to 170) 
was performed by comparison of  the 371 sequences in this work with the 
amino-acid sequence of  similar genotypes retrieved from GenBank (AY934770 
and AB188243). Distinction between naturally occurring variants and mutations 
within each genotype was made based on published data. The corresponding 
substitutions in the reverse transcriptase (RT) were determined according to the 
Stanford database (http://hivdb.stanford.edu/). 
Nucleotide sequence accession number
All sequences reported in this study were submitted to GenBank (accession 
numbers KP310929 to KP311299).
Statistical analysis 
Categorical data were analyzed using the chi-square (χ2) test, and or Fisher’s exact 
2-sided test, if  appropriate. A p-value ≤ 0.05 was considered significant.
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resUlts
Geographic distribution and diversity of  HBV genotypes
Serum samples (n = 391) collected from HBsAg-positive blood donors (344 male 
and 47 female; mean age; 30.8 years, range, 18 to 60 years) were analyzed. HBV 
DNA levels were quantified in 383 (98%) samples, and the median serum viral 
load was 785 IU/ml (range, 7 IU/ml to 3×108 IU/ml). The remaining 8 (2%) 
samples showed no detectable viral DNA. The majority of  samples (78%) had 
viral load below 104 IU/ml (Figure 1). Samples (n = 12) that were low positive by 
qPCR (< 40 IU/ml) were not confirmed by nested PCR. 
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Figure 1. HBV viral load distribution of  391 Ethiopian HBsAg-positive blood donor samples. 
Shown are the total population of  donors (black bars), donors infected with HBV genotype A (white 
bars), and donors infected with HBV genotype D (gray bars). Undet, undetectable.
Three hundred and seventy-one strains were successfully amplified and sequenced. 
All 371 HBV isolates were classified into two genotypes: A (n = 291; 78%) and 
D (n = 80; 22%). HBV genotype distribution in Ethiopia differed by geographic 
region (Figure 2). Genotype A prevails in all regions, but was predominant 
in Addis Ababa (85%), Adama (91%) and Jimma (93%), while genotype D is 
more prevalent in Mekelle (40%) and Gondar (34%) area. Of  note, genotype D 
prevalence was significantly higher in the two northern regions as compared to 
the other three regions (odds ratio (OR) 3.46, 95% confidence interval (CI) 2.07-
5.81, P < 0.001). No significant differences were observed between genotypes 
with respect to donor’s age and gender (Figure S1 A and B). 
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Phylogenetic analysis classifi ed all genotype A isolates into subgenotype A1 
(Figure S2). Figure 3A shows 130 representatives of  subgenotype A1 Ethiopian 
isolates selected from different clusters and the fi ve geographic regions based on 
the Figure S2 analysis. A1 isolates from each of  the study regions clustered into 
different HBV/A1 branches suggesting that more than one strain is circulating in 
each region (Figure 3A). Genotype D isolates split into four phylogenetic groups: 
D1 (n = 1), D2 (n = 44), D4 (n = 2), D6 (n = 7), (Figure 3B). Interestingly, 
the remaining 24 (30%) isolates formed a novel unclassifi ed cluster (Figure 3B), 
while two outliers (BL66ETH & MK141ETH) were D/A recombinants (data 
not shown). The majority of  Ethiopian genotype D belong to subgenotype D2 
(55%). 
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Figure 2. Geographic distribution of  HBV genotypes in fi ve regions of  Ethiopia. Total number 
of  samples analyzed per region are indicated in brackets and percentages of  corresponding genotypes 
in pie chart. Small black dot indicate locations of  blood bank centers, and the gray area shows 
approximate area coverage of  sample collection (70-400 km). 
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Figure 3. Maximum Likelihood phylogenetic tree of  HBV Ethiopian isolates belonging to 
(A) genotype A, 130 isolates and (B) genotype D, 78 isolates. Phylogenetic analysis inferred 
from Maximum Likelihood tree (HKY85) model) based on HBV S/pol gene sequences (700 nt) of  
Ethiopian HBV isolates and reference sequences retrieved from the GenBank database representing 
HBV genotypes (A-I) and all genotype A and D subgenotypes (A1-A4, and D1-D6). Ethiopian HBV 
isolates are shown in color (color corresponding to their geographic origin: Green = Addis Ababa; 
Pink = Adama; Red = Mekelle; Blue = Gondar; Light blue = Jimma), and reference sequences retrieved 
from GenBank shown by their accession number. Numbers in the tree represent the percentages of  
bootstrap values (1000 replicates). The novel subgenotype D cluster (NC) is highlighted in yellow.
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HBV serotypes
HBV serotype distribution in the studied population was as follows: adw2 (293/371; 
79%), ayw3 (43/371; 11.6%), ayw2 (33/371; 8.9%), and ayw1 (2/371; 0.5%). All 
genotype A isolates classified into serotype adw2. For genotype D, 43 (53.8%) 
isolates belonged to ayw3, 33 (41.2%) were ayw2, and two each belonged to ayw1 
and adw2 (found among D/A recombinant isolates BL66ETH and MK141ETH) 
(Table 1). Because of  the association between genotype and serotype (adw2 versus 
other serotypes, OR 142.86, 95% CI 37.03-500, P < 0.001), the distribution of  
serotypes varied according to geographic location, like the genotypes (Table S1, 
OR 3.5, 95% CI 2.08-5.90, P < 0.001). The distribution of  serotypes was not 
significantly different among age groups or gender (Figure S1 C & D). 
Table 1. Relationship between HBV genotype and subtypes
Genotype Number of 
samples
Subtype, Number (%)
adw2 ayw1 ayw2 ayw3
A 291 291 (100) 0 0 0
D 80 2 (2.5) 2 (2.5) 33 (41.2) 43 (53.8)
Total 371 293 (79) 2 (0.5) 33 (8.9) 43 (11.6)
HBV mutation in HBV S and RT regions
Several mutations were detected in the MHR of  HBsAg (Figure 4). Fifty-one 
out of  371 (13.8%) samples were found to have mutation (Table 2). Twenty-
six isolates (7%) had mutations that have potential impact on the detection of  
HBsAg: M103I, L109P, P120S, T126I, A128V, Q129R/H, M133T/I, F134L, 
A159V, E164G. Mutations associated with vaccine or immunotherapy escape, 
P120S, T126I, Q129H/R, N/T131S/I, M133T/I, Y134F, T140I, T143M, and 
D144E, were detected in 20 (5.4%) isolates (Figure 4). Furthermore, one amino-
acid deletion in isolate JM10ETH (Figure 4a) and a 7 amino-acid deletion in 
isolate AA12ETH (Figure 4b) was detected. Interestingly, we observed a stop 
codon W172* in GD88ETH , which was shown to be associated with low level 
secretion of  HBsAg 146. Distribution of  MHR mutations by geo-demographic 
and genotype/serotype are presented in Table 2. MHR mutations were more 
prevalent in genotype D than genotype A (OR 2.27, 95% CI 1.20-4.30, P = 0.016). 
Sequence analysis of  the RT region revealed 8 (2.2%) isolates had mutations 
(Table 2). The most prevalent resistant mutations were L180M (1.35%) and 
M204V (1.35%). Five isolates had a combination of  L180M + M240V mutation, 
one isolate had I169T mutation, and the remaining two isolates had T184A and 
A194T mutation. 
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Figure 4. Distribution of  amino acid mutations detected within the major hydrophilic region 
(99–170) of  the HBsAg among Ethiopian HBV isolates. The amino acid variations in the “a 
determinant” (124-147) region are boxed (solid line). (a) MHR amino-acid sequence alignment of  
genotype A, (b) MHR amino-acid sequence alignment of  genotype D. 
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Table 2. Distribution of  MHR mutations in the HBV S gene and RT mutations by geographic 
region, demographic variables, genotype, and serotype
Number of 
samples
Number of 
samples with 
MHR mutations
MHR 
mutation 
(%)
‘’a’’ determinant 
mutation (%)
Number of 
Samples with 
RT mutation
Total 371 51 13.8 6.8 8
Region
Addis Ababa 147 19 12.93 4.1
Adama 75 6 8 4
Gondar 64 12 18.75 10.94 7
Mekelle 70 12 17.14 11.43 1
Jimma 15 2 13.33 6.67
Gender
Male 325 43 13.23 6.46 7
Female 46 8 17.39 8.70 1
Age
< 20 13 2 15.38 7.69
20-29 168 22 13.1 6.55 4
30-39 131 21 16.03 7.63 2
40-49 45 3 6.67 4.44
≥ 50 14 3 21.43 7.14 2
Genotype
A 291 33 11.34 6.19 7
D 80 18 22.5 8.75 1
Subtype
adw 293 35 11.95 6.48 7
ayw 78 16 20.51 7.69 1
DiscUssion
Increasing evidence shows that HBV genotypes and subgenotypes display 
distinct geographic distributions and impact clinical and antiviral therapy 
outcomes 35,52,58,133,147,148. Moreover, HBV genotypes and serotypes are useful tools 
in epidemiological and transmission studies 27. To date, HBV genetic diversity 
and genotype distribution pattern in Ethiopia has not been investigated. In this 
comprehensive and nationwide study we therefore determined the HBV molecular 
epidemiology and genetic diversity in Ethiopia for the first time. Subsequently, 
we also assessed the prevalence of  mutation in the major hydrophilic region 
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(MHR) and reverse transcriptase (RT) regions. The study subjects comprise a 
geographically, socially, economically and ethnically diverse population. 
Phylogenetic analysis showed presence of  HBV genotypes A (78%) and D 
(22%) in the Ethiopian population, with genotype A being predominant. This is 
consistent with previous studies of  HBV genotype distribution in neighboring 
countries and other regions of  Africa 30,50,133,149-151. Although genotype E has been 
reported in some east-African countries we did not find genotype E in Ethiopia. 
Most importantly, HBV genotype distribution in Ethiopia showed a distinctive 
epidemiological pattern. Genotype D was more prevalent in the Northern region 
of  the country (37%) compared to the Central region (12%). In contrast, genotype 
A predominantly prevails in the Central region. As reported in neighboring 
countries, genotype A is the dominant strain in Somalia, Kenya and Uganda 133,149, 
whereas genotype D is the most prevalent strain in Sudan 151. Our findings shows 
that Ethiopia is at the border of  the genotype A and D geographical distribution 
in Africa.
HBV genotype A is highly heterogeneous and has been classified into four 
subgenotypes, A1, A2, A4 and quasi-subgenotype A3 152,153. Subgenotypes A1, 
A4, and quasi-subgenotype A3 are found mainly in Africa, whereas A2 prevails in 
Europe and North America 154. All genotype A isolates from Ethiopia belonged 
to subgenotype A1 similar as in other eastern and southern Africa countries 
30,133,150,155,156. Two distinct subgenotype A1 clades have been recognized: an African 
and an Asian-American clade 154. We found Ethiopian A1 isolates to be the most 
divergent: they cluster in both the African and the Asian-American clades (Figure 
3A). 
Genotype D was the second most dominant strain in Ethiopia, and its 
prevalence was higher in northern parts of  the country. This genotype has been 
found universally, but predominates in Europe, North Africa, and Middle East 
20,56. Genotype D isolates from Ethiopia showed a genotypic heterogeneity and 
discriminated into four subgenotypes, D1, D2, D4 and D6 56. Surprisingly, 55% 
of  genotype D isolates belonged to subgenotype D2, which is most prevalent in 
East Europe including Russia and the Baltic States 157, but less common in Africa. 
Nevertheless, Ethiopian D2 isolates clustered separately and more distantly to 
D2 of  European and Asian origin. Subgenotype D6 is second most dominant in 
our population. It has been suggested that the putative geographic area harboring 
D6 covers North Africa and as far south as the Central African Republic, which 
borders the sub-Saharan area known to be endemic for HBV/E 39. However, the 
relatively high prevalence of  D6 in Ethiopia showed that the geographic area of  
this strain extends further than proposed—as far as eastern Africa. Notably, D1 
the predominant subgenotype in North Africa and Middle East 50,56,133,151, is rare 
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and found only in one isolate. Interestingly, about 30% of  genotype D isolates 
in this study clustered in a novel monophyletic phylogenetic branch with a high 
statistical bootstrap support (100%) that is distinct from any known subgenotype. 
Further studies at complete genome level is needed to determine whether the 
currently unclassifiable isolates belong to a novel subgenotype 53,158. Another 
interesting observation in this study was the presence of  recombinant genotypes 
(A/D) and the rare subgenotype D4 in two isolates. The two HBV recombinant 
isolates were identified by jumping profile Hidden Markov Model 144. Relative to 
position on HBV reference genome AM282986 numbering, isolate BL66ETH 
had sequence of  genotype A from nucleotides 75-288 and of  genotype D from 
nucleotides 289-772, whereas isolate MK141ETH had sequence of  genotype A 
from nucleotides 472-573 and of  genotype D from nucleotides 75-471 and 574-
772. 
Importantly, the present study was also the first to describe the HBV serotypes 
prevalent in Ethiopia. Serotype adw2 was the most predominant (79%) and 
found in all subgenotype A1 isolates and in the D/A recombinant isolates 
(BL66ETH and MK141ETH). Serotype ayw2 was found in all isolates belonging 
to subgenotypes D1, D4, D6 and in most of  the unclassifiable isolates. All D2 
isolates were ayw3 apart from one isolate specifying ayw2. This result is consistent 
with previous data reporting the relationship between serotype and genotypes/
subgenotypes 30,37. Notably, we also noted that the unclassifiable isolates were not 
only phylogenetically closely related to subgenotypes D4 and D6, but also that 
they encoded similar serotype ayw2. 
In this study, the HBsAg variants were analyzed and found that 51 (13.8%) out 
of  371 isolates had mutations within the major hydrophilic region. Studies have 
shown that MHR mutants are associated with failure of  HBsAg detection, vaccine 
and immunotherapy escape 66,67,138,159. In this study, MHR variants known to be 
involved in diagnostic failures were found in 7% of  isolates although none of  
them had failed to be detected by the commercial kit utilized. Moreover, variants 
associated with immunotherapy or vaccine escape, P120S 159, T126I 160, Q129H 
161-163, Q129R 163, G130N 164, T131I 163, M133I 165, M133T 165,166, F134L 166, Y134F, 
T140I, D144E 164, were detected among 20 isolates in this study. The natural 
occurrence of  such variants in vaccine and treatment naïve population is possible 
as reported by several studies 164,166. However, a high presence of  immune-escape 
mutants in this study should be considered in the immunization program as they 
have the potential to spread undetected and thereby affect the effectiveness of  
the national vaccination program and treatment. 
Mutations related to antiviral therapy resistance were identified mainly in 
samples from Gondar region (7/64, 11%). The best-described drug resistance 
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mutation— the lamivudine resistance L180M and M204V— were both detected 
in five isolates 167,168. Other antiviral resistance mutations, I169T, T184A and 
A194T, were also detected in three isolates. Importantly, all mutants were detected 
among therapy-naive subjects. Since there is no HBV therapy in Ethiopia, the 
current findings might be naturally occurring mutants or therapy-failure mutant 
strains introduced from elsewhere.
In conclusion, this study is the first to establish the distribution of  HBV 
genotypes, guessed subgenotypes and serotypes in Ethiopia. The study shows 
the prevalence of  two genotypes and various subgenotypes, with a predominance 
of  subgenotypes/serotypes A1/adw2 and D2/ayw3. Importantly, a cluster of  
HBV isolates which could be represent a novel HBV subgenotype and also 
detected recombinants strains that should be further investigated by applying the 
full length genomes of  identified strains. Moreover, a significant level of  HBsAg 
variants and RT mutants in vaccine and treatment naïve population were detected. 
Our findings will therefore have major impact on the design of  HBV prevention, 
treatment, and diagnosis in Ethiopia.
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sUPPortinG information
Table S1. Distribution of  HBV subtypes in the five geographic regions of  Ethiopia
Region Subtype, Number (%) Total
Subtotal Subtotal
adw adw2 ayw ayw1 ayw2 ayw3
Addis Ababa 125 (85.0) 125 (85.0) 22 (15.0) 0 14 (9.5) 8 (5.4) 147
Adama 69 (92.0) 69 (92.0) 6 (8.0) 0 6 (8.0) 0 75
Gondar 42 (65.6) 42 (65.6) 22 (34.4) 2 (3.1) 5 (7.8) 15 (23.4) 64
Jimma 14 (93.3) 14 (93.3) 1 (6.7) 0 1 (6.7) 0 15
Mekelle 43 (61.4) 43 (61.4) 27 (38.6) 0 7 (10.0) 20 (28.6) 70
Total 293 (79.0) 293 (79.0) 78 (21.0) 2 (0.5) 35 (9.4) 43 (11.6) 371
A B
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Figure S1. Distribution of  HBV genotypes and subtypes by age and gender. HBV genotypes 
(A, B) and subtypes (C, D) were determined and distributed according age (A, C) or gender (B, D).
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Figure S2. Maximum Likelihood phylogenetic tree of  371 Ethiopian isolates and 110 HBV 
reference sequences. Phylogenetic analysis inferred from Maximum Likelihood tree (HKY85 model) 
based on HBV S/pol gene sequences (691 bp) of  Ethiopian HBV isolates and reference sequences 
retrieved from the GenBank database representing HBV genotypes (A-I) and all genotype A and D 
subgenotypes (A1-A4, and D1-D6). Ethiopian HBV isolates are shown in color (color corresponding 
to their geographic origin: Green = Addis Ababa; Pink = Adama; Red = Mekelle; Blue = Gondar; 
Light blue = Jimma), and reference sequences retrieved from GenBank shown by their accession 
number. Numbers in the tree represent the percentages of  bootstrap values (1000 replicates). The 
subgenotype A1 outgroup cluster, the novel subgenotype D cluster (NC) and the D/A recombinant 
strain are highlighted in yellow, orange and green, respectively.
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sUmmary
Hepatitis B virus (HBV) is genetically highly divergent and classified in ten 
genotypes and forty subgenotypes in distinct ethno-geographic populations 
worldwide. Ethiopia is a country with high HBV prevalence; however, little is known 
about the genetic variability of  HBV strains that circulate. Here, we characterize 
the complete genome of  29 HBV strains originating from five Ethiopian regions, 
by 454 deep sequencing and Sanger sequencing. Phylogenetically, ten strains 
were classified as genotype A1 and nineteen as genotype D. Fifteen genotype D 
strains, provisionally named subgenotype D10, showed a novel distinct cluster 
supported by high bootstrap value and >4% nucleotide divergence from other 
known subgenotypes. In addition, the novel D10 strains harbored nine unique 
amino acid signatures in the surface, polymerase and X genes. Seventy-two 
percent of  the genotype D strains had the pre-core premature stop codon 
G1896A. In addition, 63% genotype A and 33% genotype D strains had the basal 
core promoter mutations, A1762T/G1764A. Furthermore, four pre-S deletion 
variants and two recombinants were identified in this study. In conclusion, we 
identified a novel HBV subgenotype D10 circulating in Ethiopia, underlining the 
high genetic variability of  HBV strains in Africa.
KEYWORDS
Ethiopia; genetic variability; genotype and subgenotypes; hepatitis B virus; novel 
subgenotype D10
Abbreviations: BCP, basal core promoter; HBV, hepatitis B virus; ORF, open 
reading frames; PC, pre Core; RDP, recombination detection program 
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introDUction
Despite advances in prevention, diagnosis and treatment, hepatitis B virus (HBV) 
infection remains a major global health problem, especially in Africa and Asia, 
where seroprevalence is high 8. HBV is the prototype of  the family Hepadnaviridae 
with a partially double-stranded circular DNA genome of  3.2 kb organized into 
four overlapping open reading frames (ORFs: S, for the surface or envelope gene; 
C, for the core gene; X, for the regulatory X gene; and P, for the polymerase gene) 
27. Because its polymerase lacks proof-reading activity and its genomes undergo 
frequent recombination, HBV exhibits a high degree of  genetic heterogeneity 95. 
To date, ten genotypes, A–J, defined by an intergroup divergence of  greater than 
7.5% over the entire genome sequence have been established 30,32,33,36,37. Moreover, 
extensive phylogenetic analyses of  HBV genotypes in different studies worldwide 
have identified several subgenotypes within genotypes, A (A1–A6), B (B1–B9), 
C (C1–C16), D (D1–D9), F (F1–F4), and I (I1–I2), based on full genome 
divergence of  > 4 % but < 7.5 % 20,30,37-41,53. HBV genotypes and subgenotypes 
differ in clinical and therapeutic outcomes 58,60 and have distinct ethno-geographic 
distribution worldwide 30,52. 
Numerous studies carried out in different African countries have also unveiled 
the emergence of  a trend in the geographic distribution of  genotypes and 
subgenotypes. Subgenotype A1 is dominant in southern, central and eastern Africa 
30,133,150,155,156,169. Quasi subgenotype A3 153, previously designated as genotypes A3, 
A4, A5, and A7 40,170, is mainly found in west Africa. Subgenotype D1 is the 
most prevalent subgenotype in north Africa 133, D2 in Ethiopia 169, D3 in South 
Africa 133, D7 in Tunisia 39 and the recently described D8 in Niger 38. Genotype 
E is the most prevalent strain in central and western Africa 30,38. However, unlike 
genotypes A and D, it has very low genetic diversity and does not segregate into 
distinct subgenotypes. Moreover, in countries where several genotypes circulate 
many HBV recombinant strains have been described 38,40,49,50. 
Ethiopia is a large, culturally diverse, multiethnic country in the horn of  Africa 
located at a strategic geographical position between Africa and Eurasia. It was the 
main route of  human migration out of  Africa as well as the origin of  modern 
humans 171-175. Ethiopia has an intermediate to high HBV endemicity, with HBsAg 
prevalence of  5.8-6.3% in the general population 8. However, so far there is limited 
data available regarding the molecular diversity of  HBV in this country 169. Our 
previous study was limited to the small S gene sequence analysis and several strains 
remained unclassified. The aim of  this study was to characterize the complete 
genomes of  representative HBV strains of  different clades originating from five 
regions of  Ethiopia to classify them into subgenotypes and to gain insight into 
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the molecular diversity and evolution of  the strains in circulation. With 454 deep 
sequencing and Sanger sequencing, we identified a novel prevalent subgenotype 
D, tentatively named D10, currently circulating in Ethiopia.
materials anD metHoDs
Samples 
Twenty-nine HBV strains, 10 genotype A and 19 genotype D obtained from 
healthy blood donors, were selected for complete genome sequence analyses from 
the 371 strains previously investigated 169. These HBV strains originated from five 
regions — Addis Ababa (n = 11), Adama (n = 6), Gondar (n = 5), Mekelle (n 
= 6) and Jimma (n = 1) (Table 1). The criteria for representative strain selection 
were inclusion of  strains with identical cluster, divergent and/or separate clusters 
based on the small S-gene sequences phylogeny, and those with viral load of  ≥ 
2 log. Samples were stored at −80°C until use. The study was approved by the 
National Research Ethics Review Committee at the Federal Ministry of  Science 
and Technology, Ethiopia. 
DNA extraction, amplification, and complete genome sequencing
Viral DNA was extracted from 200 µl serum using High Pure Viral Nucleic Acid 
Kit (Roche Diagnostics, Mannheim, Germany) and QIAamp DNA Mini kit 
(Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Serum 
HBV DNA levels were quantified using an in-house quantitative real-time PCR 
(qPCR) as described previously 141,142. AcroMetrix® HBV low (112 IU/mL to 335 
IU/mL), medium (2800 IU/mL to 8900 IU/mL) and high (5.63 × 106 IU/mL to 
1.78 × 107 IU/mL) controls (Applied Biosystems, life technology, USA) were used 
as the standard reference. Next-generation 454 deep sequencing were performed 
on 13 serum samples with a high viral load (> 4 log) as described previously 
176 with modifications. The complete HBV genome for samples with low viral 
load (≤ 4 log) was amplified in 4 overlapping fragments by nested PCR using 
primers and protocols described in Table S1. The amplified HBV fragments were 
sequenced bi-directionally using Big Dye Terminator version 3.1 cycle sequencing 
kit on an ABI PRISM 3100 genetic analyzer (Applied Biosystems).
Phylogenetic analyses
The sequences obtained were assembled with the Genomic Workbench software 
version 6.0.1 (CLC Bio, Aarhus, Denmark). Multiple sequence alignments 
were performed using CLUSTAL W implemented in MEGA version 6.0 143. 
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Phylogenetic trees were constructed by the neighbor-joining method using Kimura 
two-parameter model and including reference strains of  genotypes A–H and all 
known A and D subgenotypes. To confirm the reliability of  the phylogenetic 
tree topologies, bootstrap resampling and reconstruction were carried out 1,000 
times. The obtained tree was visualized in FigTree v1.4.2 (http://tree.bio.ed.ac.
uk/software). The Kimura two-parameter and maximum likelihood models were 
used to calculate genetic divergence and pairwise distances within or between a 
given genotype and/or subgenotype. All sequences retrieved from GenBank and 
used in this study were listed in the supplementary material (Table S2).
Amino acid analyses
All nucleotide sequences in this study and those retrieved from GenBank data 
bases were translated to amino acids and aligned using CLC Bio software version 
6.0.1. Individual subgenotypes were searched for conserved amino acid signatures 
in the four different open reading frames of  the HBV genome.
Recombination analysis 
The detection of  recombinant strains was carried out by the recombination 
detection program (RDP) version 4.69 177, with the RDP, Geneconv, Chimaera, 
MaxChi, BootScan, SisScan, 3Seq, and LARD methods. A multiple-comparison-
corrected p-value cutoff  of  0.01 was used throughout the analyses. Only potential 
recombination events detected by three or more out of  the eight independent 
recombination detection methods implemented in RDP4.69 were considered 
as genuine recombination events. The analysis was based on a pairwise distance 
model with a window size of  200, step size of  20, and 1000 bootstrap replicates. 
These potential recombinant sequences were further validated with SimPlot 
v3.5.1 178 and jumping profile Hidden Markov Model (jpHMM) 144.
Nucleotide sequence accession numbers
The GenBank accession numbers for sequences determined in this study are 
KX357622-KX357650.
resUlts
Phylogenetic analyses of  complete HBV genome sequences from Ethiopia
Of  the 29 HBV samples selected, complete genome sequences were successfully 
determined for 28 HBV samples (9 genotype A and 19 genotype D viruses) and 
for one sample (AA11ETH), only 2230 nucleotide was amplified, due to shortage 
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of  serum. The demographic and molecular characteristics of  29 sequences are 
summarized in Table 1. A total of  28 complete and 1 nearly complete HBV 
genome sequences were phylogenetically analyzed with HBV reference sequences 
of  genotypes A-H retrieved from the GenBank database. Phylogenetically, 
ten strains grouped with genotype A and 19 strains with genotype D (Figure 
1). All the 10 genotype A strains were further classified into subgenotypes A1, 
but separated into two clades. The majority of  strains (9 strains) clustered in 
the Asian-American clade (aac) and one strain in the African clade (ac) (Figure 
1). Interestingly, the nine A1 strains are phylogenetically related to strains from 
Japan, Haiti, Brazil, Philippines and Somalia. The mean intergroup nucleotide 
divergence between Ethiopian A1 strains (excluding AA46ETH) and strains from 
those countries were: 1.7% (Japan), 1.9% (Haiti and Somalia), 2% (Brazil), and 
2.1% (Philippines), while its divergence from sub-Saharan African strains was 3%. 
The nineteen complete genotype D sequences clustered into three distinct groups 
(Figure 1). Three strains previously shown to belong to subgenotype D2 (Table 
1), were also classified within D2 at the complete genome level. As shown in 
Figure 1, of  the remaining sixteen strains, fifteen D strains clustered separately 
from all other D subgenotypes and formed a distinct novel cluster with a strong 
bootstrap support (100%), whereas one strain (MK141ETH) was an outgroup. 
As inclusion of  the recombinant strains into phylogenetic analysis might change 
the topology of  the tree, a second phylogenetic tree was constructed for genotype 
D by omitting D8 and D9 (Figure 2). In the second phylogenetic tree, the 
MK141ETH clustered with subgenotype D7 (D7 is a major parent as seen later 
from recombinant analysis) but all the fifteen novel strains clustered separately 
again. Because these novel strains formed a distinct monophyletic cluster with 
a significantly high bootstrap support (100%), we tentatively assigned them to a 
novel subgenotype, D10. 
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Table 1. Demographic and molecular characteristics of  29 HBV sequences 
St
ra
in
a
A
ge
Se
x
V
ir
al
 lo
ad
 lo
g 
 
IU
 m
L-
1
Genotype and subgenotypeb
N
uc
le
ot
id
e 
 le
ng
th
 
(b
p)
Po
si
ti
on
s o
f  
pr
e-
S2
 d
el
et
io
ns
 
S 
ge
ne
(p
re
vi
ou
s 
st
ud
y)
d
Fu
ll 
ge
no
m
e 
 
(t
hi
s s
tu
dy
)
Se
ro
ty
pe
AA33ETH 33 Male 5 D/ND D10 ayw2 3182 n/a
AA95ETH 29 Male 6 D2 D2 ayw3 3182 n/a
AA124ETH 28 Male 3.5 D/ND D10 ayw2 3182 n/a
AA141ETH 30 Male 3 D/ND D10 ayw2 3158 32-55
AA164ETH 40 Male 3 D/ND D10 ayw2 3182 n/a
BL43ETH 45 Male 8 D/ND D10 ayw2 3182 n/a
BL63ETH 29 Male 3 D/ND D10 ayw2 3282 n/a
BL60ETH 35 Male 2 D/ND D10 ayw2 3182 n/a
BL70ETH 22 Male 3 D/ND D10 ayw2 3182 n/a
GD39ETH 23 Male 8 D/ND D10 ayw2 3182 n/a
GD65ETH 33 Male 4 D/ND D10 ayw1 3173 50-55 & 3172-
3174
GD69ETH 22 Male 4 D/ND D10 ayw2 3182 n/a
GD82ETH 34 Female 8 D2 D2 ayw3 3182 n/a
GD104ETH 32 Male 3 D/ND D10 ayw2 3182 n/a
MK20ETH 42 Male 6 D2 D2 ayw3 3182 n/a
MK74ETH 30 Male 5 D4 D10 ayw2 3182 n/a
MK75ETH 30 Male 4 D/ND D10 ayw2 3182 n/a
MK152ETH 46 Male 3 D/ND D10 ayw2 3176 50-55
MK141ETH 25 Male 2 D/A D/A/E adw2 3212 n/a
AA11ETH 35 Male 3 A1 A1 adw2 2230c n/a
AA46ETH 25 Male 2 A1 A1/D adw2 3221 n/a
AA81ETH 30 Male 2 A1 A1 adw2 3223 n/a
AA86ETH 40 Male 3 A1 A1 adw2 3221 n/a
AA152ETH 24 Male 6 A1 A1 adw2 3170 5-55
AA162ETH 23 Male 7.5 A1 A1 adw2 3221 n/a
BL13ETH 26 Female 7 A1 A1 adw2 3221 n/a
BL185ETH 33 Male 8 A1 A1 adw2 3221 n/a
JM16ETH 22 Male 7 A1 A1 adw2 3221 n/a
MK156ETH 22 Male 7 A1 A1 adw2 3221 n/a
aStrain origin; the first two letters indicate region (AA= Addis Ababa, BL= Adama, GD= Gondar, 
JM= Jimma, MK= Mekelle) and the last three letters country (ETH= Ethiopia).
bND, not determined; n/a, not applicable;  cAA11 partial sequence (2230 nt, excluding the polymerase 
C terminal and the X gene). dHundie et al.169
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Figure 1. Phylogenetic tree constructed by the neighbour-joining method, based on the 
complete sequences of  HBV strains. Ethiopian sequences determined in this study are indicated 
by color (green = genotype A: red = genotype D). The reference sequences used in this comparison 
are indicated by their accession numbers, followed by the letter of  the corresponding genotype/
subgenotype. Bootstrap resampling was carried out 1000 times and is indicated on the respective 
branches as a percentage
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Genetic characteristics of  the novel HBV subgenotype D10
To further explore the characteristics of  the strains belonging to the novel D10 
subtype, phylogenetic trees were constructed for each of  the four ORFs; preS/S, 
P, preC/C, and X, and the representative sequences of  subgenotypes D1 to D7 
were used as references. As depicted in Figure 3A-D, the HBV D10 strains formed 
a distinct monophyletic cluster in all four individual ORFs (preS/S, P, preC/C, 
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Figure 2. Phylogenetic analysis of  Ethiopian HBV strains belonging to genotype D compared 
with reference sequence of  each genotype (A-H) and seven subgenotypes of  D (D1–D7). 
Genetic distances were estimated using the Kimura two-parameter model, and phylogenetic tree 
was constructed using the neighbor-joining method. GenBank accession numbers of  all published 
sequences used, followed by the letter of  the corresponding genotype or subgenotype, are indicated. 
Ethiopian strains are shown in color and the novel subgenotype D10 depicted in red. Bootstrap 
resampling was carried out 1000 times and is indicated on the respective branches as a percentage. 
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and X) supported by high bootstrap values. This result further confirmed that the 
D10 strains cluster distinctly not only at complete genome level but also when 
analyzing each of  the four individual ORFs. It is noteworthy that D10 strains 
were distantly close to strains belonging to subgenotypes D1 and D2 in the X 
ORF tree (Figure 3D), and to D7 in the preS/S, P and preC/C ORFs tree (Figure 
3A-C). This characteristic was also observed when analyzing the different shared 
amino acid residues in these ORFs.
To further characterize the D10 strains, we compared intergroup nucleotide 
divergence (mean ± SD %) over the complete genome to 132 different HBV 
sequences representing subgenotypes D1–D7. The mean divergence of  the novel 
strains was found to be 4.9 ± 0.4% from each D1 and D2, 5.4 ± 0.4% from D3, 
4.0 ± 0.3% from each D4 and D7, 6.2 ± 0.4% from D5, and 4.8 ± 0.4% from 
D6. Therefore, our data further provide support for the current definition of  
subgenotype 30,37,53. 
Furthermore, comparison of  amino acid sequences of  each of  the four 
ORFs/genes (preS/S, P, preC/C and X) between HBV D10 strains and other 
subgenotypes (D1–D9) identified nine amino acid signature positions unique to 
D10 strains; five of  them were exclusively unique to D10, and four of  them 
were shared with one or two strains of  other D subgenotypes (Table 2). Of  the 
five unique amino acid sites, three were found in the P gene and one each in the 
preS/S and X genes. Briefly, all the D10 strains had Pro78 in the spacer, Tyr124 in 
reverse transcriptase and Gln/Asn136 in terminal protein of  the P gene, Ser33 in 
the preS2 gene, and Pro47 in the X gene (Table 2). The four amino acid sites that 
are unique to D10 but shared with a few other D strains includes Thr28 in the 
preS1 gene and Leu89 in terminal protein, His/Tyr31 in the spacer and Ala317 in 
the reverse transcriptase of  the P gene (Table 2). No D10- specific amino acid 
residues were found in the core and small S regions. Amino acid substitutions 
present within each subgenotype are shown in Table 2. The subgenotype-specific 
amino acid residues are shown in italic and the dominant ones in bold. 
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Figure 3. Neighbour-joining trees based on phylogenetic analysis of  the four open reading 
frames (ORFs) of  34 HBV strains belonging to genotype D; (a) preS/S, positions 2848-3182, 
1-835, (b) polymerase, positions 2307-3182, 1-1623 (c) preC/C, positions 1814-2452, and (d) X , 
positions 1374-1838. Reference sequences of  seven subgenotypes of  HBV genotype D (D1–D7) 
retrieved from GenBank were used for the construction of  the phylogenetic tree. The tree was built 
using the Kimura two-parameter model and neighbor-joining method, and bootstrap resampling was 
carried out 1000 times and is indicated on the respective branches as a percentage. Ethiopian D10 
strains are shown in red, MK141ETH in blue, and reference sequences are indicted by GenBank 
accession numbers, followed by the letter of  the corresponding subgenotype. 
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Mutations in the BCP/Precore region in Ethiopian HBV strains 
Ethiopian HBV strains in this study were analyzed for mutations in the basal core 
promoter (BCP) and precore (PC) region. The most common BCP mutation, a 
double A1762T/G1764A nucleotide substitution, was found in five (5/18; 27.8%) 
genotype D and one (1/8; 12.5%) genotype A strain. In addition, six strains, four 
from genotype A and one each from genotype D and the recombinant strain 
(AA46ETH) had a single G1764A mutation. One genotype A strain and two 
genotype D strains had triple BCP mutations, A1762T, G1764A and T153C. 
Overall, 63% of  genotype A strains and 33% of  genotype D strains had either 
double or single BCP A1762T/G1764A mutations. The PC premature stop codon 
G1896A was identified in thirteen of  eighteen (72.2%) investigated genotype D 
strains and in both recombinant strains (MK141ETH and AA46ETH). None 
of  the genotype A strains carried the precore stop codon mutation. Another 
PC mutation, G1899A, was found in nine (50%) genotype D strains and the 
two recombinant strains but not in genotype A strains. Moreover, two genotype 
D strains (AA141ETH and BL70ETH) had PC start codon mutations, and 1 
genotype A strain (AA81ETH) had two nucleotide insertions at nucleotide 1839. 
Overall, genotype D strains exhibited a high frequency of  BCP/PC mutations, 
with 15 strains out of  18 (83.3%) disclosed these mutations. Notably, 80% (12/15) 
of  the D10 strains had at least one mutation in the BCP or PC region.
Pre-S deletion mutations in Ethiopian HBV strains 
The prevalence of  the pre-S mutations was also assessed in this study. Of  the 29 
HBV strains investigated, four strains (13.8%) revealed a pre-S deletions, ranging 
from 6 nt to 51 nt (Table 1). Three of  these strains are from genotype D and one 
strain is from genotype A. All of  the pre-S deletions occurred in the N- terminal 
of  the pre-S2 region of  the HBV genome. In addition, one genotype D strain 
(AA33ETH) had a pre-S2 start codon mutation.
Recombination analysis
All 29 sequences from Ethiopia were evaluated for potential recombination 
events using RDP4, SimPlot and jpHMM methods. Two strains were found to be 
a putative recombinant. Strain MK141ETH was identified as a triple recombinant 
between genotype D, E and A by jpHMM (Figure S1), and classified as a genotype 
D/E recombinant by RDP4 and SimPlot. As shown in Figure 4B, MK141ETH 
had genotype E sequence in the Pol N-terminal and preS2 regions from position 
2702 to 2978 (beginning breakpoint 99% confidence interval (Cl): 2680-2755; 
end breaking point 99% Cl: 2793-2995), and genotype D (subgenotype D7) 
sequence in rest of  the genome. Strain AA46ETH, which belongs to subgenotype 
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A1, showed a genotype D sequence in the X and pre-core region from position 
1558-1916 (beginning breakpoint 99% Cl: 1391-1633; end breaking point 99% Cl: 
1859-1983) (Figure 4A) as analyzed by RDP4 and jpHMM (Figure S1).
DiscUssion
This is the first study describing the full-genome molecular characterization of  
HBV strains circulating in different geographic regions of  Ethiopia. Here, we 
investigated 29 complete HBV genome sequences, ten sequences belonging to 
genotype A and 19 to genotype D. The most important finding of  this study 
was the identification of  novel HBV strains that clearly form a new separate 
cluster, proposed subgenotype D10, within genotype D. Firstly, these strains 
were obtained from unrelated blood donors from different regions of  Ethiopia. 
Secondly, complete genome and separate ORF phylogeny revealed that they 
formed a distinct monophyletic cluster strongly supported by high bootstrap value 
(100%). Thirdly, the mean inter-subgenotype nucleotide divergence compared 
with reference sequences of  all existing subgenotypes D was > 4 % and < 7.5%. 
Lastly, they had nine unique amino acid substitution positions, five of  those were 
exclusively unique to D10.
In our previous study, we reported a unique distribution of  genotype D viruses 
in Ethiopia, with 55 % (44/80) of  strains belonging to subgenotype D2 and 30% 
(24/80) unassigned new strains, based on the small S-gene sequence variations 
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169. In the present study, we performed a complete genome sequence analysis 
on fourteen unassigned new strains, three strains from D2, and one strain each 
from D4 and a suspected recombinant. As expected, the three strains were 
classified into D2, confirming our earlier findings. It is noteworthy that D2 is a 
major subgenotype in Europe but less frequent in Africa 157. Interestingly, strain 
MK141ETH that was suspected as D/A recombinant in the previous study was 
found to be a triple recombinant (D/A/E) in this study. It is well known that 
recombination between HBV genotypes is a common event in countries where 
multiple genotypes are prevalent 38,40,49,50. However, strains belonging to genotype 
E has not been reported so far in Ethiopia. Thus, this finding highlights a need 
for more sequences from this region. On the other hand, strain MK74ETH 
previously classified as D4 was classified as D10 at complete genome level. It is 
noteworthy to say, subgenotype classification may not be applicable to some HBV 
strains on the basis of  the small S-gene sequence alone 53. Interestingly, the novel 
D10 strains distinctly clustered not only on the complete genome level but also in 
each of  the four open reading frames (preS/S, P, preC/C and X). This consistent 
result provides concrete evidence that D10 strains have homologous sequences 
throughout the genome and is free of  hybrid sequences and recombination. This 
result was further confirmed by HBV recombinant analysis. In addition, the mean 
inter-subgenotype nucleotide divergence over the complete genome sequence 
between D10 and the recognized D subgenotypes ranged from 4 % (with D4 and 
D7) to 6.2% (with D5), which is the minimum requirement for definition of  a 
new subgenotype 30,37,53. 
Most recently, Pourkarim and colleagues 53 suggested that to introduce a novel 
subgenotype, strains harboring specific amino acid motifs should be identified. 
Fascinatingly, besides amino acid residues previously reported 30,56,157, D10 strains 
disclosed nine unique amino acid signatures, five exclusively unique to D10, 
and four only shared with very few other D strains. The novel D10 is easily 
distinguished from all subgenotypes, D1-D9, by Ser33 in the preS2 gene, Pro47 in 
the X gene, and Pro78, Tyr124 and Gln/Asn136 in the P gene. Remarkably, many 
other amino acids residues specific to D10 but shared with few D4 or D7 strains, 
or common to all the three subgenotypes were identified. As seen in this study, 
the novel D10 is distantly related more to D4 and D7 than other subgenotypes 
from some amino acid signatures they shared, which was also revealed in the 
phylogenetic tree. However, the three subgenotypes prevail in geographically 
and historically unrelated regions, D4 in Oceania 30 and D7 in Maghreb 39,56. 
Hence, further investigation is needed to determine the molecular evolutionary 
relatedness between the three subgenotypes.
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Subgenotype A1, the main African A subgenotype, is the predominant strain 
in Ethiopia 169, alike most sub-Saharan African countries 27,133,150. Surprisingly, the 
majority of  Ethiopian A1 strains in this study clustered in the Asian-American 
clade together with Somalian strains than to the African clade. They are more 
closely related to strains from Japan, Haiti, Brazil, Somalia, and the Philippines. 
This result might strengthen the previous hypothesis of  the dispersal of  A1 into 
these regions from eastern Africa possibly through migration or slave trade 154. 
A study in Haiti suggests that A1 was introduced from eastern Africa to Haiti 
during the slave trade around the turn of  the 18th century 179. Another study in 
Brazil revealed the close relatedness of  the Brazilian, Asian and Somalian isolates, 
and suggests that the Brazilian A1 strains originate from southeast Africa at the 
middle of  the 19th century 180. Moreover, in the recent subgenotype A1 of  HBV-
tracing human migrations in and out of  Africa, the co-clustering of  Somalian 
and Latin American strains and the plausible sites of  A1 origin and dispersal 
routes to Asia and Latin America are presented 154. Furthermore, Ethiopia was 
the main route of  human migration out of  Africa and also the origin of  modern 
humans as abundant key fossil evidence for human origins and evolution is found 
in modern-day Ethiopia 171-175. From these shreds of  evidence we speculate that 
Ethiopian strains might be the oldest lineage of  the Asian-American clade, but 
should be studied further using modern phylogenetic analyses. 
Another important observation in the present study was the high frequency of  
the classical precore and basal core mutations, and the pre-S deletion mutations. 
The majority (75%) of  genotype D strains in this study harbored the precore 
premature stop codon G1896A mutation. This is in agreement with some studies 
181,182. In addition, 63% genotype A strains and 33% genotype D strains had the 
BCP mutation. Previous studies have indicated that BCP/PC mutations are the 
strongest viral factor associated with advanced liver disease progression in HBV 
carriers 183-185. Moreover, it has been described that mutations in the BCP/PC 
region are correlated with HBV genotypes 41,184. Thus, it is noteworthy to suggest 
that the clinical impact of  the novel D10 strain in chronic HBV carriers needs 
further study. Besides, we detected one strain (AA81ETH) with two nucleotide 
insertion at position 1839 of  the core region that was confirmed in 3 independent 
experiments. This insertion resulted in a frameshift and caused a premature stop 
codon that resulted in a truncated form of  the core protein. We have also noted 
that 13.8% of  strains in the present study harbored a pre-S deletion and one strain 
had a pre-S2 start codon mutation. These mutations were reported in a number 
of  studies and suggested as independent risk factors for the development of  
hepatocellular carcinoma 186,187. As the aforementioned mutations were observed 
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among healthy blood donors, our finding has thus an impact on the establishment 
of  HBV patient management in Ethiopia. 
In conclusion, this is the first report of  complete HBV genome sequences from 
Ethiopia, where there have been scant molecular data on HBV. We identified a 
novel subgenotype D10 with a well-defined pattern, including unique amino acid 
signatures. This study highlights that HBV is still evolving genetically, and further 
studies in HBV endemic areas where molecular data are lacking are of  paramount 
importance.
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Table S2. List of  GenBank accession numbers of  reference sequences used in this study
Genotype GenBank accession number
A1 AB937796, AB937791,AB453988, AB453987,FJ692590, FJ692557, 
FJ692574,FJ692578,FJ692588, FJ692563, FJ692571, FJ692560,FJ692564, FJ692565, 
FJ692569, FJ692559, FJ692566, AB241115, AY934774, EU410082, AB241114, AB116094, 
M57663, AB116093, AY934769, AY934768, AY934770, AY934771, AY934767, KJ854705, 
KJ854692, KJ854702, KJ854687, FJ692591, KJ854704, KJ854697, KJ854707, KJ854703, 
KJ854696, KJ854694, KJ854706, KJ854700, KJ854688, KJ854686, KJ854690, JX154581, 
AM494718, JX154580, AB076678, AY934773, HM535200, FM199979, KT347088, 
AY233288, FM199980, JN182328, FM199981, FM199977, DQ020002, AY934772, 
FM199974, AB076679, AY934766, DQ020003, KJ854689
A2 AF297622, AY233286
A3 AB194950, AM184126
A6 GQ331048, GQ331047
B D00331, D00329
C D00630, D12980
D1 FJ904432, FJ904421, FJ904420, GQ477459, GU456653, JF754596, FJ904415, AF151735, 
GU456655, FJ899792, AJ344116, GU456646, GQ183483, GU456640, GU456647, 
AB188244, JF754602, GU456684, GU456639, JF754632, JF754624, AB583680, JF754601, 
AF280817, AB104709, AB104711, AF121242, JF754634, FJ904424, GQ477458, GU456651
D2 AB078033, AB078031, AB078032, AB109477, AB109478, EU594425, EU594430, 
EU594405, EU594433, EU594410, EU594402, EU594400, GQ477457, EU594407, 
EU594428, EU594409, EU594432, EU594398, AF043594, GQ477453, JX096957, 
EU594399, KF679996, KR905424, JF754597,  AY090453, JN642143, JN642160, EU594401, 
EU594406, EU594431, EU594416, AB110075
D3 AY902768, AY902769, AY902777, AY902773, AY902770, AJ344117, DQ315776, 
HQ236014, AY233296, HQ236015, GQ922001, HQ236016, AY233294, EU594434, 
GQ922000, KP090181, KP322602, AB583679, EU594382
D4 FJ692532, FJ692533, FJ692536, HE974373, AB033559, GQ922003, AB048701, KJ470884, 
KJ470890, KJ470886, KJ470888, KJ470891, KJ470887, KM606744, KF192831, KF192841, 
KF192837, KF192839, KF192830, KJ470889, KF192834, KF192838, KM606752, 
KF192840, KF192836
D5 DQ315779, GQ205384, GQ205377, GQ205387, GQ205378, GQ205389, GQ205379, 
GQ205382, GQ205385, GQ205388, AB033558
D6 AB493846, AB554016, AB554023, AB554024, AB493848, AB493845
D7 FJ904410, FJ904409, FJ904447, FJ904407, FJ904408, FJ904403, FJ904394, FJ904404, 
FJ904419, FJ904395, FJ904398, FJ904414, FJ904405, FJ904396, FJ904435, FJ904430, 
FJ904437, FJ904417, FJ904416, FJ904413, FJ904406, FJ904442, FJ904439, FJ904436, 
FJ904440, FJ904441, FJ904400, KM606751, KM606750
D8 FN594769, FN594770, FN594771
D9 JN664919, JN664920, JN664921, JN664922, JN664942
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abstract
Hepatitis C virus (HCV) is genetically highly divergent and classified in seven major 
genotypes and approximately hundred subtypes. These genotypes/subtypes have 
different geographic distribution and response to antiviral therapy. In Ethiopia, 
however, little is known about their molecular epidemiology and genetic diversity. 
The aim of  this study was to investigate the distribution and genetic diversity 
of  HCV genotypes/subtypes in Ethiopia, using 49 HCV RNA positive samples. 
HCV genotypes and subtypes were determined based on the sequences of  the 
core and the nonstructural protein 5B (NS5B) genomic regions. Phylogenetic 
analysis revealed that the predominant was genotype 4 (77.6%) followed by 2 
(12.2%), 1 (8.2%), and 5 (2.0%). Seven subtypes were identified (1b, 1c, 2c, 4d, 
4l, 4r and 4v), with 4d (34.7%), 4r (34.7%) and 2c (12.2%) as the most frequent 
subtypes. Consistent with the presence of  these subtypes was the identification of  
a potential recombinant virus. One strain was typed as genotype 2c in the NS5B 
region sequence and genotype 4d in the core region. In conclusion, genotype 4 
HCV, subtypes 4d and 4r, are the most prevalent in Ethiopia. This genotype is 
considered to be difficult to treat, thus, our finding has an important impact on 
the development of  treatment strategies and patient management in Ethiopia.
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introDUction 
Hepatitis C virus (HCV) is an important human pathogen that causes substantial 
morbidity and mortality worldwide. The most recent study estimated that more 
than 185 million people are chronically infected with HCV and 3–4 million new 
infections occur each year 75. HCV is one of  the leading causes of  end-stage liver 
disease, cirrhosis and hepatocellular carcinoma 188, resulting in over 700,000 deaths 
annually 6. In addition, HCV is the most common cause of  death in HIV-positive 
patients on highly active antiretroviral therapy 80. Consequently, the burden of  
HCV-related morbidity and mortality will likely continue to increase over the next 
twenty-five years due to the existing pool of  chronic HCV infections in low-
income countries 189. 
HCV is an enveloped, positive-sense, single-strand RNA virus belonging to 
the genus Hepacivirus in the family Flaviviridae. The viral genome is ~9.6 kb 
in length and contains a single open reading frame that encodes a polyprotein 
of  about 3,000 amino acids 190. HCV shows extreme genetic diversity and 
classified into seven main genotypes (1–7), further classified into 67 confirmed, 
20 provisional, and 21 unassigned subtypes 94. The HCV genotypes differ from 
each other by approximately 30-35%, and the subtypes differ from each other by 
at least 15% over complete genome 94,95. Different HCV genotypes and subtypes 
display distinct geographic distribution patterns and levels of  genetic diversity 190. 
Overall, genotypes 1–3 are globally distributed, causing the majority of  cases in 
the world, whereas genotypes 4–7 are more geographically restricted 95. Genotype 
4 is found mainly in Central Africa and the Middle East 191,192, genotype 5 in 
South Africa 96, and genotype 6 in Southeast Asia 107,193. The recently identified 
genotype 7 has been isolated from a Congolese immigrant in Canada 103. This 
genetic diversity and geographic variation of  HCV have an important impact on 
disease epidemiology and clinical practice because it is one of  the most important 
predictors of  response to anti-viral therapy 96,190. Therefore, for the development 
of  treatment strategies and patient management, an in-depth understanding of  
the prevalent genotype and subtypes in different geographic regions, including 
Ethiopia is highly important.
Ethiopia is a large, geographically diverse nation, home to over 100 million 
inhabitants. Available data shows that its adult population has a low to moderate 
prevalence of  HCV infections (0.52 to 5.8%) 102,194,195. In Africa, distribution of  
HCV genotype exhibits two epidemiological patterns: one characterized by high 
genetic diversity, distributed in West Africa, with genotypes 1 and 2 106,107,196, and 
the other in Central and Norther Africa, with genotype 4 197. However, little is 
known about the HCV genotype distribution in Easter Africa in general and in 
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Ethiopia in particular. The only study reporting on HCV genotypes in Ethiopia 
was limited to few patients attending a voluntary counseling and testing center 
in Addis Ababa. A total of  18 HCV RNA positive samples were analysed and a 
dominance of  genotype 4 (50%, nine cases) followed by 2 (6 cases), 5 (2 cases) and 
1 (1 case) was found 198. However, no country-wide studies have been published 
and information on the HCV molecular diversity throughout the country is 
lacking. The aim of  the present study was, therefore, to investigate the prevalence 
and genetic diversity of  HCV genotypes and subtypes in different geographic 
regions of  Ethiopia.
materials anD metHoDs
Study Area and Population 
This study was conducted using serum samples collected between March 2013 
and April 2014 from voluntary healthy blood donors at blood bank centers in five 
geographic regions: Addis Ababa (the capital, central) Adama (Oromia, central-
east) Gondar (Amhara, north-west) Mekelle (Tigray, north) and Jimma (Oromia, 
south-west). A total of  56 885 sera were collected, of  which 294 were tested anti-
HCV antibody positive in Ethiopia 195. Of  these, 98 sera were stored at −80°C 
until use and shipped to the Netherlands for further molecular study. The study 
was approved by the National Research Ethics Review Committee at the Federal 
Ministry of  Science and Technology, Addis Ababa, Ethiopia. Informed written 
consent was given by all participants.
Serological assays
The serological markers for HBsAg and anti-HCV antibodies were tested using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits 
(DIALB Diagnostics GmbH, Vienna, Austria). Serum was also screened for anti-
HIV-1 and -HIV-2 antibodies by ELISA (Vironostika HIV Ag/Ab, Bio-Merieux, 
Boxtel, The Netherlands) and anti-Treponema Pallidum antibodies by Rapid 
Plasma Reagin Test (RPR) (DIALB Diagnostics GmbH, Vienna, Austria). All 
tests were carried out in accordance with the manufacturers’ instructions. Anti-
HCV antibody-positive serum samples from donors co-infected either with HBV 
or HIV were excluded from the present study. As the study subjects are healthy 
blood donors, clinical chemistry parameters like AST and ALT are not available.
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HCV RNA extraction, RT-PCR amplification, and sequencing
HCV RNA was extracted from 140μL serum using QIAamp Viral RNA mini 
kit (QIAGEN, Hilden, Germany) or High Pure Viral Nucleic Acid kit (Roche). 
Complementary DNA (cDNA) was synthesized using random Hexamer primers 
(Promega, Madison, WI, USA) and SuperScriptIII (SSIII) First-Strand Synthesis 
System (Invitrogen) according to the manufacturers’ instruction. Briefly, the RT 
reaction mixture included 10μl of  viral RNA, 1μl of  random hexamers, 1μl of  
40U/μl RNasin, 4μl of  5× First Strand Buffer, 2μl of  0.1M DTT, 1μl of  dNTP mix 
(20 mM) and 1μl (200 U/μl) SSIII reverse transcriptase; in a final volume of  20μl. 
A nested PCR technique was used to amplify DNA fragments in the core and the 
nonstructural protein 5B (NS5B) genes. The first round of  PCR was performed 
with 5μl cDNA in a total reaction mixture of  50μl containing 10μl of  5× HotStar 
HiFidelity PCR Buffer, 1μl HotStar HiFidelity DNA Polymerase (QIAGEN) and 
1μl each forward and reverse outer primers (20 pmol/μl) described below. The 
same conditions were used in the second round PCR except 2μl of  first round 
PCR product and 1μl each forward and reverse inner primers used here. The core 
gene fragment (287 -751 nt, according to the position of  reference HCV isolate 
H77 GenBank accession number AF009606) was amplified by nested PCR with 
outer primers s17, 410 and inner primers 953, 954, 951, as described previously 
199 with some modifications. The NS5B gene (8244 to 8656 nt, according to H77) 
was amplified by nested PCR with a combinations of  primers Pr1, Pr2, Pr3, Pr4, 
122, 1204, 123 and 1203, as described previously 199,200. All PCR reactions were 
conducted with the following thermal profile 95°C for 5 min, then 40 cycles of  
95°C for 1 min, 48°C/50°C for 1 min and 72°C for 1 min, with a final elongation 
step at 72°C for 10 min. The amplified products were gel-purified by MinElute 
Gel Extraction kit (QIAGEN, Hilden, Germany) and bi-directionally sequenced 
using Big Dye Terminator v3.1 kits and an ABI prism 3130xl auto-sequencer 
(Applied Biosystems, Foster City, California, USA).
HCV genotyping and phylogenetic analyses
Sequences were assembled and edited with SeqMan Pro (DNASTAR Lasergene 
10). Comparative analyses were performed using the CLUSTAL W multiple 
sequence alignment program, MEGA 6 software 143. HCV genotypes and subtypes 
were determined by aligning to the reference sequences retrieved from GenBank 
or the Los Alamos (http://hcv.lanl.gov/content/sequence/NEWALIGN/align.
html) databases and geno2pheno software (http://www.geno2pheno.org/). 
Bayesian inference (BI) analyses were conducted using MrBayes v3.2 201. For the 
construction of  the Kimura two-parameter model and neighbor-joining method. 
Genetic distances were estimated using the Bayesian phylogeny, we selected the 
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best model of  nucleotide substitution based on the lowest Bayesian information 
criterion (BIC) and Akaike information criterion (AIC) score using TOPALi 
v2.5 202. The best model selected was a general time reversible (GTR) with a 
gamma-distributed rate variation across sites and a proportion of  invariant sites 
(GTR+I+G). The Bayesian phylogenetic tree was constructed in MrBayes v3.2 
with GTR+I+G model using 4 chain simultaneous run for 10 million generations, 
a sampling frequency of  100, and a 50% burn-in. The obtained trees were 
visualized in FigTree v1.4.2 [ http://tree.bio.ed.ac.uk/software]. Finally, mutation 
in the NS5B region, codons 230-347, were assessed by geno2pheno software 
(http://www.geno2pheno.org/).
Nucleotide sequence accession numbers 
The nucleotide sequences of  HCV Core and NS5B partial regions determined 
in this study have been deposited in the GenBank sequence database, under the 
accession KY627917-KY628007.
resUlts
Demographic characteristics
A total of  98 anti-HCV positive healthy blood donors sera (51 from Addis Ababa, 
13 from Adama, 15 from Gondar, 3 from Jimma and 16 from Mekelle) were 
analyzed in the present study. Of  these, 72 (73.5%) were males and 26 (26.5%) 
were females. The mean age was 31. 8 years (range: 18-60 years) (Table 1). 
HCV genotypes and phylogenetic analysis
HCV RNA was successfully amplified in 49 out of  the 98 anti-HCV-positive 
samples. In 49 samples, even after repeated nested PCR with a combination of  
different primers, no genome fragment could be amplified, which could be due 
to storage conditions, a high rate of  false positive anti-HCV antibody results or 
HCV clearance. Among the PCR positive samples, 42 could be genotyped both in 
the NS5B and core regions, 4 in the NS5B region and 3 in the core region only. 
Hence, 46 and 45 samples were successfully sequenced in the NS5B and core 
regions, respectively (Table 2). 
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Table 1. Demographic characteristics of  blood donors enrolled in the study and PCR result 
(HCV-RNA)
Variables
Regions
Total
Addis Ababa Adama Gondar Jimma Mekelle
Sex
Male 35 (68.6%) 11 (84.6%) 13 (86.7%) 2 (66.7) 11 (68.8%) 72 (73.5%)
Female 16 (31.4%) 2 (15.4) 2 (13.3%) 1 (33.3) 5 (31.2%) 26 (26.5%)
Age, years
≤ 20 7 (13.7%) 0 2 (13.3%) 1 (33.3%) 1 (6.2%) 11 (11.2%)
21-30 14 (27.5%) 8 (61.5%) 6 (40.0%) 0 9 (56.3%) 37 (37.6%)
31-40 20 (39.2%) 3 (23.1%) 3 (20.0%) 1 (33.3%) 5 (31.3%) 32 (32.7%)
41-50 8 (15.7%) 1 (7.7%) 4 (26.7%) 1 (33.3%) 1 (6.2%) 15 (15.3%)
> 50 2 (3.9%) 1 (7.7%) 0 0 0 3 (3.1%)
PCR
Positive 33 (64.7%) 3 (23.1%) 3 (20.0%) 2 (66.7%) 8 (50.0%) 49 (50.0%)
Negative 18 (35.3%) 10 (76.9%) 12 (80.0%) 1 (33.3%) 8 (50.0%) 49 (50.0%)
A phylogenetic tree of  the NS5B region was constructed of  46 Ethiopian 
sequences obtained in this work and reference sequences retrieved from 
GenBank. Four HCV genotypes (1, 2, 4 and 5) with seven subtypes (1b, 1c, 2c, 
4d, 4l, 4r and 4v) were identified. As shown in Figure 1, the predominant was 
genotype 4, found in 35 strains (76.1%), followed by 2 (n = 6, 13%), 1 (n = 4, 
8.7%), and 5 (n = 1, 2.2%). Of  the 35 genotype 4 strains, 16 strains belong to 
subtype 4r, 15 strains to 4d, 3 strains to 4l and one isolate to 4v (Table 2). All 
genotype 2 strains belong to subtype 2c and 75% of  genotype 1 strains to subtype 
1b. All the genotypes and subtypes were confirmed by geno2pheno software 
(http://www.geno2pheno.org/). A Bayesian inference phylogenetic tree for the 
core region was also constructed using the 45 sequences (42 from strains used 
in NS5B and 3 additional strains) and reference sequences from the GenBank. 
The most commonly detected genotype was genotype 4 (n = 38, 77.6%), with 
predominant subtypes 4d (n = 18, 36.7%) and 4r (n = 17, 34.7%), followed by 
4l (n = 2, 4.1%) and 4v (n = 1, 2.0%). Genotype 1 (n = 3, 6.1%) comprised the 
subtypes 1b (n = 2, 4.1%) and 1c (n = 1, 2.0%). Genotype 2c was represented 
by 3 strains (6.1%) while one strain was classified into genotype 5a (Figure 2). 
Genotyping was consistent when analyzed by either NS5B or core regions, except 
one strain (MK32ETH) which was 2c in the NS5B region but 4d in the core 
region, suggesting the identification of  a novel recombinant HCV (Figure 1 and 
2). Further full genome sequencing of  this sample however failed.
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Table 2. Concordance of  HCV genotypes/subtypes between Core and NS5B regions.
Isolates Genotypes/subtypes
Core region NS5B region
AA328ETH 1b 1b
AA331ETH 1c 1c
AA332ETH 4d 4d
AA333ETH 4r 4r
AA345ETH 4d 4d
AA346ETH 4d 4d
AA347ETH 4d 4d
AA348ETH 4r 4r
AA350ETH 4d 4d
AA351ETH 4r 4r
AA352ETH 4d 4d
AA393ETH 4l 4l
AA394ETH 4r 4r
BL68ETH 4v 4v
BL78ETH NAb 4l
JM19ETH 4d 4d
MK07ETH 4r 4r
MK08ETH 4r 4r
MK32ETHa 4d 2c
MK144ETH 5a 5a
AA07ETH 4d 4d
AA44ETH 4r 4r
AA58ETH 2c 2c
AA108ETH 4d 4d
AA19ETH 4r 4r
AA148ETH 4r 4r
AA55ETH 4r 4r
AA57ETH 4l 4l
AA67ETH 4d 4d
AA71ETH NA 1b
AA214ETH 4d 4d
AA230ETH 4r 4r
AA232ETH 4d 4d
AA237ETH 4d 4d
AA174ETH 2c 2c
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Table 2. Concordance of  HCV genotypes/subtypes between Core and NS5B regions. 
(continued)
Isolates Genotypes/subtypes
Core region NS5B region
AA175ETH 4r 4r
AA188ETH 4r 4r
AA197ETH 4r 4r
AA239ETH 4d 4d
AA323ETH 4d 4d
GD07ETH 1b 1b
GD45ETH 2c 2c
GD93ETH NA 2c
JM05ETH 4d 4d
BL94ETH NA 2c
MK116ETH 4r 4r
MK58ETH 4r NA 
MK159ETH 4d NA
MK114ETH 4d NA
aPotential recombinant virus 
bNA; not available (the genomic region couldn’t be amplified for the corresponding isolate)
Table 3 shows HCV genotype distribution in Ethiopia by age and gender. All genotype 2 strains were 
observed among males. Overall, no significant differences were observed between HCV genotypes 
with respect to donor’s age and gender.
Table 3. HCV genotypes distribution by age and gender № (%).
Variables
Genotype 1 № 
(%)
Genotype 2 № 
(%)
Genotype 4 № 
(%)
Genotype 5 № 
(%)
Total № 
(%)
Age group
< 20 0 0 3 (7.9) 0 3 (6.1)
21-30 1 (25.0) 1 (16.7) 13 (34.2) 1 (100) 16 (32.7)
31-40 2 (50.0) 5 (83.3) 14 (36.8) 0 21 (42.9)
41-50 1 (25.0) 0 6 (15.8) 0 7 (14.3)
>50 0 0 2 (5.3) 0 2 (4.0)
Gender
Male 2 (50.0) 6 (100) 28 (73.7) 0 36 (73.5)
Female 2 (50.0) 0 10 (26.3) 1 (100) 13 (26.5)
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Figure 1. Bayesian inference phylogenetic tree of  the NS5B region. A phylogenetic tree was 
constructed based on the NS5B region (356 nucleotides), corresponding to nucleotide numbering of  
8288-8643 in the H77 genome, using the GTR+I+G model of  evolution. Numbers on the branches 
are posterior probabilities from the Bayesian inference analysis. Reference sequences are labeled to 
the right of  each branch in the order of  subtype hyphen GenBank accession number. Ethiopian 
sequences are shown in color (color corresponding to their geographic origin: Red = Addis Ababa; 
Blue = Adama; Green = Mekelle; Pink = Gondar; Light blue = Jimma), a potential recombinant 
MK32ETH highlighted in yellow.
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Figure 2. Bayesian inference phylogenetic tree of  the core region. A phylogenetic tree was 
constructed based on the core region (418 nucleotides), corresponding to nucleotide numbering of  300-
717 in the H77 genome, using the GTR+I+G model of  evolution. Numbers on branches are posterior 
probabilities from the Bayesian inference analysis. Reference sequences are labeled to the right of  each 
branch in order of  subtype hyphen GenBank accession number. Ethiopian sequences are shown in color 
(color corresponding to their geographic origin: Red = Addis Ababa; Blue = Adama; Green = Mekelle; 
Pink = Gondar; Light blue = Jimma), a potential recombinant MK32ETH highlighted in yellow.
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Mutation in NS5B region
Mutations in the NS5B region spanning amino acid codons 230-347 were 
investigated using the geno2pheno software. We found that all the 46 Ethiopian 
sequences had mutations ranging from one to thirteen amino acid changes (S1 
Table). Interestingly, the 316N variant associated with resistance to the direct 
acting antiviral Dasabuvir was detected in two subtypes 1b strains (AA328ETH 
and GD07ETH) (S1 Table).
DiscUssion
Knowledge of  the HCV genotypes and subtypes has gained importance, because 
it plays a vital role in predicting the therapeutic and clinical outcome of  the 
HCV infection 190,203. Moreover, the global epidemiological data show that HCV 
genotypes and subtypes distributions vary in different geographic regions, even 
among regions of  the same country 96. However, there is very limited information 
on the molecular epidemiology and genetic diversity of  HCV infections in Eastern 
Africa including Ethiopia. In this study we report the first nationwide molecular 
epidemiology and genetic diversity of  HCV in Ethiopia, one of  the geographically 
diverse and the second most populous country in Africa. We found a high level 
of  HCV genetic diversity, with four major genotypes (1, 2, 4 and 5) and seven 
subtypes are circulating in the country.
Phylogenetic analysis revealed that the majority of  Ethiopian HCV strains are 
belonging to genotype 4 (78%). This genotype is the most frequent cause of  
chronic hepatitis C in the Middle East, Egypt and Central Africa, accounting for 
more than 80% of  HCV infections 204. For instance, more than 90% of  HCV 
infections in the Central African Republic, the Democratic Republic of  Congo, 
Gabon and Egypt were attributed to genotype 4 204,205. In Eastern Africa, however, 
due to the paucity of  data the prevalence of  HCV genotype 4 is currently not 
well known 197. In recent years, the epidemiology of  genotype 4 has changed 
and this genotype has begun spreading beyond its strongholds in Africa and the 
Middle East to several Western countries, particularly in Europe, due to variations 
in population structure, immigration and injection drug use (IDU) 191,206. For 
example, 10 to 24% of  chronic HCV infections in southern Europe, particularly 
in France, Italy, Greece, and Spain and 11% of  chronic HCV infections in The 
Netherlands were attributed to genotype 4 191,207,208. In addition, a high frequency 
of  genotype 4 (42%) was found among Somali immigrants in Minnesota, USA 
209. Nowadays, a wide-ranging overview of  genotype 4 epidemiology and diversity 
may prove useful for public health assessments not only in Africa but also outside 
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Africa, because it accounts for 20% of  total global HCV infection 197,207,210. In 
addition, genotype 4 is considered difficult to treat and has a poor sustained 
virological response rate of  43-63% to the standard pegylated IFN/ribavirin 
combination therapy 208, which is relatively higher than genotype 1 but lower than 
genotypes, 2, 3, 5, and 6 210,211.
Overall, the presence of  four different subtypes (4d, 4r, 4l, and 4v) of  genotype 4 
in Ethiopia is indicative of  a greater genetic diversity compared to HCV genotype 
4 viruses reported in the surrounding countries. In our study, subtypes 4d and 
4r are the predominant subtypes, accounting for 89% of  the HCV genotype 4 
infections. These subtypes are of  interest because subtype 4r is not commonly 
reported while 4d is mostly reported in Saudi Arabia and in the majority of  
European IDU population 191,204,206,212. This result is thus different from studies in 
other African countries where subtypes 4a is the predominant subtype in Egypt 
204,211, 4f  in Cameroon 213, 4e in Gabon 192,205, 4k in the Central African Republic 
and Democratic Republic of  the Congo 197,214, 4c in the Republic of  Congo 215, 
and 4q/4v in Rwanda 197. The high diversity and predominance of  genotype 4 
suggests that this genotype has been endemic for a longer time in Ethiopian 
population. A previous study also showed the dominance of  this genotype in 
Ethiopia 198.
The risk factors for genotype 4 and its subtypes transmission are determined 
by the geographical distribution of  this genotype. Intravenous drug use is the 
most common route of  transmission for genotype 4 infection in Europe while 
unsafe medical practice cause most cases in endemic countries 211. In Ethiopia, 
although we didn’t assess the risk concerning genotype 4 in the present study, we 
suggest that sharing contaminated needles and razor blades during tattooing, body 
piercing, scarification, and circumcision may be the main mode of  transmission, 
as these are common practices particularly in rural Ethiopia.
Genotype 2 was the second most prevalent HCV genotype in our study. HCV 
genotype 2 originated from Western Africa and disseminated to the globe through 
trans-Atlantic slave trade, colonial history and migrations 104,106,216. In Africa, it 
is frequently prevalent in West Africa and its prevalence relative to other HCV 
genotypes declines from west to east 106,216. Our result is in agreement with the 
aforementioned studies. HCV genotype 2 in West Africa exhibits high genetic 
diversity with several subtypes identified within this genotype 104,106. The HCV 
genotype 2 from Ethiopia was found to be less diverse and belong to a single 
epidemic subtype 2c, suggesting that it might be introduced from western Africa 
to eastern Africa. This could be due to frequent travel of  people from this 
geographical location to Ethiopia and vice versa.
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Unlike hepatitis B virus 217, recombination between genotypes is not a common 
event in HCV. To date, ten HCV recombinants have been identified worldwide, 
of  which only recombinant 2k/1b was detected multiple times and in different 
countries 94,99,100. In the present study, we found that strain MK32ETH was 
characterized as genotype 2c in the NS5B gene (Figure 1) and genotype 4d in 
the core gene(Figure 2) as revealed by 3 different independent experiments. 
However, although we tried to obtain the complete genome as we did previously 
218, using the Bull et al. method 219, as well as 454 deep sequencing, all methods 
were unsuccessful. 
In conclusion, this study provides important data on HCV genotypes and 
subtypes in Ethiopia, where four main genotypes and seven subtypes were 
identified. HCV infection in Ethiopia is characterized by the predominance of  
HCV genotype 4 (4d and 4r), with high genetic diversity, suggesting that this 
genotype has been endemic for a long time in Ethiopia. However, further large-
scale studies on the molecular epidemiology of  HCV in Ethiopia are needed. As 
genotype 4 is difficult to treat, our findings have a major impact in developing 
treatment guidelines and patient management.
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abstract
Hepatitis B virus (HBV) quasispecies genetic diversity may influence the clinical 
course and treatment outcomes of  chronic HBV infection. Therefore, we applied 
a full-genome deep-sequencing approach to identify potential association of  
baseline viral variants with HBeAg status and viral loads of  HBV patients. A total 
of  186 plasma samples obtained from treatment-naive chronic hepatitis B patients 
(HBeAg-positive, n = 99; HBeAg-negative, n = 87) were analyzed by ultra-deep 
Illumina sequencing. Deep-sequencing analysis revealed a total of  4615 variants 
across the full-genome of  5 different genotypes (A to E). Although genotype A 
and B viruses showed a relatively higher range of  variants, insignificant variant 
composition was seen between genotypes C and D, but variant diversity was 
significantly higher in viruses from HBeAg-negative compared to HBeAg-positive 
patients. We identified 30 HBV genome variants that can predict HBeAg status, 
with G1896A being the most important predictor, followed by G1899A, A1762T, 
G1764A, A1934T, and T1753C. At least 15 variants including G1896A, G1899A, 
A1762T, G1764A were found to be associated with HBeAg-negative status. We 
also identified 22 HBV variants that had a significant association (p <0.05) with 
HBV DNA load; the majority of  variants that are associated with low DNA 
loads also were found to be associated with HBeAg-negative status, indicating a 
correlation between HBeAg and viral load. In conclusion, we identified several 
viral variants that are significantly associated with HBeAg and viral load as well as 
variants that can predict the HBeAg status of  the patient. 
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introDUction
Hepatitis B virus (HBV) is a 3.2 kb relaxed circular, partially double-stranded 
DNA virus, with a unique genomic organization and replication mechanism. HBV 
replicates through an error-prone reverse transcriptase that lacks proofreading 
capacity. The lack of  proofreading activity of  the HBV reverse transcriptase 
combined with high viral replication rates (1012 virions per day) results in the 
generation of  quasispecies — defined as a population of  genetically distinct 
but closely related variants 65,97,220. This HBV quasispecies contains a spectrum 
of  mutant variants that possess different fitness levels, which allow them for a 
rapid adaptation to a highly mutagenic environment when the virus is subject 
to selective pressures such as host immunity, vaccine or antiviral agents 221,222. 
Such HBV variants have important implications in the pathogenesis, persistence, 
disease progression, clinical as well as therapeutic outcomes 223-226. 
Many studies have disclosed some of  these clinically important variants in 
different regions of  the HBV genome 63,227-229. Such variants include the G1896A 
(W28*) mutation in the precore (PC), A1762T, G1764A, and A1762T/G1764A 
double mutations in the basal core promoter (BCP) that have been shown to be 
associated with different clinical courses 65,226. These mutations either completely 
abolish or decrease hepatitis B virus e antigen (HBeAg) production up to 70%, 
but enhance viral replication 65. As noted, the presence of  HBeAg in serum 
is a marker of  high levels of  virus replication while its seroconversion is an 
established therapeutic endpoint or clearance of  the virus. Several studies revealed 
this correlation between HBeAg status and HBV viral load in chronic hepatitisB 
patients 230-233. Besides PC and BCP variants, various mutant variants that are 
related to clinical characteristics have been described in the pre-surface (preS1/
S2) 234,235, surface, polymerase and X regions 228 of  the HBV genome. Hence, early 
detection of  these quasispecies variants with low frequency is very important. 
Nevertheless, most of  the previous studies regarding the genetic diversity 
of  HBV quasispecies variants were performed mainly using population-based 
sequencing which has low sensitivity for the detection of  mutant variants with 
low frequencies (< 20%) 236. In addition, those studies usually focused either on 
certain known specific HBV mutants or genomic regions, which therefore may 
have overlooked the potential influence of  other novel viral variants. However, 
the next generation sequencing (NGS) enables the detection of  viral variants 
with much greater sensitivity at frequencies as low as 0.5-1% in the quasispecies 
pool 221,237,238. Nowadays, this method has been applied in HBV studies to analyze 
minor antiviral resistance mutations 239,240, quasispecies heterogeneity in reverse 
transcriptase and pre-S region 241,242, and mutations in BCP/PC regions 243. Thus 
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far, these studies mostly focused on targeted HBV genes in specific clinical groups, 
still lacking full-genome investigation and evaluation of  baseline quasispecies 
diversity in association with a clinical characteristic such as HBeAg status, viral 
DNA levels and alike. In light of  this, it would be important to investigate a 
comprehensive full-gnome evaluation of  baseline HBV quasispecies diversity 
using NGS to uncover novel viral variants that have a potential association with 
the patient’s clinical characteristics. 
The aim of  this study was to investigate the association of  baseline HBV 
quasispecies diversity with patient clinical characteristics such as HBeAg status 
and viral load in chronic hepatitis B patients using a full-length HBV genome 
Illumina deep-sequencing. 
materials anD metHoDs 
Patients and samples
A total of  186 plasma samples consecutively collected from chronic HBV patients 
during the period from 1985 to 2012 and stored at the Erasmus University 
Medical Center in Rotterdam, the Netherlands were used in the present study. 
This study was conducted in accordance with the guidelines of  the Declaration 
of  Helsinki and the principles of  Good Clinical Practice. The study was approved 
by the ethical review board of  the Erasmus Medical Center, Rotterdam, The 
Netherlands. Due to retrospective nature of  the study, written informed consent 
was not needed from each patient.
Data acquisition
Data on demographics (sex, age, race, ethnicity, height, weight, route of  HBV 
transmission) and clinical data were obtained from the electronic medical charts 
at the Erasmus University Medical Center in Rotterdam, the Netherlands. Data on 
liver biochemistry (alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutyltransferase (γ-GT), bilirubin, albumin), and virological results 
(serum qualitative HBsAg, anti-HBs, HBeAg, anti-HBeAg, HBV viral load) at 
the baseline were obtained from the clinical laboratory and the department of  
Virology at the Erasmus Medical Center.
DNA isolation and PCR amplification
HBV DNA was extracted from 200 μl plasma using the QIAamp MinElute 
Virus kit (Qiagen) or the Roche MagNA Pure LC instrument according to the 
manufacturer’s instructions. Samples with a viral load >100000 IU/ml were 
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isolated with Roche MagNA Pure (LC) instrument, eluted in 50 µl elution buffer. 
Whereas samples with a viral load <100000 IU/ml or samples that remained 
negative with Roche MagNA Pure (LC) instrument were isolated with the 
QIAamp MinElute Virus kit (Qiagen, Hilden, Germany), eluted in 20 µl elution 
buffer. A well-characterized sample containing a known viral load was used as 
positive control. The full-length HBV genome was amplified either by single-
step PCR or nested PCR method using the Expand high-fidelity PCR kit (Roche 
Molecular Systems) and combinations of  different sets of  primers developed 
by DDL Diagnostic Laboratory (Rijswijk, Netherlands). Briefly, the first PCR 
contains a primer set (forward and reverse primers) that amplifies the complete 
genome. If  this PCR is negative, a nested PCR is deployed using semi-nested 
primers to amplify the entire genome. If  this PCR was also negative then 2 partial 
PCRs were used to amplify the genome in two parts using sets of  2 outer and 2 
nested primers. The generated amplimers are then fragmented for the ultra-deep 
sequence (UDS) analysis using Illumina technology. 
Deep sequencing and data analysis
The deep sequencing of  HBV samples was conducted by DDL Diagnostic 
Laboratory (Rijswijk, Netherlands). The PCR products that showed a clear band 
of  the expected size after gel-electrophoresis were purified and cleaned up by 
Agencourt AMPure XP PCR purification system (Beckman Coulter) to remove 
primer-dimers and small nonspecific PCR products. The purified PCR products 
were quantified using the Quant-iT PicoGreen dsDNA kit (Life Technologies), 
followed by dilution and pooling of  targets. The diluted PCR products (DNA 
strands) were fragmented and tagged using the Nextera XT sample preparation 
kit (Illumina, San Diego, California, USA) according to the manufacturer’s 
instructions. Index primers were added by limited cycle PCR using the Nextera 
XT Index kit, and a beads-based normalization of  each library was performed 
using beads with maximum binding capacity (Nextera XT sample preparation kit) 
according to the manufacturer’s instructions to ensure equal library representation 
in the pooled sample. Multiplexed paired-end sequencing was performed on the 
Illumina MiSeq platform using the MiSeq v2 sequencing kit with 300 cycles. The 
outputs generated as demultiplexed FASTQ reads were quality trimmed and 
mapped to a genotype-specific reference sequence (GenBank accession numbers 
X02763, AB219428, GQ924620, AF121240 and AB106564, of  genotype A to 
E respectively) in DDL’s Athena pipeline for Quality Based Variant Detection. 
Sequences were trimmed to remove nucleotides with a quality score (Q) lower 
than 30. The alignment and trimming procedure were performed using Bowtie2 
v2.2.2 (http://bowtie-bio.sourceforge.net) with the script written in the Python 
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programming language (Python 2.6.6). The minimum read length was ≥ 50 
nucleotides and the minimum coverage was 5,000 sequencing reads. The quality-
based variant detection is performed with DDL’s Athena pipeline proprietary 
software (DDL Diagnostic Laboratory) which was specifically designed for 
detection of  mutations within HBV populations. The threshold for detection of  
the variants by deep sequencing was set at 1% and the variant detection cut off  
coverage at ≥ 500.
Statistical analysis
Statistical analyses were performed using the R program (version 3.4.1). All 
analyses conducted were based on variant calls that passed quality control criteria. 
Linear regression was used to assess the association of  quasispecies variants with 
HBeAg status and viral load of  the patient. Statistical significance was adjusted 
for multiple hypotheses testing using the Benjamini-Hochberg method using a 
false discovery rate of  0.05. Random Forest analysis was used to predict HBeAg 
status. Genetic diversity was measured using Shannon entropy 244.
resUlts
Characteristics of  the study cohort 
The baseline characteristics of  the 186 chronic hepatitis B patients used in this 
study are summarized in Table 1. The patients included 128 males and 58 females, 
with a mean age of  35 ± 13.5 years (mean ± sd). Eighty-seven of  the patients 
were HBeAg negative (HBeAg-) and 99 were HBeAg positive (HBeAg+), with a 
mean serum HBV DNA level of  6.7 log IU/ml (range, 3.5 log IU/ml to 9.85 log 
IU/ml). In total, 186 HBV samples were analyzed for viral quasispecies diversity, 
of  these 58 were of  genotype A, 19 of  genotype B, 44 of  genotype C, 63 of  
genotype D and 2 of  genotype E (Table 1).
HBV quasispecies variants diversity
The HBV full-genome sequences were analyzed for quasispecies variants diversity. 
A total of  4,615 single nucleotide variants were found across the full-length HBV 
genome of  all sequences. These variants were present at a threshold of  ≥1% and 
found at least in one patient. There is sufficient evidence for differences in variant 
diversity between genotypes (A to D) (Figure 1). Genotype A samples had on 
average 171 variants; the majority of  variants appeared in fewer than 10 patients 
with most variants (n = 987) only found once across all patients. In contrast, 
samples consisting of  genotype B had on average 207 variants. There was a trend 
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(p =0.054) towards a significant difference between genotype A and B in the mean 
number of  variants per patient. There were a similar number of  variants found 
in each patient for genotype C (average 153 variants) and genotype D (average 
132 variants). Genotype D had significantly fewer variants per patient than either 
genotype A or B. Only n = 208 variants were found to be shared across genotypes 
A-D. For all genotypes, HBV variant diversity across the genome was higher in 
HBeAg negative patients than HBeAg positive patients (Figure 2). 
Table 1. Baseline characteristics of  Patients
Characteristics Value, number (%)
Number of patients 186
Male 
Female
128 (68.8%) 
58 (31.2%)
Age, mean (±sd) 35 (13.5)
Route of transmission
Blood transfusion
Sexual contact
Vertical transmission
Unknown
Parental 
Needles, other
1
15
161
5
3
1
HBV genotype
 A
 B
 C
 D
 E
58
19
44
63
2
HBeAg (+)
HBeAg (-)
99 (53.2%)
87 (46.8%)
Log10 HBV DNA load IU/ml, mean (±sd) 6.7 (2.0)
Table 2 summarizes the 20 most frequent found variants at the nucleotide level 
and their ranks corresponding to a number of  variants exceeding 10% or 50%. 
The BCP variants G1764A and A1762T and PC stop codon variant G1896A 
are the most frequently observed ones. Similarly, the most frequently observed 
variants at the amino acid level were analyzed across the different regions of  the 
HBV genome (Table 3). Almost 50% of  the variants were seen in the polymerase 
region. The HBV variants harboring the W28* (G1896A) precore stop codon, 
K130M (A1762T), and V131I (G1764A) were among the most frequently 
observed variants.
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Figure 1. Normalized Shannon entropy variant diversity count per HBV genome position 
according to genotype. The box plot shows median values, upper and lower quartiles and the largest 
and smallest observations.
A   B  C   D    E A   B  C   D    E
Genotype
Genotype
HBeAg negative HBeAg positive
Figure 2. Normalized Shannon entropy  variant diversity count per HBV genome position 
according to HBeAg status. The box plot shows median values, upper and lower quartiles and the 
largest and smallest observations.
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Prediction of  HBeAg status using different HBV genome variants 
Predictive analysis using machine-learning methods allows fast data processing 
and real-time predictions. In this study, we used the Random Forest model to 
predict the HBeAg status from HBV quasispecies variants. Using this model, 
we 30 identified variants that can predict the HBeAg status with an accuracy of  
92% (Figure 3). The majority (66.7%) of  these variants were located in the basal 
core promoter/core region followed by surface region (23.3%). G1896A is the 
most important predictor, followed by G1899A, A1762T, G1764A, A1934T and 
T1753C. 
Table 2. The 20 most important variants at nucleotide levels and their ranks based on number 
of  variants exceeding 10% or 50%.
mutation Variants >10%, No. (rank)  Variants >50%, No. (rank)
G1764A 83 (1) 75 (2)
A2011G 82 (2) 81 (1)
C2570T 76 (3) 75 (2)
A1762T 74 (4) 66 (5)
A2095G 69 (5) 68 (4)
G1896A 67 (6) 54 (31)
A562C 63 (7) 63 (6)
T843C 63 (7) 63 (6)
C2540T 63 (7) 62 (8)
A1173G 62 (10) 61 (11)
T2009C 62 (10) 62 (8)
T2539C 62 (10) 62 (8)
G842A 61 (13) 61 (11)
G2439A 61 (13) 61 (11)
C2534A 61 (13) 60 (14)
T3099C 61 (13) 59 (16)
G2797A 60 (17) 60 (14)
A1026T 59 (18) 59 (16)
C1239T 59 (18) 59 (16)
C1306A 59 (18) 57 (20)
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Figure 3. Relative importance of  HBV variants to prediction of  HBeAg status. The plot 
indicates each variants contribution to the mean decrease in the Gini index.
Table 3. The 20 most important variants at amino acid level and their ranks based on number 
of  variants exceeding 10% or 50%.
Region Substitution >10%, number (rank) >50%, number (rank)
Pre core W28* 69 (1) 57 (13)
X V131I 66 (2) 57 (13)
Polymerase F78S 61 (3) 61 (1)
Polymerase M480L 61 (3) 61 (1)
Core G180E 60 (5) 60 (3)
Polymerase D45N 60 (5) 60 (3)
Polymerase H36N 59 (7) 59 (5)
Polymerase R164H 59 (7) 59 (5)
Polymerase S240G 59 (7) 59 (5)
Polymerase K248R 59 (7) 59 (5)
105
Hepatitis b virus quasispecies variants associated with Hbeag and viral load
C
ha
pt
er
 6
Table 3. The 20 most important variants at amino acid level and their ranks based on number 
of  variants exceeding 10% or 50%. (continued)
Region Substitution >10%, number (rank) >50%, number (rank)
Pre S1 R66G 59 (7) 59 (5)
Core V93M 58 (12) 58 (10)
Core P171Q 58 (12) 58 (10)
Polymerase F265L 58 (14) 56 (15)
Pre S1 D51H 58 (14) 58 (10)
X K130M 58 (14) 51 (26)
Polymerase N312S 57 (17) 54 (19)
PS2 T11A 57 (17) 54 (19)
Polymerase R230H 56 (19) 56 (15)
Polymerase S402T 56 (19) 56 (15)
Pre S1 V48I 56 (19) 56 (15)
Association of  quasispecies variants with patients HBeAg status 
Linear regression was used to analyze the association with the proportion 
variation found for a particular variant and the HBeAg status in the presence of  
multiple hypothesis testing. As depicted in Table 4 and Table S1 (not shown), the 
coefficient (slope) shows the gradient of  the linear regression, and mean is the 
average of  all patients for a particular nucleotide substitution. A positive value for 
the slope means that the mean variation in HBeAg+ is greater than those with 
HBeAg- while a negative slope means that the variation in HBeAg- is greater than 
HBeAg+. Based on this analysis, we found that fifteen mutations including the 
PC (G1896A, G1899A) and BCP (A1762T, G1764A, T1753C, C1653T) variants 
are significantly associated with HBeAg- status (Table 4). Similarly, seventeen 
variants were found to be associated with HBeAg+ (Table S1, not shown). The 
indicated results only include mutations for which the mean variation across all 
patients was at least 10%.
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Table 4. Linear regression analysis of  variants associated with HBeAg- in the presence of  
multiple hypothesis testing. Slope shows the gradient of  the linear regression (with a gradient 
<-0.2), mean is the average variation of  all patients for a particular nucleotide substitution.
Mutation Coefficient Mean P-value
G1896A* -0.685 0.304 <0.001
A1934T* -0.622 0.147 <0.001
G1899A* -0.575 0.156 <0.001
G2129C* -0.539 0.109 <0.001
T1753C* -0.483 0.131 <0.001
T2139C* -0.438 0.165 <0.001
C1653T* -0.437 0.123 <0.001
G1764A* -0.374 0.411 <0.001
G774A* -0.358 0.176 <0.001
C2245T* -0.309 0.102 0.012
A1762T* -0.285 0.359 <0.001
T2660G -0.283 0.101 0.029
T147C* -0.381 0.131 0.011
A111C* -0.269 0.155 0.009
G1727A* -0.249 0.198 0.009
T1912C -0.236 0.130 0.031
T2167C -0.221 0.234 0.012
T2507A -0.219 0.195 0.019
C1773T -0.218 0.145 0.043
C820T* -0.213 0.268 0.011
* Statistically significant in the presence of  multiple hypothesis testing based on the Benjamini-
Hochberg method using a false discovery rate of  0.05.
Variants associated with HBV DNA load 
Quasispecies variants were analyzed for possible association with HBV viral load 
of  the patient. There were n = 22 variants that had a significant association (p 
<0.05) with HBV DNA load when 10e4 IU/ml (<20,000 IU/mL was used as a 
threshold) used as a threshold to define high versus low status (Figure 4); 10e4 
represents the lower end of  the range for the definition of  chronic hepatitis in 
HBeAg positive samples in the EASL guidelines. Some of  the variants that have 
a significant association with low viral loads include the PC (G1896A, G1899A) 
and BCP (A1762T, G1764A, T1753C, C1653T) variants. Interestingly, those 
variants that are highly associated with HBeAg-negative are exhibiting low viral 
load, indicating a correlation between HBeAg and low viral loads. 
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DiscUssion 
Understanding the diversity of  HBV genome, and identifying quasispecies 
variants that are associated with patients clinical characteristics are important for 
the management of  chronic HBV infections. In light of  this, we investigated 
HBV quasispecies variants and their associations with relevance to clinical 
characteristics of  the patients using a full-genome deep-sequencing approach. We 
identifi ed a total of  4615 different variants that appear at least in one patient at a 
threshold of  1% across the whole HBV genome. There is suffi cient evidence for 
a difference in variant diversity among different genotypes (A-D), with genotype 
A and B show a greater range of  variants across patients. Overall, genotype A 
shows n=989 unique variants. Of  the 4615 variants that were identifi ed across the 
whole data set only n =208 were found in genotypes A-D. The greatest number 
of  shared variants was between genotypes A and D (n=759). Interestingly, for all 
genotypes, HBV variant diversity across the genome was higher in viruses from 
HBeAg- negative patients than HBeAg-positive patients. 
It is well-known that the presence of  HBeAg in serum is a marker of  high levels 
of  virus replication and infectivity while its seroconversion is used as a critical 
endpoint of  treatment or clearance of  the virus 245. However, different mutations 
in the HBV genome may cause HBeAg-negative chronic hepatitis, in which 
replicative infection continues and HBV viral load remains detectable. In this 
study, we identifi ed more than 15 HBV variants that are signifi cantly associated 
with HBeAg-negative patients. As expected, the uppermost variant was G1896A 
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Figure 4: HBV DNA load (log10 IU/ml) using log10 4 IU/mL as a threshold for high or low 
HBV DNA load status. There was a signifi cant difference between the mean HBV DNA load for 
high and low status (p < 0.001).    
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followed by variants including G1899A, A1762T, G1764A, A1934T, and T1753C. 
The G1896A variant is a G-to-A mutation at nucleotide1896, which creates a 
premature stop codon and results in complete loss of  HBeAg synthesis. Some 
reports indicated that patients who undergo HBeAg seroconversion are more 
likely to have improved long-term outcomes, including disease remission, lower 
cirrhosis and HCC incidence, and increased survival rates 246,247. Nevertheless, 
this is not the case in HBeAg negative patients with the G1896A PC mutation. 
For instance, it has been shown that patients harboring this mutant continue to 
synthesize HBV DNA at sufficient levels that eventually lead to the progression of  
liver disease to a more advanced stage 185,248. Similarly, the BCP A1762T/G1764A 
mutant variants increase the risk of  liver cirrhosis and HCC development 65,71. 
BCP variants do not result in absolute HBeAg negativity compared to the PC 
variant, rather cause a substantial decrease in HBeAg production (~70%) and 
an apparent increase in viral replication 65. As the loss of  HBeAg alone can’t be 
indicative of  viral clearance or disease remission, it is of  utmost importance to 
screen viral variants that are associated with HBeAg-negative and have a clinical 
impact.
The prediction of  HBeAg status using different groups of  HBV genome 
variants was assessed in the present study. To our knowledge, this is the first 
such study although HBV variants were previously used to predict the significant 
fibrosis in HBV patients, which unveiled the risk of  having significant fibrosis 
was independently associated with the presence of  PC and BCP variants and 
suggested that detection of  these variants may be helpful for monitoring of  
fibrosis 249. Importantly, we identified at least thirty viral variants that can predict 
the HBeAg status, with G1896A being the most powerful predictor. The next most 
important predictors are variants of  the basal core promoter and precore regions 
including G1899A, A1762T, G1764A, A1934T, and T1753C. Interestingly, all of  
these variant results in a nonsynonymous substitution and with the exception of  
A1934T, the variant we found in association with both HBeAg and low viral load, 
their clinical importance is well studied 71,185. Our results show that in the absence 
of  the well-known variants, G1899A, A1762T, G1764A, other variants could 
contribute to HBeAg reduction and therefore helpful in monitoring patients in 
the clinics. 
Lastly, we evaluated HBV variants that are associated with baseline HBV 
DNA levels of  the patient. We found twenty-two variants that were significantly 
associated with low viral load. The well-known PC (G1896A) and BCP (G1764A, 
A1762T) variants were highly associated with low viral loads when 10e4 IU/
ml used as a threshold to define high versus low status. Although there have 
been reports regarding the association of  BCP and PC mutants with HBV viral 
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loads, the association remains controversial: no correlation 243, associated with 
high viral loads 250, associated with low viral loads 251,252. In addition, other variants 
(G1899A, A1934T, G2129C, T2139C, T1753C, C1653T, C2093T) of  the precore 
and core region of  the HBV genome were also found to be associated with low 
viral loads. Interestingly, these variants are significantly associated with HBeAg-
negative, indicating a correlation between HBeAg and viral load.
In conclusion, with a full-genome deep-sequencing approach we identified 
several viral variants in different HBV genomic regions to be significantly 
associated with baseline levels of  viral loads and HBeAg status. It is interesting 
to note that 30 variants, including the well-characterized G1896A, A1762T, and 
G1764A, predicated HBeAg status with 92% accuracy as seen in this study. 
Hence, having a high-quality HBV genome deep-sequencing data can provide 
novel insight into HBV quasispecies diversity and its relationship to patient 
clinical characteristics.
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abstract
Current standard-of-care treatment of  chronically infected hepatitis C virus 
(HCV) patients involves direct-acting antivirals (DAA). However, concerns exist 
regarding the emergence of  drug -resistant variants and subsequent treatment 
failure. In this study, we investigate potential natural drug-resistance mutations in 
the NS5B gene of  HCV genotype 1b from treatment-naïve patients. Population-
based sequencing and 454 deep sequencing of  NS5B gene were performed 
on plasma and liver samples obtained from 18 treatment- naïve patients. The 
quasispecies distribution in plasma and liver samples showed a remarkable overlap 
in each patient. Although unique sequences in plasma or liver were observed, in 
the majority of  cases the most dominant sequences were shown to be identical 
in both compartments. Neither in plasma nor in the liver codon changes 
were detected at position 282 that cause resistance to nucleos(t)ide analogues. 
However, in 10 patients the V321I change conferring resistance to nucleos(t)ide 
NS5B polymerase inhibitors and in 16 patients the C316N/Y/H non-nucleoside 
inhibitors were found mainly in liver samples. In conclusion, 454-deep sequencing 
of  liver and plasma compartments in treatment naïve patients provides insight 
into viral quasispecies and the pre-existence of  some drug-resistant variants in the 
liver, which are not necessarily present in plasma.
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introDUction
Hepatitis C virus (HCV) is a positive-strand enveloped RNA virus, classified in 
the genus Hepacivirus, family Flaviviridae. This virus displays very high genetic 
variability, a primary problem for the development of  an effective HCV vaccine 
and an explanation for the emergence of  resistance during antiviral therapy. 
Accumulation of  nucleotide substitutions in the virus has resulted in diversification 
into numerous subtypes and distinct genotypes 95,253. The genetic diversity is due 
to an error-prone RNA-dependent RNA polymerase, which generates on average 
1.7 × 10-3 base substitutions per site per year, a high virion production rate (up 
to 1 × 1012 particles produced per day), recombination, and deletion 218,254,255. 
Consequentially, mutations including those associated with drug resistance are 
spontaneously generated many times daily in each patient and drug-resistant 
variants, therefore, may already pre-exist as a minor population within a pool of  
closely related virus variants called quasi-species 256,257. 
Until recently, the only treatment for patients with chronic hepatitis C was a 
combination of  pegylated interferon alpha (Peg-IFN) and ribavirin (RBV), shown 
to be relatively ineffective with a viral eradication rate of  approximately only 50% 
258. Besides, this antiviral therapy is associated with numerous side effects, which 
excluded up to 50% of  patients upfront from antiviral therapy 259. There is a clear 
medical need for more efficacious therapies, and nowadays, several novel direct-
acting antivirals (DAAs) that target NS3/NS4A protease, NS5B polymerase and 
NS5A protein either combined with Peg-IFN/ RBV or IFN-free combinations 
of  DAAs have shown potent antiviral effects resulting in high cure rates in 
HCV- infected patients 260-262. Antiviral therapy suppressing the wild-type virus 
but not the pre-existing resistant minority viruses, in due process, may function 
as a positive selective pressure leading to the rapid outgrowth of  drug-resistant 
variants 263-267. 
The most common method of  detecting drug-resistant variants in HCV-infected 
patients is population-based Sanger sequencing. Using standard Sanger sequencing 
methods, the abundant HCV diversity in chronically HCV-infected patients cannot 
be fully mapped as relevant proportions of  minority variants can be missed 262. 
Deep sequencing (DPS), however, now allows for identification of  rare minority 
drug-resistant human immunodeficiency virus variants which are not detectable 
by standard sequencing techniques 268,269, and recent studies also identified minor 
drug-resistant variants in plasma of  HCV-infected patients 262,264-267. In this study, 
we developed a DPS approach to obtain insight into HCV NS5B viral quasi-species 
and the presence of  drug-resistance associated NS5B variants in the plasma and 
liver tissue of  treatment naïve chronic HCV infected patients. 
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resUlts
Validation of  the deep sequencing assay 
To allow analysis of  HCV quasi-species in liver and plasma of  HCV-infected 
treatment-naïve patients and in-depth analysis of  the presence of  drug-resistant 
HCV variants, a DPS approach was developed to analyze a 339 bp nucleotide 
genome fragment spanning amino acid positions 226 to 337 of  the NS5B region. 
The frequency and nature of  potential errors were analyzed by comparing DPS 
sequence reads of  an HCV-1b NS5B plasmid to a consensus sequence obtained 
from the same construct by Sanger sequencing. To examine errors introduced 
by PCR and DPS, the plasmid was quantified and diluted to 106 copies per 
ml, amplified by conventional PCR, and sequenced using the deep sequencing 
protocol. The contribution of  reverse transcription to the error rate of  the 
protocol was analysed using RNA synthesized from the plasmid, after which 
cDNA, PCR, and 454-sequencing were performed.
The raw sequence data generated in these experiments contained many errors, 
not uniformly distributed over the amplified region (Figure 1A). Especially GC-
rich areas in the sequence (8 to 11 bp GC-rich stretches) led to an increased 
number of  insertions and deletions. A position-specific error rate per nucleotide 
was determined before read-cleaning algorithms were applied for the control 
experiments (Figure 1A). The average error rate before read cleaning in all 
six experiments across the amplicon was similar and ranged from 0.3-0.34%, 
with on average 1.02-1.16 errors per read. The average error rate after read 
cleaning in all six experiments across the analyzed amplicon was more dissimilar 
although not significantly different, ranging from 0.014-0.018% for plasmids 
and 0.0023-0.0065% for transcripts (Figure 1A). On average, every read retained 
0.04-0.06 (plasmids) and 0.008-0.02 (transcripts) errors. These data indicate 
that most sequencing errors were introduced by PCR and DPS and not by 
reverse transcription. Similarly, position-specific error rates per amino acid were 
determined for translated amino acid sequences from the cleaned reads in the 
six control experiments (Figure 1B). The average error rate after read cleaning 
was 0.042-0.056% errors per amino acid for plasmids (0.14-0.19 errors per 
translated read on average) and 0.010-0.021% for transcripts (0.03-0.1 errors per 
translated read on average) (Figure 1B). This suggests that error introduction 
through the deep sequencing protocol is less pronounced when starting from 
RNA transcripts compared to plasmid DNA, although differences did not reach 
statistical significance. 
The read cleaning approach aims to purge errors potentially caused by DPS (but 
not by PCR or reverse transcription). To examine the effectiveness of  the deep 
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Figure 1. Validation of  the next-generation sequencing assay.  (A) A position-specific error rate 
per nucleotide was determined before or after read-cleaning algorithms were applied for the control 
experiments with plasmid (P) or RNA transcript (T) in 3 independent next-generation sequencing 
experiments (1-3) each. Mean ± sem are shown. (B) For confirmation, a position-specific error rate 
per amino acid position was determined after read-cleaning algorithms were applied for the control 
experiments with plasmid (P) or RNA transcript (T) in 3 independent next-generation sequencing 
experiments (1-3) each. Mean ± sem are shown. (C) Haplotypes and their frequencies in the dataset 
after read-cleaning were determined for the control experiments with plasmid (P) or RNA transcript 
(T) in 3 independent next-generation sequencing experiments (1-3) and plotted against each other 
with a cut-off  value of  0.1%.
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sequencing analysis, two sets of  reads with different 454-specific error profiles 
were artificially simulated from the sequence of  the plasmid. Before read cleaning, 
the average error rate of  the simulated reads was 0.77% and 3.2%, respectively, 
thereby exceeding the number of  errors effectively encountered in the six control 
experiments. After analysis, all errors were removed (average error rate of  ~0% 
at every position, not shown), indicating the effectiveness of  the read cleaning 
approach in the removal of  errors that are typically associated with the deep 
sequencing technique.
For haplotype reconstruction, the set of  reads after read cleaning was 
translated into amino acid sequences and analyzed for redundancy (Figure 1C). 
One dominant haplotype was encountered in these control experiments, with a 
frequency of  ~90%. Multiple minor haplotypes that are generated by remaining 
sequencing errors, which together add up to ~10%, are still present. Most of  these 
errors occur in less than 0.1% of  the reads but at certain amino acid positions 
especially in the control experiments starting from the plasmid DNA, a haplotype 
generated by sequencing error can occur in percentages as high as ~2.5% of  the 
total cleaned read population (Figure 1C). 
As the error rates per nucleotide position are highly diverse, it is unreliable 
to define a cut-off  value based on average error rate per nucleotide position. 
Instead, each nucleotide or amino acid position should be evaluated separately, 
which can be achieved for specific positions of  special interest, for example, 
known drug resistance positions. If  the variation across the entire genome is 
of  interest, another type of  analysis with reconstruction of  haplotypes can be 
performed and the cut-off  value can be determined based on data from control 
experiments with plasmid DNA or RNA transcripts, which in our case was placed 
at a haplotype threshold frequency of  1% (Figure 1C).
Analysis of  HCV quasispecies in liver and plasma of  chronically HCV-
infected patients
The HCV quasispecies in liver tissue and plasma from eighteen chronically 
infected, untreated individuals infected with HCV-1b were analyzed using DPS. 
All samples were successfully amplified by the NS5B nested-PCR method. The 
number of  RNA molecules subjected to cDNA synthesis was not significantly 
different between plasma and liver samples (data not shown). Phylogenetic analysis 
of  either nucleotide or amino acid consensus sequences determined by Sanger 
sequencing revealed that plasma and corresponding liver sequences clustered 
together (Figure 2). After DPS, we obtained a total of  862,618 reads from 18 
paired liver tissue and plasma samples with a median number of  reads per sample 
of  ~24,000 (range 8,605 to 37,164, Supplementary Table S3). Subsequently, the 
117
Identification of HCV resistant variants against direct acting antivirals
C
ha
pt
er
 7
data were cleaned and corrected for DPS sequencing errors to obtain relatively 
error-free reads. During this process, reads were discarded from each sample and 
a median of  ~23,000 (8,400 to 36,292) reads remained for each sample. 
For haplotype reconstruction, the set of  corrected reads after read cleaning 
was translated into amino acid sequences and analyzed for redundancy. The 
frequency of  the haplotypes was determined by counting the number of  amino 
acid sequences with an identical sequence. Most haplotypes in each sample were 
found at very low frequencies (less than 0.1%). Based on our control experiments 
with plasmid DNA and RNA transcripts, these haplotypes could be generated 
through sequencing errors, not cleaned from the reads. To achieve comparability 
between the different samples while maintaining a concise number of  haplotypes, 
Fig. 2  
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Figure 2. Phylogenetic analysis of  the partial NS5B consensus nucleotide (A) and deduced 
amino acid (B) sequences from plasma and corresponding liver biopsies from HCV patients. 
Phylogenetic trees were generated using MEGA5, with the neighbour-joining method with p-distance 
model and 1,000 bootstrap replicates. Bootstrap values are shown. The different patients are indicated 
by colour, shape, and numbering with liver (L) and plasma (P) sequences indicated.
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only haplotypes occurring at a frequency of  1% or more were taken into account 
for further phylogenetic and population analyses (Figure 1C). On average, 5.8 
(range 2 to 14) and 4.6 protein haplotypes (range 2 to 7) were observed per liver 
or plasma sample, respectively. These haplotypes represented 79.3% of  the whole 
population of  sampled reads (Supplementary Table S3). Each sample consisted 
of  one or two major protein haplotypes and several minor protein haplotypes 
(Figure 3). In almost all patients, the most prevalent haplotype in plasma was also 
present in the liver (Figure 3), except for patient 3, consistent with the results 
presented in Figure 2A. Compartment unique sequences were observed in all 
patients (Figure 3). The Simpson’s diversity index of  the haplotype population was 
estimated, considering the number of  haplotypes, the total number of  sequences, 
and the proportion of  the total number of  reads found for each haplotype. The 
diversity index in both compartments was found to be comparable for most 
patients analyzed (Supplementary Table S3). 
Figure 3. The number and variation of  HCV haplotypes in 18 paired liver and plasma samples. 
The graphs indicate the number and frequency of  each haplotype with a cut-off  of  a frequency of  
1% or higher per haplotype, per liver (yellow) and plasma (red) sample of  each patient (indicated by a 
number above the graphs).
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Variability at drug resistance positions 
To determine whether NS5B gene drug-resistant variants pre-existed, specific 
codon positions implicated in resistance to NS5B inhibitors or associated with 
response to IFN/ribavirin treatment were analyzed. To note that within the region 
analyzed, codon positions 282, 316, and 321 have been implicated in resistance 
to NS5B inhibitors 261,270-272; the S282T mutation, for example, confers resistance 
to 2’-modified nucleotide analogues including the recently approved sofosbuvir. 
In our patient cohort, no codon changes from S282 (cut-off  position-specific 
error rate 0) were detected either in plasma or in the liver by either Sanger or 
deep sequencing (Supplementary Table S4). Sanger sequencing did detect C316N, 
C316Y, and/or C316H mutations in 9 patient liver and/or plasma samples (50%), 
whereas deep sequencing detected such a mutation as minor variant in an additional 
7 patients in liver and/or plasma samples (89%) with a cut-off  of  0.2% based on 
the position-specific error rate determined in the control experiments (Figure 4 
and Supplementary Table S4). The V321I substitution was detected by Sanger 
sequencing in 1 patient (5.6%) and deep sequencing detected this mutation as a 
minor variant in 10 patients (55.6%) with a cut-off  of  0 based on the position-
Figure 4. The number and variation of  HCV haplotypes in 18 paired liver and plasma samples. 
The graphs indicate the number and frequency of  each haplotype with a resistance mutation. The 
upper bars indicate the liver samples, whereas the lower bars represent plasma samples from the same 
patient (indicated by a number above the graphs). The colours represent different variants: Black, 
C316N; Red, C316H+V321I; Blue, Q309R; Cyan, C316N+Q309R; Yellow, C316Y+Q309R. Only 
haplotypes with a cut-off  of  a frequency of  1% or higher per haplotype are depicted.
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specific error rate determined in the control experiments (Supplementary Table 
S4). Of  interest, double mutations of  C316H and V321I were observed in 2 
patients in liver and/or plasma samples.
We analyzed six additional codons (310, 329, 244, 309, 326 and 333) that 
have been associated with a decreased response to IFN/ribavirin therapy 
(Supplementary Table S4), although none of  these variants have been confirmed 
to be associated with virologic treatment outcome and nothing is known about 
potential functional associations with the mechanism of  action of  interferon and/
or ribavirin 273-275. All codon positions showed a position-specific error rate in the 
control experiment of  0, except for position 333 for which the specific error rate 
was 0.4%. The A333E mutation was not encountered in any of  the patients. The 
D310N mutation was found in 9 liver and 8 plasma samples as a minor variant 
in a total of  11 patients. The D244N mutation was found in 5 liver and 9 plasma 
samples as a minor variant in a total of  10 patients, whereas the S326G mutation 
was found in 8 liver and 9 plasma samples as a minor variant in a total of  12 
patients. The T329I mutation was observed in 11 liver and plasma samples from 
11 patients and the Q309R mutation was found in 14 liver and plasma samples 
as a minor variant and in 4 patients as a major variant. The Q309R mutation 
was found in conjunction with C316 mutations in three patients. Overall, 22/198 
variants were detected in the liver but not in the plasma whereas less unique 
variants were observed in the plasma (12/198). 
DiscUssion
In this study, a deep sequencing approach was developed and validated to 
analyze liver and plasma HCV NS5B quasi-species and drug resistance-associated 
variants from eighteen treatment naïve patients. We optimised DPS protocols, 
data cleaning, and error correction strategies using a reference plasmid as input. 
The data indicated that the intra-assay precision was very high and that most 
sequencing errors were introduced by PCR and deep sequencing and not by 
reverse transcription. Although the average error rate after read cleaning was 
very low in the control experiments, ~0.01% and ~0.03% on the nucleotide 
and amino acid level, respectively, the range of  the error rates per nucleotide 
or amino acid was 0%-3%. Similar observations in control experiments with a 
similar deep sequencing platform for HIV-1 quasi-species analysis were obtained 
previously 268,269. Thus, each nucleotide- or amino acid-specific position should 
be evaluated separately, which can be achieved for specific positions of  special 
interest, for example, known drug resistance positions. For the analysis of  NS5B 
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quasi-species in liver and plasma, haplotypes were reconstructed and based on the 
control experiments, a conservative cut-off  was placed at a haplotype frequency 
of  1%. Interpretation of  the data generated in this study requires some caution 
as the liver needle biopsy specimen may not be representative for an entire liver. 
HCV quasi-species diversity has been implicated to play a role in HCV clearance 
and disease progression with a limited diversity being favourable for HCV 
clearance but not for disease progression 276-279. In the majority of  patients, the 
most prevalent haplotype(s) were identical in plasma and liver but compartment 
unique sequences were observed as reported previously 256,263,280-284. Comparison 
of  the Simpson’s diversity index showed that the extent of  diversity was relatively 
similar between the liver and plasma compartments per patient in 15 patients. A 
deterministic evolution selecting for the fittest (dominant) strain can be envisaged, 
based on the apparent presence of  the same dominant haplotypes in both plasma 
and liver in most patients. Although the absence of  a unique minority haplotype 
from plasma does not imply the absence of  that haplotype in the liver and vice 
versa, quite a number of  compartment unique haplotypes were obtained. Two 
hypotheses may explain these observations. One possible explanation could be 
that extrahepatic HCV replication occurs or a constant and dynamic flow of  viral 
minority quasi-species between the two compartments, plasma and liver, may not 
occur. Alternatively, minority haplotypes are being generated in some liver areas, 
but their fitness constraints apparently do not allow them to occupy a large part 
of  the sequence space and therefore are not detected in plasma.
A new era in HCV therapeutics has arrived with the development of  direct-acting 
antivirals therapy and the management of  antiviral resistance. We determined 
whether pre-existing direct-acting antiviral drug resistance mutations in NS5B in 
plasma and liver tissue of  treatment naïve chronic HCV infected patients occurred. 
Already quite a number of  drug resistance mutations have been described using 
in vitro selection protocols or in vivo, among which the S282T, C316N,H, Y, and 
V321Y mutations confer resistance to NS5B (non)-nucleoside inhibitors 270-272,285. 
The NS5B S282T variant is associated with a decrease in replicative fitness in 
vitro and has hardly been yet encountered in clinical trials in patients 270,272,286-288. 
For instance, in a recent comprehensive analysis of  1344 HCV isolates focussing 
on the NS5B gene, S282T was present in just one isolate for each genotype 1a, 
1b, 3, and 4 at frequencies of  0.17%, 0.24%, 1.24%, and 1.63%, respectively 289. 
In our cohort of  treatment-naïve patients, the S282T mutation was not detected 
not even as a minority variant either in plasma or liver tissue. However, the other 
nucleos(t)ide inhibitors resistant variant V321A was detected in 10 out of  18 
patients (~56%) mainly as minority haplotypes. As non-nucleoside inhibitors 
bind more distantly to the active site of  NS5B, resistance-associated variants 
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often occur more frequently with these compounds 290. Mutations that confer 
resistance to non-nucleoside inhibitors at position 316 in NS5B in vivo have been 
described in treatment-naïve patients at frequencies of  0.19% - 24% by Sanger 
sequencing analyses 274,291-293. We noticed this mutation in 16 out of  18 patients 
(~89%) either as dominant (50%) or minority haplotypes (39%). These values are 
much higher than those obtained with Sanger sequencing and suggest that the 
presence of  certain drug-resistant variants prior to treatment and minority variants 
are relatively high. In addition, variants containing two mutations in the same 
genomic strand involved in drug resistance against different compounds were 
encountered. Two patients showed mutations described in conferring resistance 
to non-nucleoside compound HCV796 and PSI-352938, a cyclic monophosphate 
prodrug of  2’-alfa-F-2’-beta-C-methylguanosine. Double mutants in position 
C316, involved in resistance against compound HCV796, and Q309R, which is 
associated with a decreased response to IFN/ribavirin therapy, were also detected 
in two patients. In three out of  four patients, the double mutant haplotype was 
also the dominant haplotype. As drug-resistant mutations can confer a decrease in 
viral fitness compared to wildtype viruses, it is surprising that they were observed 
as dominant haplotype in all patient. Possibly compensatory mutations may 
have evolved in these viruses to increase viral fitness. Unlike deep-sequencing 
platforms with very short read lengths, such as Illumina, our 454-sequencing 
approach provides the opportunity to look at the linkage of  mutations and 
identification of  double-resistant virus variants, provided that they are located in 
the same amplicon. 
Several other mutations associated with resistance to response to IFN/
ribavirin therapy were observed at much higher frequencies in DPS than with 
Sanger sequencing approaches 273-275. The D244N, S326G, T329I, and D310N 
mutations were encountered as a minority variant in 10-12 patients (~60%). The 
Q309R mutation was encountered most frequently (in all patients) and even as 
a major haplotype in 4 patients, which is similar to previous observations 274. 
However, when we analysed the presence of  drug resistance populations in both 
compartments we noticed that for mutations at most positions with discrepancies 
between plasma and liver, the prevalence of  the resistant variants was higher in 
the liver as compared to plasma. Thus, the use of  plasma is most likely sufficient 
to detect HCV quasispecies and drug-resistance associated variants. However, 
additional studies with large cohorts of  paired samples, including analysis of  
other genome regions targeted by DAAs would be needed to reveal the clinical 
implications of  the findings. Overall, our data thus provide insight into the HCV 
NS5B quasi-species population in liver and plasma in treatment-naïve patients 
obtained through state-of-the-art sensitive sequencing technologies. 
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materials anD metHoDs
Patients and samples
A total of  eighteen patients chronically infected with HCV genotype 1b (HCV-
1b) and naïve to direct-acting antivirals (DAAs) treatment were included. Plasma 
samples and liver biopsies were obtained and stored at -80°C and RNAlater, 
respectively, until testing. The baseline clinical characteristics of  patients are 
summarized in Supplementary Table S1 online. The amount of  HCV RNA was 
determined by RT-PCR using Cobas Amplicor HCV Monitor version 2.0 (Roche 
Diagnostics, Branchburg, NJ) and HCV genotype was determined using INNO-
LiPA HCV II (Innogenetics N.V., Ghent). All experimental protocols in this 
study was approved by the institutional ethics committees of  Erasmus Medical 
Center, Rotterdam, the Netherlands. Informed consent was obtained from all 
subjects. All methods were performed in accordance with the relevant guidelines 
and regulations. Paired liver biopsies and plasma were only available from patients 
infected with genotype 1b in accordance with the approved study protocol for 
these specific patients.
Viral RNA isolation, cDNA synthesis and PCR amplification
Viral RNA was extracted from 140 to 280 µl of  plasma using the QIAamp viral 
RNA mini kit (Qiagen) and from liver biopsies (approximately 10 mg tissue was 
used) using RNeasy mini kit (Qiagen) and the RNA was eluted with 40 µl buffer 
according to the manufacturer’s instructions. To ensure a sufficient amount of  
viral copies for reliable detection of  minor variants, the number of  HCV RNA 
copies in the extracted RNA sample was determined by real-time quantitative 
polymerase chain reaction (qPCR). Ten microliter RNA was reverse transcribed 
with the Superscript III first-strand synthesis system (Invitrogen Corp) using 
random hexamers. The cDNA was used to amplify a 401 bp nucleotide genome 
fragment spanning amino acid positions 215 to 348 (nucleotides positions 8242 
to 8642 according to GenBank accession no AJ238799) of  the HCV NS5B 
polymerase gene with a nested PCR approach using the Hotstar Hifidelity Taq 
DNA polymerase (Qiagen). Both PCRs were carried out as follows: one initial 
denaturation step of  95°C for 5 min, followed by 35 cycles of  95°C for 30 s, 48°C 
for 30 s, 72°C for 40 s and a final extension of  72°C for 10 min. The primers 
used were, external sense primer Pri3, external antisense primer Pri4, inner sense 
primer Pri1, inner antisense primer Pri2 200. The inner sense and antisense primers 
were linked to DPS adapters A and B, respectively. To distinguish each sample 
in the multiplexed DPS, eight unique sequence tags were inserted between the 
adapter and the gene specific primer (Supplementary Table S2).
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454 deep sequencing 
PCR amplicons were purified from gel using the QIAquick gel extraction kit 
(Qiagen) and extracted DNA was again purified using Agencourt AMPure XP PCR 
purification system (Beckman Coulter). The quality and length of  the amplicons 
were verified using Agilent 2100 bioanalyzer (Agilent Life Science, Santa Clara, 
California) and the concentration was quantified using Quant-iT PicoGreen 
dsDNA Reagent (Invitrogen) on a TECAN fluorometer (TECAN infinite 
F200). After quantification, amplicons were pooled in equimolar concentrations, 
followed by emulsion PCR (emPCR) and bead enrichment according to the 454 
Titanium emPCR and enrichment bead recovery protocols (Roche), according 
to instructions of  the manufacturer. The enriched beads were sequenced in both 
forward and reverse direction on the 454 Life Science platform (454 GS Junior, 
Roche Applied Science) according to the manufacturer’s instructions.
Sanger sequencing 
To analyse the deep sequencing data and to verify the sample authenticity, the NS5B 
polymerase gene from all plasma and liver tissue samples were PCR amplified 
as described above and sequenced directly on both strands using the BigDye 
Terminator version 3.1 Cycle sequencing kit on an ABI PRISM 3100 genetic 
analyser (Applied Biosystems). To exclude contamination between samples, the 
Sanger sequences were used to reconstruct a neighbour-joining phylogenetic tree 
with MEGA 5.05 software using the p-distance model with gamma distributed 
rate across sites (α= 0.5) 294. Statistical support for internal branches in the tree 
was obtained by 1000 bootstrap replicates. The GenBank accession numbers of  
the sequences obtained in this study are KF730703-KF730738.
Determination of  errors introduced by reverse transcription, PCR and DPS
Errors caused by cDNA synthesis, PCR, or DPS are referred to as sequencing 
errors throughout the study. To quantify the frequency and nature of  potential 
sequencing errors, we synthesized an HCV-1b NS5B polymerase plasmid 
(GenBank accession No: AJ238799) with T7 promoter (Eurogentech, Belgium). 
To discriminate between synthetic plasmid and natural HCV sequences, we 
introduced two mutations in the evolutionarily very well-conserved GDD (GHH) 
motif  present in the active site for the HCV NS5B polymerase in the plasmid. To 
ensure this synthetic plasmid contained only one plasmid sequence, E.coli bacteria 
were transformed and a plasmid was isolated from a single bacterial clone. The 
sequence of  the plasmid was confirmed by Sanger sequencing. 
To assess the error rate of  the polymerases in PCR in combination with DPS, 
the plasmid was quantified using Quant-iT PicoGreen dsDNA reagent, diluted to 
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106 copies per ml (an input copy number similar to that of  HCV RNA in samples), 
and amplified by conventional PCR using the Hotstar Hifidelity Taq DNA 
polymerase (Qiagen). To measure the error rate of  reverse transcriptase, RNA 
was synthesized from the plasmid using RiboMAX large scale RNA production 
system SP6 and T7 (Promega Corporation, Madison, WI, USA). Subsequently, 
template DNA was digested with DNase1 and absence of  template plasmid in 
the RNA transcript was verified from serially diluted transcript using the nested 
PCR system as mentioned above. DNA-free RNA was reverse transcribed using 
the Superscript III reverse transcriptase and amplified by PCR using Hotstar 
Hifidelity Taq DNA polymerase (Qiagen). PCR amplified products were analyzed 
using the DPS protocol; the entire procedure from sample preparation to DPS was 
repeated three times in the two experiments using plasmid DNA or transcribed 
RNA. 
Deep sequencing data analysis
The deep sequencing reads were sorted into their sample of  origin according to 
their unique sequence tag in the primers (Supplementary Table S2). The primer, tag, 
and adapter sequences were trimmed from the reads. If  an average Phred quality 
score lower than 12 was encountered in a window of  four bases across a read, 
the low-quality bases were removed and the read split at the respective position. 
Remaining reads were kept if  they were longer than 200 bases. The trimming 
procedure was performed with scripts written in the Python programming 
language (Python 2.7.3) using Biopython tools (version 1.5.9) 295.
Reads of  each sample were aligned to the respective reference sequence with 
MOSAIK (version 1.3.88, https://code.google.com/p/mosaik-aligner/) as 
implemented in runMosaik.pl provided in ReadClean454 v1 (RC454) 296. Aligned 
reads were corrected for homopolymer stretch polymorphisms (in homopolymers 
larger than 2N), for ‘carry forward and incomplete extension’ (CAFIE) errors 297 
and for insertion and deletions (InDels) causing frameshifts if  they occurred in 
less than 25% of  the reads with RC454. The corrected reads were passed to 
V-Phaser v1.0 298, which combines information regarding covariation (“phasing”) 
in reads and an expectation maximization algorithm. Nucleotide and amino acid 
frequency tables were extracted with V-Profiler 296. The amount of  variation in 
the deep sequencing reads per nucleotide or translated amino acid position was 
derived from the frequency tables. Variations were considered as such if  at least 
two high-quality reads exhibited the variant. 
The average percentage of  variation was determined for the entire amplicon 
of  the control experiments. Furthermore, the variation per position encountered 
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before read cleaning, which included the errors that were subsequently cleaned, 
was compared to the variation per position after read cleaning.
Validation of  read cleaning by deep sequencing analysis
To assess the validity of  the read cleaning approach, two sets of  reads with 
different 454 deep sequencing-specific error profiles were simulated from the 
plasmid sequence using Mason methodology 299. First, 20000 reads were sampled 
with an error rate with the standard parameters of  Mason-454, resulting in an 
average of  2.6 errors per reads. Second, 20000 reads with a higher error rate were 
simulated, with an average of  10.8 errors per read. The simulated reads were 
subjected to deep sequencing analysis as described above and the variation after 
read cleaning determined.
Variant reconstruction
For haplotype reconstruction, the set of  corrected reads was analyzed for 
redundancy. The amplified product was sequenced as a single fragment; therefore, 
the frequency of  the haplotypes was directly estimated by counting the number 
of  reads with an identical sequence. Each read was translated in all three possible 
reading frames. Translated reads that contained either an undetermined amino 
acid or a STOP codon were excluded as these do not represent genuine viruses. 
To ensure comparability among the samples and to exclude haplotypes generated 
by sequencing errors, only haplotypes that occurred at a frequency of  at least 1% 
were selected for comparison. Alignments of  the amino acid haplotype with a 
frequency of  greater than or equal to 1% from liver and plasma of  each patient 
was performed with Muscle v3.7 and distribution of  haplotypes visualized using 
R statistical software version 2.13.1.
The diversity of  the haplotypes was estimated using Simpson’s index of  
diversity 1-D 300, which considers the number of  haplotypes, the total number 
of  sequences, and the proportion of  each haplotype of  the total number of  
sequences. This value ranges from 0-1 with 0 indicating low diversity and 1 
indicating high diversity. Samples were grouped based on the average Simpson’s 
diversity index per patient (liver and plasma) and were considered to have low and 
high diversity when Simpson’s diversity index ≤ 0.5 or > 0.5, respectively.
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sUPPlementary information
Supplementary Tables
Table S1: Patient characteristics at baseline
Patient Age (Years) Sexa
Serum viral load (IU/
ml) ALT Fibrosis
1 55 M 2.60 ×106 195 5
2 48 F 4.95 ×106 91 3
3 45 M 3.66 ×106 79 3
4 29 M 1.63 ×106 67 2
5 43 F 2.30 ×106 35 1
6 25 F 3.90 ×106 48 1
7 47 M 4.60×106 68 2
8 36 M 6.98 ×106 85 NA
9 54 M 1.71 ×106 107 4
10 54 M 4.20 ×106 59 3
11 37 F 7.81×105 31 3
12 45 F 1.65 ×106 43 0
13 53 M 1.84 ×106 19 1
14 39 M 5.13 ×106 86 5
15 27 M 1.65 ×106 61 2
16 21 M 4.81 ×105 65 1
17 31 M 2.23 ×106 41 NA
18 60 M 6.46 ×106 73 3
a M, male; F, female; NA, not available
Table S2: DPS primer sequence 
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Table S3: Amount of  HCV reads, haplotypes, and Simpson’s diversity index per liver (L) or 
plasma (P) sample of  each patient.
Patient No of reads
No of 
“cleaned” 
reads
No reads of 
haplotypes with 
frequencies of more 
than 1%
No 
haplotypes
Simpson’s 
Diversity Index
1L 16049 15650 13588 4 0.14
1P 17913 17540 15725 2 0.08
2L 18885 18411 16381 4 0.23
2P 18361 18010 16240 6 0.21
3L 14094 13672 8185 11 0.77
3P 27949 27102 23350 2 0.06
4L 27468 26241 21966 6 0.48
4P 29496 28706 23879 5 0.48
5L 29960 28893 23641 6 0.47
5P 31467 30685 24433 5 0.45
6L 25874 24743 19848 2 0.5
6P 26824 25742 21612 4 0.37
7L 29932 27883 22646 5 0.29
7P 27569 26828 21128 4 0.41
8L 24848 24111 21144 3 0.06
8P 21393 20198 16800 5 0.24
9L 17643 16750 10546 14 0.89
9P 21213 20267 15883 6 0.37
10L 13760 12948 9933 7 0.82
10P 26634 25865 21036 4 0.58
11L 16836 16013 13191 4 0.45
11P 24273 23343 19020 7 0.58
12L 14365 13498 12056 3 0.28
12P 22374 21430 18806 6 0.3
13L 17245 16327 14248 4 0.15
13P 23966 22655 19090 5 0.33
14L 33251 31536 24757 7 0.61
14P 36010 34662 28486 7 0.64
15L 28058 27543 24066 5 0.49
15P 37164 36292 31941 4 0.48
16L 32415 30081 22151 4 0.24
16P 22707 22075 19664 2 0.02
17L 28402 27409 21067 10 0.72
17P 25854 24885 21212 5 0.56
18L 8605 8400 7089 5 0.56
18P 23761 23209 19571 3 0.26
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Table S4: Detection of  HCV-NS5B resistant variants by DPS (% of  total cleaned reads). 
Pa
ti
en
t 
S2
82
T
C
31
6N
C
31
6H
C
31
6Y
V
32
1I
D
24
4N
Q
30
9R
D
31
0N
S3
26
G
T
32
9I
A
33
3E
cutoff 0 0.2 0.2 0.2 0 0 0 0 0 0 0.4
1L 0 99.9 0 0 0 0 0.23 0.02 0 0 0
1P 0 99.92 0 0 0 0 0 0 0 0 0
2L 0 0 0 0 0 0 0 0 0 0 0
2P 0 4.38 0 0 0.03 0 0.54 0 0 0 0
3L 0 65.66 3.12 5.63 0 0.02 5.82 0 0 0.02 0
3P 0 99.81 0 0 0 0 0.18 0.03 0 0.07 0
4L 0 99.93 0 0 0.02 0 0.11 0 0 0 0
4P 0 99.88 0 0 0 0.02 0.19 0.04 0.03 0 0
5L 0 20.77 0 0 0 0 0.25 0.22 0.03 0.04 0
5P 0 0 0 0 0.04 0.05 0.21 0.08 0.06 0.07 0
6L 0 99.92 0 0 0.02 0 0.35 0.88 0 0 0
6P 0 99.83 0 0 0 0 0.21 0 0 0 0
7L 0 0.28 0 0 0.02 0.11 0.51 0.02 0.02 0.08 0
7P 0 0 0 0 0.01 0.04 0.62 0.03 0.06 0.09 0
8L 0 0.34 0 99.47 0.03 0.07 99.53 0.07 0.02 0.14 0
8P 0 13.66 0.8 85.26 0 0.04 85.28 0.03 0.08 0.07 0
9L 0 11.55 43.91 1.39 0.02 0.01 2.42 0.2 0.17 0.2 0
9P 0 13.27 0 0 0 0.13 0.48 0.02 0.03 0.16 0
10L 0 73.55 0.64 0 0 0 0.9 0.1 0 0.12 0
10P 0 99.56 0 0 0 0.08 0.4 0 0.05 0.07 0
11L 0 0 0 0 0.03 0 0.68 0 0.07 0.03 0
11P 0 0 0 0 0 0 0.42 0.03 0.06 0.11 0
12L 0 0.3 0.65 0 0 0 0.16 0 0 0 0
12P 0 7.31 0 0 0 0.04 0.28 0 0.03 0 0
13L 0 0 1.7 0 0 0 94.17 0 0 0.01 0
13P 0 0 0 0 0 0 83.41 0 0.11 0.17 0
14L 0 0 97.41 0 0 0 2.53 0.09 0.28 0.05 0
14P 0 0 99.73 0 0.02 0.01 0.88 0.02 0 0.04 0
15L 0 99.93 0 0 0.03 0.09 72.61 0.02 0 0.85 0
15P 0 99.91 0 0 0 0.06 71.42 0 0 0.8 0
16L 0 99.84 0 0 0 0 0.25 0 0.05 0 0
16P 0 97.78 0 0 0 0 0.18 0 0 0 0
17L 0 2.9 0 0 0 0 94.69 0 0.01 0.03 0
17P 0 0.55 0 0 0 0 98.82 0 0 0.08 0
18L 0 0 0 0 0 0 0.23 0 0 0 0
18P 0 0 0 0 0 0 0.39 0 0 0 0
L, liver; P, plasma. Cut-off, position specific error rate determined in control experiments.
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Overview
Hepatitis B and C viruses are a major cause of  morbidity and mortality worldwide 
6. According to the World Health Organization (WHO) report, viral hepatitis 
caused 1.34 million deaths in 2015, a number comparable to annual deaths caused 
by tuberculosis but higher than those caused by either HIV or malaria 301. However, 
in contrast to these other three infectious diseases, viral hepatitis has received 
relatively little attention. Worldwide, only 9% of  HBV and 20% of  HCV infected 
individuals have access to affordable hepatitis testing. Even more worrisome is the 
fact that antiviral treatment is available for only 8% of  those diagnosed with HBV 
and 7.4% of  those diagnosed with HCV 301. This is even more problematic in 
countries like Ethiopia where more than 80% of  the population are living in rural 
areas with a very limited access to healthcare. Besides that, viral hepatitis has never 
been considered a health priority in Ethiopia due to a lack of  awareness and the 
fact that no national antiviral treatment and diagnostic guidelines or surveillance 
were developed. In addition, only in 2007, the universally available HBV vaccine 
was incorporated into the national neonatal immunization program in three doses 
of  pentavalent vaccine (DTP-HepB-Hib). Consequently, these viruses continue to 
spread and the burden remains substantial. On-top-of-that, both HBV and HCV 
exhibit high genetic diversity that affects clinical and treatment outcomes. Most 
importantly, this genetic diversity revealed by different genotypes, subgenotypes, 
subtypes, quasispecies, and recombinants, differs in geographic distribution 54,102. 
Therefore, for a proper management and prevention of  these viruses in Ethiopia, 
understanding their prevalence and genetic diversity is extremely important. In 
chapter 2 we investigated the seroprevalence of  HBV and HCV infection in 
Ethiopia. The molecular epidemiology and genetic diversity of  HBV in different 
geographic regions of  Ethiopia were described in chapter 3. The in-depth 
complete genome analyses of  important and selected strains were determined in 
chapter 4. The genetic diversity of  HCV in Ethiopia was explored in chapter 
5. In chapter 6 the relevance of  HBV quasispecies variant diversity and their 
association with patients’ clinical characteristics such as HBeAg status and viral 
load was assessed. Finally, in chapter 7 potential pre-existence of  direct-acting 
antivirals resistance-associated variants were investigated in treatment naïve 
chronic HCV patients.
Hepatitis B and C viruses in Ethiopia
In Ethiopia, due to the lack of  national surveillance program and availability 
of  routine diagnostic tests for patients, the burden of  HBV and HCV infection 
largely remains unknown. Previous studies showed seroprevalence variations in 
HBV (2.1 to 25.0%) and HCV (0.7 to 13.3%) infections 113-115,119. However, most 
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of  these reports are either from a limited number of  subjects (small sample size) 
or among specific groups (HIV-infected subjects, liver patients, commercial or 
replacement blood donors, pregnant women etc.) and may not represent the true 
national burden of  viral hepatitis in the general population. In the present study, 
we tried to fill in this gap by recruiting a large number of  voluntary healthy blood 
donors (56 885) drawn from five distinct geographic regions that are approximately 
100 to 1 500 kilometers distant from each other and differ in their socioeconomic, 
culture and ethnicity (Chapter 2). We found an overall nationwide seroprevalence 
of  3.9% (ranging from 3.7 to 5.91%) for HBV and 0.52% (ranging from 0.37 to 
0.65%) for HCV. These prevalence rates classify the country as an intermediate (2 
–7%) endemic area for HBV infection and low (< 1.5%) for HCV rather than a 
default classification of  the country as a highly endemic for HBV (> 8%) because 
of  its geographic location in sub-Saharan Africa. Countrywide, the prevalence of  
HBV was higher in the eastern region (Adama) compared to the other regions. 
This could be due to occupational and lifestyle differences as the majority of  the 
population in the eastern region are pastoralists who commonly share unsterile 
and re-used equipment. In addition, this region is the main route of  trade in 
and out of  the country, associated also with changes in human behavior such as 
increased risk for sexual transmitted diseases. 
The most recent global assessment of  the country-level population prevalence 
of  chronic HBV infection reported a seroprevalence of  6.03% in Ethiopia 
8, which is in coherence with our findings (intermediate prevalence). HCV 
seroprevalence of  0.9%, 1.0%, and 0.3% was found in the general population 
of  the neighboring countries Somalia, Sudan, and Djibouti, respectively 302. 
Our nationwide seroprevalence data undoubtedly indicate the overall picture of  
HBV and HCV epidemiology in the country but might be underestimated due 
to exclusion of  blood donors with clinical signs and symptoms of  hepatitis. In 
summary, the burden due to viral hepatitis in Ethiopia is substantial and there 
is a need for robust national-level surveillance and public campaigns to raise 
awareness of  viral hepatitis.
HBV molecular epidemiology and genetic diversity in Ethiopia
HBV exhibits a high genetic diversity with 10 main genotypes, more than forty 
subgenotypes and numerous recombinants recognized worldwide. In Africa, 
mainly three major genotypes circulate with different epidemiological trends. 
Genotype A (subgenotype A1) is predominant in Eastern and Southern Africa, 
genotype D (D1 and D7) in Northern Africa, and genotype E in Western and 
Central Africa 53. In Ethiopia, we found two main genotypes, A (78%) and D 
(22%) based on S/pol gene sequence analysis of  371 samples obtained from 
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five regions: Addis Ababa (central), Adama (central-east), Gondar (northwest), 
Jimma (southwest), and Mekelle (north) (Chapter 3, Figure 2). Both genotypes are 
prevailing throughout the country but with a different epidemiological pattern. 
Genotype D was more prevalent in the northern region of  the country compared 
to the central and southwestern regions. For instance, about 40% of  the HBV 
isolates in Mekelle belongs to genotype D whereas in Jimma and Adama the 
prevalence of  genotype D is below 10%. In contrast, genotype A is predominantly 
distributed in the central and southwestern regions (Chapter 3, Figure 2). When 
we analyze the epidemiology of  HBV in the neighboring countries, genotype 
A is the predominant genotype in Somalia, Kenya, Rwanda, and Uganda 133,303, 
while genotype D is the most prevalent genotype in Sudan and Egypt 151,304. It 
is noteworthy to say that Ethiopia is at the border of  the genotype A and D 
geographic distribution in Africa based on these observations. 
Of  note, all genotype A isolates from Ethiopia belong to subgenotype A1 
similar as in other eastern and southern Africa countries 30,133,150. However, they 
are genetically divergent from the majority of  strains from these regions, because 
these strains from Ethiopia cluster in both the African and the Asian–American 
clades (Chapter 3 Figure S2). Fascinatingly, most of  the Ethiopian strains clustered 
more closely to the Asian-American clades (strains from Brazil, Haiti, Japan, 
India, Philippines) rather than to the African clade (Rwanda, Malawi, Uganda, 
Tanzania or South Africa). It has been suggested that genotype A originates in 
Africa and did spread from Eastern Africa to Southern Asia during the last 1000-
2000 years by coastline travel and trade 305. Similar studies in Central and South 
America also found that A1 originates in East Africa and were introduced to these 
regions during the 19th century slave trade and human migration 179,180. Taking 
into consideration the early split of  A1 strains from Ethiopia in the phylogenetic 
tree and Ethiopia’s location at a strategic geographic position between Africa and 
Eurasia, combined with the knowledge on the main route of  human migration 
out of  Africa as well as the origin of  modern humans 172-174, we hypothesize that 
HBV strains from Ethiopia could be the oldest lineage of  the African and the 
Asian-American A1 clade. 
Genotype D, the second most prevalent genotype in Ethiopia is genetically 
highly diverse and differentiated into five subgenotypes: D1, D2, D4, D7 and 
one unassigned subgenotype (now named D10, see chapter 4). Interestingly, 
the majority of  genotype D strains (85%) belonged to two subgenotypes: D2 
(55%) and the novel D10 (30%). It is important to recall that subgenotype D2 
is prevalent in Eastern Europe including Russia and the Baltic countries 157, but 
less common in Africa where D1 is the dominant subgenotype. Nevertheless, 
the Ethiopian D2 strains clustered separately and more distantly to D2 of  the 
137
summarizing discussion
C
ha
pt
er
 8
European and Asian origin with strong bootstrap support (100%) (Chapter 3, 
Figure 3B). The D2 strains from Ethiopia are found throughout the country and 
are quite divergent. Furthermore, Ethiopia does not have a historical relationship 
with those European countries where D2 predominates. Interestingly, D2 was also 
reported among Ethiopian immigrants living in Australia 306. Thus, we suggest 
that D2 from Ethiopia evolved separately in a distinct ethno-geographic to that 
of  the European D2 and has a long natural history in the Ethiopian population. 
Novel HBV subgenotype D10 
As discussed in chapter 3, two main genotypes (A and D) and around 6 
subgenotypes are prevailing in Ethiopia, with subgenotypes A1, D2 and the 
unassigned subgenotype hereafter called D10 being dominant. However, as that 
study was limited to the small S gene sequence analysis, several strains remained 
unclassified and the ambiguity of  some sequences undetermined. So, to better 
descripe HBV evolution in Ethiopia 29 HBV strains — 10 genotype A and 
19 genotype D (14 unassigned strains, 3 subgenotype D2, 1 D4 and 1 D/A 
recombinant) — were selected for full-genome sequence analysis. Except for 
strain AA44Eth (Figure 4A, chapter 4) which was a putative A1/D recombinant, 
all genotype A strains belonged to A1, and the majority of  them clustered in the 
Asian-American clade together with Somalia strains than to the African clade 
(Figure 1, chapter 4), confirming our earlier findings. Similarly, the three D2 
strains were once again classified again into subgenotype D2 but with a distinct 
branch (Figure 2, chapter 4). Notably, strain MK141ETH that was suspected to be 
a D/A recombinant in the previous study, was found to be a triple recombinant 
(D/A/E) when analyzing the complete genome sequence (Figure 4B, chapter 
4). Although genotype E has been largely reported in the neighboring country 
Sudan 151, it has not been reported in Ethiopia until most recently 307. However, 
the two genotype E strains reported among human immunodeficiency virus-
positive patients were based on core region fragment sequence analysis 307 and 
could be D/E recombinant as D strains showed a higher signal for genotype E 
than genotype D in the X to core region39. In addition, D/E recombinant strains 
were also found among Ethiopian children living in Australia (unpublished data). 
In general, these putative genotype E signal indicates that genotype E could also 
circulate in Ethiopia and thus emphasizes a need for more HBV sequences from 
this region of  the world. 
Interestingly, the unassigned strains display a distinct monophyletic tree and 
possess unique distinguishing features, which is ample evidence to classify them 
into a novel subgenotype D10. In the first place, these strains were obtained from 
unrelated blood donors from different regions of  Ethiopia. Secondly, they formed 
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a distinct monophyletic cluster strongly supported by high bootstrap value both 
in the complete genome (Figure 2, chapter 4) as well as in the four separate open 
reading frames (ORFs) phylogenetic trees (Figure 3, chapter 4). Thirdly, the mean 
inter-subgenotype nucleotide divergence compared with reference sequences 
of  all existing subgenotypes D was >4% and <7.5%, which is the minimum 
requirement for the definition of  a new subgenotype 53. Lastly, they had nine 
unique amino acid substitution positions in the surface, polymerase, and X genes; 
five of  those were exclusively unique to D10 (Table 2, Chapter 4). Moreover, 
unlike its preceding subgenotypes D9 41 and D8 38 which are recombinant of  
C/D and D/E respectively, the novel D10 is free of  any recombination. This can 
be noticed in the four ORFs phylogenetic trees which were further confirmed 
by different HBV recombinant analysis methods (RDP4, SimPlot and jpHMM). 
Furthermore, the D10 strains exhibited an unusual mutation in different regions 
of  the HBV genome. For instance, 67% of  the D10 strains harbor the PC 
premature stop codon mutation (G1896A) and 27% the preS2 deletion (6 to 
51 nucleotide deletion). The clinical importance of  these mutations was shown 
in several studies 65,186,187,226, however, the biological/molecular reason why D10 
strains have high mutations and whether these mutations contributed to the 
evolution of  D10 needs further study.
In summary, the identification of  novel D10 and a unique distribution of  
subgenotype D2 in Ethiopia, indicate the high genetic variability and evolution 
of  HBV in Africa, particularly in Ethiopia. 
HCV genetic diversity in Ethiopia
HCV, the etiologic agent of  185 million chronic hepatitis infections and the 
leading cause of  liver cirrhosis and HCC, is characterized by a great genetic 
variability. The virus is classified into 7 genotypes and more than 100 subtypes 
94. Each of  these genotypes is unique with respect to its nucleotide sequence, 
geographic distribution, and therapeutic response. Genotypes 1, 2 and 3 have a 
worldwide distribution, while genotypes 4, 5, 6, and 7 have restricted geographic 
distribution 102. In Africa, the dominant genotypes are 1, 2, 4 and 5, with different 
epidemiological patterns. Genotype 1 and 2 are most prevalent in Central and 
West Africa, 4 in Central and North Africa, and 5 in South Africa 96. Nevertheless, 
little is known about the prevailing genotypes and subtypes in Eastern Africa, 
including Ethiopia. In the present nationwide study, we found that 4 major 
genotypes (1, 2, 4, and 5) and seven subtypes (1b, 1c, 2c, 4d, 4l, 4r, and 4v) 
are circulating in Ethiopia (chapter 5). Genotype 4 is by far the most dominant 
accounting for 78% of  the HCV strains characterized, followed by genotype 2c. 
The most frequent subtypes are 4d and 4r, each accounting for 35% of  the HCV 
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strains circulate. This genotype prevails throughout the country as seen from the 
data analyzed from the five geographic regions. However, unlike HBV, regional 
differences in the distribution of  HCV genotypes could not be established due to 
a limited number of  samples studied. In addition, a potential natural recombinant 
virus was identified inconsistent with the presence of  the two main genotypes (4 
and 2) through analysis of  two distinct regions of  the HCV genome (Chapter 5 
Figure 1 and 2). Overall, the findings from the present study underline the need 
for further molecular characterization of  HCV from this region.
It is well known that knowledge of  HCV genotype information is useful for 
making treatment decisions, such as treatment duration, type of  medicine to use, 
and the likelihood of  treatment response. Genotype 4 is one of  the most difficult 
to treat genotypes with the available standard treatment, peginterferon alpha plus 
ribavirin 210. Nowadays, pan-genotypic direct-acting antivirals are the choice of  
treatment in the western world 308. However, use of  these agents in resource-
limited countries endemic for HCV genotype 4 is currently hindered by the very 
high costs. The ever-increasing epidemiology of  genotype 4 in western countries 
due to immigration from endemic regions 191,309 could make these drugs available 
in resource-limited countries subsequently. Hence, having ample information 
on the prevalent genotype/subtype and presence of  mutations associated with 
resistance to direct-acting antivirals is highly essential for the future development 
of  treatment guidelines and patient management in regions like Ethiopia where 
no national hepatitis treatment policy in place at the moment.
HBV quasispecies variants association with patients HBeAg status and 
viral load 
In the last decade, ample information has been obtained on the HBV genetic 
diversity. Although deep-sequencing of  selected genome regions allowed the 
detection of  viral variants of  low frequencies 221, variant analysis at the full 
genome level has not been performed in detail. We studied the association of  
HBV quasispecies variants using full genome sequencing with HBeAg status and 
viral load in chronically infected HBV patients. We identified a total of  4615 
different quasispecies variants across the full-genome of  five HBV genotypes 
(A to D) in 186 patients at a threshold of  1% frequency. This quasispecies 
variant diversity was significantly higher in viruses from HBeAg-negative patients 
compared to HBeAg-positive patients (Figure 2, chapter 6). HBeAg is clinically 
important because its presence in serum is a marker of  viral replication and 
its seroconversion is a potential endpoint of  therapy. However, there are HBV 
variants that can reduce or eliminate the HBeAg production, allowing the virus 
to evade host immune attack and continued replication 28,65. As a result, the loss 
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of  HBeAg alone can’t be indicative of  viral clearance or disease remission, it is 
of  utmost importance to identify viral variants that are associated with HBeAg 
status. We identified multiple variants that are significantly associated with HBeAg 
status (Table 4 and Figure 3, chapter 6). The majority of  these variants were 
located in core gene followed by surface gene, which might be resulted from 
the highly selective immune pressure exerted in these regions 28. In addition, we 
noted that about one-third of  these variants found to be associated with low viral 
load, indicating the correlation between HBeAg and HBV DNA levels. Indeed, 
the prevalence of  HBeAg negative chronic hepatitis B has been increasing over 
the past few decades and has become the commonest type of  HBV infection in 
many countries of  the world 310. Overall, these results show that in addition to the 
well-known PC and BC variants that reduce or eliminate the HBeAg production, 
other variants could contribute to HBeAg reduction and therefore helpful in 
monitoring patients. To conclude, a high-quality HBV genome deep-sequencing 
approach can provide novel insight into HBV quasispecies variant diversity and 
its relationship to patient clinical characteristics.
Direct-acting antivirals resistance associated HCV variants 
In the early 2000s, the combination of  pegylated interferon plus ribavirin was 
the standard-of-care treatment for HCV infection. However, these drugs are 
associated with frequent and sometimes serious adverse effects with limited 
efficacy 308, leaving researchers to look for alternative options. Since 2011, the 
HCV treatment has dramatically changed due to the advent of  DAAs. These drugs 
target the nonstructural coding genes (NS3/4A, NS5A, NS5B), which plays an 
important role in the cleavage of  the viral polyprotein as well as viral replication, 
resulting in high sustained virological response rates (> 90%) 311. However, drug 
resistance-associated variants (RAVs) have emerged as a potential challenge for 
the treatment of  HCV infection due to the high genetic variability in the HCV 
quasispecies population 93. These RAVs can be present in treatment-naive patients 
as naturally occurring variants usually at low levels, although more frequently they 
are selected upon treatment failure and become the predominant variants (Figure 
1). In chapter 7, we investigate the pre-existence of  RAVs in the NS5B region 
(spanning amino acid positions 215 to 348 known to confer resistance to NS5B 
polymerase inhibitors) in the liver and plasma compartments of  treatment naïve 
patients infected with HCV genotype 1b by 454-deep sequencing.
In our cohort of  18 paired treatment-naïve patients, the nucleoside inhibitor 
(NI) resistance-associated variant S282T was not detected not even as a minority 
variant either in plasma or liver tissue. S282T variant has rarely been detected in 
vivo due to the low replicative fitness of  this variant 93. For instance, in a recent 
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comprehensive NS5B gene analysis of  1,344 HCV isolates, S282T was present at 
frequencies of  0.17%, 0.24%, 1.24%, and 1.63%, in just one isolate for genotypes 
1a, 1b, 3, and 4, respectively 289. Nevertheless, the other NI resistant variant 
V321A was detected in 10 out of  18 patients (~56%) mainly as minor variant 
(Table S4). On the other hand, we noticed mutations that confer resistance to 
non-nucleoside inhibitors at position 316 (C316N/Y/H) in 16 out of  18 patients 
(~89%) either as dominant (50%) or minor variant (39%). Another study also 
found a high frequency of  C316N as naturally occurring polymorphisms in 
never treated patients, especially in persons infected with HCV genotype 1b 312. 
Overall, the quasispecies distribution in both plasma and liver samples showed a 
remarkable overlap in each patient (Chapter 7, Figure 2), underlining the use of  
plasma is most likely sufficient enough to detect HCV quasispecies and RAVs. In 
conclusion, although some of  the variants in the present study confer only a low 
level of  resistance, the presence of  mutant HCV variants at baseline should be 
taken into consideration in the context of  DAA therapy.
Conclusion and future remarks
The work in this thesis describes insights into the molecular and genetic diversity 
of  HBV and HCV in Ethiopia. This is the first such study from this region that 
can serve as a benchmark for future studies. Due to their largely asymptomatic 
nature, HBV and HCV infections remain a silent killer for decades. Most people 
are unaware of  their infection and do not seek treatment until the disease has 
Figure 1. Emergence and selection of  drug resistant variants. Adopted from 93.
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progressed to serious liver damage. This problem is enormous in countries like 
Ethiopia where there is little awareness and knowledge of  viral hepatitis both in 
the general population and even among key health policymakers. In Ethiopia, there 
is a widespread belief  that hepatitis “yewof  beshita”, a liver disease manifests as 
yellow skin/eyes and dark urine, is caused by bat urine (bat flying overhead). A 
person with such symptoms is traditionally advised to go to traditional healers. As 
such, about 80% of  the Ethiopian population still relies on traditional medicines 
for primary health cares. Hence, much more work is needed in this country to 
create awareness and knowledge at the national and regional levels regarding the 
impact of  viral hepatitis. 
When we started this study in 2012, viral hepatitis has been largely ignored as 
a health priority in low-income countries, including Ethiopia. Nowadays, owing 
to the increasing disease burden, viral hepatitis is gaining better attention at the 
global level. The WHO declared (Glasgow Declaration on Hepatitis – September 
2015) viral hepatitis as a serious public health threat and set a new global strategy 
to reduce new infections by 90% & mortality by 65%, by 2030. To achieve this 
goal the strategic framework defines a set of  priority actions to be undertaken: 
increasing information system to understand viral hepatitis epidemics, expanding 
service coverage of  testing and treatment, delivering hepatitis services through 
a public health package, financing to sustainability for universal health coverage, 
and accelerating innovations 301. In response to WHO’s call to action, Ethiopia 
also needs to prepare national policy and strategies in areas including surveillance, 
identification of  risk group, diagnosis, treatment, resource mobilization, public 
awareness and advocacy. Such efforts need a strong political commitment and a 
high degree of  attention equal to what has been relentlessly given to HIV, TB, and 
malaria. In addition, since the standard serological method cannot detect occult 
hepatitis B infection — HBsAg negative but viral DNA positive — Ethiopia 
should start incorporating nucleic acid testing in blood donor screening at national 
and regional blood banks.
Genotypes and genetic variants determination in chronic HBV and HCV 
infection are important in estimating disease progression and planning optimal 
antiviral treatments especially with the current direct-acting antivirals and pan-
genotypic drugs. In Ethiopia, as shown in this study both HBV and HCV exhibit 
a wide range of  genotypic diversity. Therefore, guidelines for the prevention, 
care, and treatment of  HBV and HCV infection should take into account the 
genotypes that circulate in the country. In addition, the clinical impact of  HBV 
and HCV genotypes in Ethiopia should be studied, which haven’t been addressed 
in the present study. 
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Hepatitis B- en C-virussen zijn wereldwijd een belangrijke oorzaak van morbiditeit 
en mortaliteit. Volgens het rapport van de Wereldgezondheidsorganisatie 
(WHO) veroorzaakte virale hepatitis 1,34 miljoen doden in 2015, een aantal 
vergelijkbaar met jaarlijkse sterfgevallen veroorzaakt door tuberculose maar hoger 
dan die veroorzaakt door HIV of  malaria. In tegenstelling tot deze andere drie 
infectieziekten heeft virale hepatitis echter relatief  weinig aandacht gekregen. 
Wereldwijd heeft slechts 9% van hepatitis B virus (HBV) en 20% van de met 
hepatitis C virus (HCV) besmette personen toegang tot betaalbare hepatitis-tests. 
Nog zorgwekkender is het feit dat antivirale behandeling beschikbaar is voor 
slechts 8% van degenen met HBV en 7,4% van degenen met HCV. Dit is nog 
problematischer in landen als Ethiopië, waar meer dan 80% van de bevolking 
op het platteland woont met een zeer beperkte toegang tot gezondheidszorg. 
Daarnaast is virale hepatitis nog niet beschouwd als een prioriteit in Ethiopië 
vanwege een gebrek aan bewustzijn en het feit dat er geen nationale antivirale 
behandeling en diagnostische richtlijnen of  surveillance zijn ontwikkeld. 
Bovendien werd pas in 2007 het universeel verkrijgbare HBV-vaccin opgenomen 
in het nationale neonatale immunisatieprogramma. Bijgevolg blijven deze virussen 
zich verspreiden. Daarom hebben we in dit proefschrift de seroepidemiologie 
en genetische diversiteit van HBV en HCV in Ethiopië bestudeerd en daarnaast 
analyseren we niuewe methodes om de differentiatie van HBV en HCV 
quasispecies met behulp van next generation sequencing-technologie mogelijk te 
maken.
Hepatitis B- en C-virussen in Ethiopië
Vanwege het gebrek aan nationaal surveillanceprogramma en de beschikbaarheid 
van routinematige diagnostische tests voor patiënten blijft de omvang van HBV- 
en HCV-infecties in Ethiopië grotendeels onbekend. Eerdere studies toonden 
aan dat de seroprevalentie van HBV (2,1 tot 25,0%) en HCV (0,7 tot 13,3%) 
infectie nogal varieerden. De meeste van deze meldingen zijn echter gedaan 
op basis van een beperkt aantal personen (kleine steekproefomvang) of  van 
specifieke groepen (HIV-geïnfecteerde patiënten, leverpatiënten, commerciële of  
vervangende bloeddonoren, zwangere vrouwen, enz.)Deze vertegenwoordigen 
daarom mogelijk niet de echte nationale omvang van virale hepatitis in de 
algemene bevolking. In de huidige studie probeerden we deze lacune op te vullen 
door gebruik te maken van een groot aantal vrijwillige gezonde bloeddonoren (56 
885) uit vijf  verschillende geografische regio’s die zich op ongeveer 100 tot 1 500 
kilometer van elkaar bevinden en verschillen in hun sociaaleconomische, cultuur 
en etniciteit (hoofdstuk 2). We vonden een algemene landelijke seroprevalentie 
van 3,9% (variërend van 3,7 tot 5,91%) voor HBV en 0,52% (variërend van 0,37 
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tot 0,65%) voor HCV. Deze prevalentiepercentages classificeren het land als een 
intermediair (2 -7%) endemisch gebied voor HBV-infectie en laag (<1,5%) voor 
HCV. Dit in tegenstelling tot de standaardindeling van het land als zeer endemisch 
voor HBV (> 8%) vanwege de geografische locatie in Afrika ten zuiden van de 
Sahara. Ons resultaat is in overeenstemming met de meest recente algemene 
beoordeling van de prevalentie op landelijk niveau van chronische HBV-infectie 
die een seroprevalentie van 6,03% in Ethiopië rapporteerde. HCV-seroprevalentie 
van 0,9%, 1,0% en 0,3% werden gevonden in de algemene bevolking van de 
buurlanden Somalië, Soedan en Djibouti, respectievelijk. Onze landelijke 
seroprevalentie gegevens wijzen ongetwijfeld op het algemene beeld van de HBV- 
en HCV-epidemiologie in het land, maar kunnen mogelijk worden onderschat 
vanwege de uitsluiting van bloeddonoren met klinische tekenen en symptomen 
van hepatitis. Samengevat is de belasting van virale hepatitis in Ethiopië aanzienlijk 
en is er behoefte aan surveillance op nationaal niveau en publieke campagnes om 
het bewustzijn te vergroten.
Moleculaire epidemiologie en genetische diversiteit van HBV in Ethiopië
HBV vertoont een hoge genetische diversiteit met 10 genotypes, meer dan veertig 
subgenotypes en talloze recombinanten. In Afrika hebben hoofdzakelijk drie 
belangrijke genotypes de overhand met verschillende epidemiologische trends. 
Genotype A (subgenotype A1) is dominant in Oost- en Zuidelijk Afrika, genotype 
D (D1 en D7) in Noord-Afrika en genotype E in West- en Centraal-Afrika. In 
Ethiopië vonden we twee belangrijke genotypen, A (78%) en D (22%) op basis 
van sequentieanalyse van 371 monsters verkregen uit vijf  regio’s: Addis Ababa, 
Adama, Gondar, Jimma en Mekelle. Beide genotypes zijn overheersend in het 
hele land maar laten een ander epidemiologisch patroon zien. Genotype D kwam 
vaker voor in de noordelijke regio van het land in vergelijking met de centrale 
en zuidwestelijke regio’s. Ggenotype A wordt voornamelijk gezien in de centrale 
en zuidwestelijke regio’s (hoofdstuk 3). In de buurlanden is genotype A het 
overheersende genotype in Somalië, Kenia, Rwanda en Oeganda, terwijl genotype 
D het meest voorkomende genotype is in Soedan en Egypte. Het is opmerkelijk 
om te vermelden dat Ethiopië op basis van deze waarnemingen de grens van de 
geografische verspreiding van genotype A en D vormt.
Verder valt op te merken dat alle genotype A-isolaten uit Ethiopië behoren 
tot subgenotype A1, vergelijkbaar met die in andere Oost- en Zuid-Afrikaanse 
landen. Ze verschillen echter genetisch van de meeste stammen uit deze regio’s, 
omdat deze stammen uit Ethiopië zich in zowel de Afrikaanse als de Aziatisch-
Amerikaanse clades nestelen (hoofdstuk 3). Fascinerend genoeg zijn de meeste 
Ethiopische stammen nauwer geclusterd met de Aziatisch-Amerikaanse clades 
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(soorten uit Brazilië, Haïti, Japan, India, de Filippijnen) dan met de Afrikaanse 
clade (Rwanda, Malawi, Uganda, Tanzania of  Zuid-Afrika). Er is gesuggereerd 
dat genotype A afkomstig is uit Afrika en zich in de laatste 1000-2000 jaar heeft 
uitgebreid van Oost-Afrika naar Zuid-Azië door reizen en handel langs de kust 
en naar Midden- en Zuid-Amerika tijdens de negentiende-eeuwse slavenhandel 
en door menselijke migratie. Rekening houdend met de vroege splitsing van A1-
stammen uit Ethiopië in de fylogenetische boom en de locatie van Ethiopië op 
een strategische geografische positie tussen Afrika en Eurazië, gecombineerd met 
de kennis over de hoofdroute van menselijke migratie vanuit Afrika evenals de 
oorsprong van moderne mens, veronderstellen we dat HBV-stammen uit Ethiopië 
de oudste afstamming van subgenotype A1 zouden kunnen zijn.
Genotype D, het op een na meest voorkomende genotype in Ethiopië, is genetisch 
zeer divers en onderscheidt zich in vijf  subgenotypes: D1, D2, D4, D7 en één 
niet-toegewezen subgenotype (nu D10 genoemd). Interessant genoeg behoorde 
het grootste deel van genotype D-stammen (85%) tot twee subgenotypen: 
D2 (55%) en de nieuwe D10 (30%). Het is belangrijk om te onthouden dat 
subgenotype D2 voorkomt in Oost-Europa, inclusief  Rusland en de Baltische 
staten, maar minder gebruikelijk is in Afrika, waar D1 het dominante subgenotype 
is. Desondanks groepeerden de Ethiopische D2-stammen zich afzonderlijk van 
Europese en Aziatische virussen. De D2-stammen uit Ethiopië zijn overal in het 
land te vinden en variëren genetisch nogal behoorlijk. Bovendien heeft Ethiopië 
geen historische relatie met die Europese landen waar D2 de boventoon voert. 
We stellen daarom voor dat D2 uit Ethiopië afzonderlijk is geëvolueerd in een 
specifieke etno-geografische omgeving en een lange natuurlijke geschiedenis 
heeft in de Ethiopische bevolking.
Zoals besproken in hoofdstuk 3, identificeerden we één niet eerder 
toegewezen subgenotype, hierna D10 genoemd, gebaseerd op analyse van 
kleine genensequenties. Om de HBV-evolutie in Ethiopië beter te beschrijven, 
onderzochten we vervolgens 14 niet-toegewezen stammen door een 
sequentieanalyse van het volledige genoom (hoofdstuk 4). Interessant is dat de 
niet-toegewezen stammen een duidelijke monofyletische boom vertonen met 
unieke onderscheidende kenmerken, wat voldoende bewijs is om ze in te delen in 
een nieuw subgenotype D10. In de eerste plaats werden deze stammen verkregen 
van niet-verwante bloeddonoren uit verschillende regio’s van Ethiopië. Ten 
tweede vormden ze een afzonderlijke monofyletische cluster welkee sterk werd 
ondersteund door een hoge bootstrapwaarde, zowel in het complete genoom als 
in de vier afzonderlijke fylogenetische bomen met open lees ramen (hoofdstuk 
4). Ten derde was de gemiddelde inter-subgenotype nucleotide divergentie in 
vergelijking met de referentiesequenties van alle bestaande subgenotypes D 
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> 4% en <7,5%, wat de minimale vereiste is voor de definitie van een nieuw 
subgenotype. Ten slotte hadden ze negen unieke aminozuur substitutie posities 
in de oppervlakte-, polymerase- en X-genen; vijf  ervan waren exclusief  uniek 
voor D10. Bovendien is, in tegenstelling tot de voorgaande subgenotypes D9 en 
D8 die respectievelijk recombinant zijn van C / D en D / E, de nieuwe D10 vrij 
van enige recombinatie. Dit kan worden gezien in de vier fylogenetische bomen 
van de ORF’s die verder werden bevestigd door verschillende HBV-recombinante 
analysetools. Samenvattend wijzen de identificatie van nieuwe D10 en een unieke 
verdeling van subgenotype D2 in Ethiopië, op de hoge genetische variabiliteit en 
evolutie van HBV in Afrika, met name in Ethiopië.
Genetische diversiteit van HCV in Ethiopië
HCV, de etiologische agens van 185 miljoen chronische hepatitisinfecties en 
de belangrijkste oorzaak van levercirrose en HCC, wordt gekenmerkt door 
een grote genetische variabiliteit. Het virus is ingedeeld in 7 genotypen en 
meer dan 100 subtypes. Elk van deze genotypen is uniek met betrekking tot 
de geografische distributie en therapeutische respons. Genotypen 1, 2 en 3 
hebben een wereldwijde verdeling, terwijl genotypes 4, 5, 6 en 7 een beperkte 
geografische spreiding hebben. In Afrika zijn de dominante genotypen 1, 2, 4 
en 5, met verschillende epidemiologische patronen. Toch is er weinig bekend 
over de heersende genotypen en subtypen in Oost-Afrika, waaronder Ethiopië. 
In de huidige landelijke studie vonden we dat 4 belangrijke genotypen (1, 2, 4 
en 5) en zeven subtypes (1b, 1c, 2c, 4d, 4l, 4r en 4v) overheersen in Ethiopië 
(hoofdstuk 5). Genotype 4 is verreweg het meest dominant in de analyse van 78% 
van de HCV-stammen die werden gekarakteriseerd, gevolgd door genotype 2c. 
De meest voorkomende subtypen zijn 4d en 4r, waarbij elk verantwoordelijk is 
voor 35% van de HCV-stammen circuleren. Dit genotype prevaleert in het hele 
land, zoals blijkt uit de geanalyseerde gegevens van de vijf  geografische regio’s. 
Bovendien werd door analyse van twee verschillende gebieden van het HCV-
genoom een potentieel natuurlijk recombinant virus geïdentificeerd consistent 
met de aanwezigheid van de twee belangrijkste genotypen (4 en 2) . Over het 
algemeen onderstrepen de bevindingen van de huidige studie de noodzaak van 
verdere moleculaire karakterisering van HCV uit dit gebied.
Het is bekend dat kennis van HCV-genotype-informatie nuttig is voor het nemen 
van behandelbeslissingen, zoals de duur van de behandeling, het type medicijn 
dat moet worden gebruikt en de waarschijnlijkheid van een behandelingsreactie. 
Genotype 4 is een van de moeilijkst te behandelen genotypes met de beschikbare 
standaardbehandeling, peginterferon alpha plus ribavirine. Tegenwoordig zijn 
pan-genotypische direct werkende antivirale middelen de keuze voor behandeling 
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in de westerse wereld. Daarom is het hebben van voldoende informatie over 
het gangbare HCV-genotype / -subtype van groot belang voor de toekomstige 
ontwikkeling van behandelingsrichtlijnen en patiëntbeheer in regio’s zoals 
Ethiopië, waar op dit moment geen nationaal hepatitis-behandelingsbeleid bestaat.
HBV quasispecies varianten 
In het laatste decennium is ruime informatie verkregen over de genetische 
diversiteit van HBV. Hoewel deep-sequencing van geselecteerde genoom 
gebieden de detectie van virale varianten van lage frequenties mogelijk maakte, 
is variant analyse op het volledige genoom niveau niet in detail uitgevoerd. We 
bestudeerden de associatie van HBV quasispecies-varianten met behulp van 
volledige genoom sequencing met HBeAg-status en virale belasting bij chronisch 
geïnfecteerde HBV-patiënten. We identificeerden een totaal van 4615 verschillende 
quasispecies-varianten over het volledige genoom van vijf  HBV-genotypen (A tot 
D) bij 186 patiënten. Deze quasispecies variante diversiteit was significant hoger 
in virussen van HBeAg-negatieve patiënten in vergelijking met HBeAg-positieve 
patiënten (hoofdstuk 6). HBeAg is klinisch belangrijk omdat de aanwezigheid 
ervan in serum een  marker is van virale replicatie en de seroconversie ervan een 
potentieel eindpunt van de behandeling is. Er zijn echter HBV-varianten die de 
HBeAg-productie kunnen verminderen of  elimineren, waardoor het virus de 
immuun aanval van de gastheer en de voortdurende replicatie kan omzeilen. 
Als gevolg hiervan kan het verlies van HBeAg alleen niet indicatief  zijn voor 
virale klaring of  remissie van de ziekte, het is van het grootste belang om virale 
varianten te identificeren die zijn geassocieerd met de HBeAg-status. We hebben 
meerdere varianten geïdentificeerd die significant geassocieerd zijn met de 
HBeAg-status (hoofdstuk 6). De meerderheid van deze varianten bevonden zich 
in het core gen gevolgd door het oppervlakte-gen, dat mogelijk het gevolg was 
van de zeer selectieve immunologische druk die in deze regio’s werd uitgeoefend. 
Bovendien merkten we dat ongeveer een derde van deze varianten geassocieerd 
bleek te zijn met lage virale hoeveelheden in het bloed, wat de correlatie aangeeft 
tussen HBeAg- en HBV-DNA-niveaus. Over het algemeen laten deze resultaten 
zien dat naast de welbekende PC- en BC-varianten die de HBeAg-productie 
verminderen of  elimineren, andere varianten ook kunnen bijdragen aan HBeAg-
reductie en daarom nuttig zijn bij het controleren van patiënten. Concluderend 
kan een hoogwaardige HBV-genoom-deep-sequencing-benadering nieuw inzicht 
verschaffen in de diversiteit van HBV quasispecies en de relatie ervan tot klinische 
kenmerken van de patiënt.
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Direct werkende antivirale resistentie-geassocieerde HCV-varianten
Tot voor kort was de combinatie van gepegyleerd interferon plus ribavirine 
de standaardbehandeling voor HCV-infectie. Deze medicijnen worden echter 
geassocieerd met frequente en soms ernstige bijwerkingen met beperkte 
werkzaamheid, waardoor onderzoekers op zoek gaan naar alternatieve opties. 
Sinds 2011 is de HCV-behandeling dramatisch veranderd als gevolg van de komst 
van DAA’s. Deze geneesmiddelen richten zich op de niet-structurele coderende 
genen van het HCV-genoom, wat resulteert in hoge aanhoudende virologische 
responspercentages (> 90%). Echter, geneesmiddelresistentie-geassocieerde 
varianten (RAVs) zijn naar voren gekomen als een potentiële uitdaging voor de 
behandeling van HCV-infectie vanwege de hoge genetische variabiliteit in de 
HCV-quasispecies populatie. Deze RAV’s kunnen aanwezig zijn in therapie naïeve 
patiënten als van nature voorkomende varianten gewoonlijk op lage niveaus, hoewel 
ze vaker worden geselecteerd na falen van de behandeling en de overheersende 
varianten worden. In hoofdstuk 7 onderzoeken we de pre-existentie van RAVs 
als we naar de NS5B-regio kijken (spreiding van aminozuurposities 215 tot 348 
waarvan bekend is dat ze resistentie verlenen tegen NS5B-polymerase remmers) 
in de lever- en plasma compartimenten van naïeve patiënten die 454 met HCV 
genotype 1b zijn geïnfecteerd. In ons cohort van 18 gepaarde behandelingsnaïeve 
patiënten werd de nucleosideremmer (NI) resistentiegeassocieerde variant S282T 
niet als een minderheid variant gedetecteerd, noch in plasma noch in leverweefsel. 
Over het algemeen is de S282T-variant in vivo zelden gedetecteerd vanwege de 
lage replicatieve fitheid van deze variant. Echter werd de andere NI-resistente 
variant V321A gedetecteerd bij 10 van de 18 patiënten (~ 56%), voornamelijk 
als minder belangrijke variant. We zagen ook mutaties die resistentie verlenen 
aan niet-nucleosideremmers op positie 316 (C316N / Y / H) bij 16 van de 18 
patiënten (~ 89%). Over het algemeen vertoonde de quasispecies distributie 
in zowel plasma- als levermonsters een opmerkelijke overlap in elke patiënt 
(Hoofdstuk 7), wat onderstreept dat het gebruik van plasma hoogstwaarschijnlijk 
voldoende is om HCV-quasispecies en RAV’s te detecteren. Hoewel sommige van 
de varianten in de huidige studie slechts een laag niveau van resistentie verlenen, 
moet de aanwezigheid van HCV-varianten op baseline in aanmerking worden 
genomen in de context van DAA-therapie.
Het werk in dit proefschrift beschrijft nieuwe inzichten in de moleculaire en 
genetische diversiteit van HBV en HCV in Ethiopië. Dit is de eerste dergelijke 
studie uit deze regio die als referentie kan dienen voor toekomstige studies. 
Toen we in 2012 met dit onderzoek begonnen, werd virale hepatitis grotendeels 
genegeerd als gezondheidsprioriteit in landen met lage inkomens, waaronder 
Ethiopië. Tegenwoordig wint virale hepatitis, als gevolg van de toenemende 
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ziektelast, wereldwijd meer aandacht. De WHO verklaarde (Glasgow Declaration 
on Hepatitis - september 2015) virale hepatitis als een ernstige bedreiging voor 
de volksgezondheid en stelde in 2030 een nieuwe globale strategie om nieuwe 
infecties met 90% en mortaliteit te verminderen met 65%. Om dit doel te 
bereiken, definieert het strategisch kader een reeks prioritaire acties die moeten 
worden ondernomen: verbetering van het informatiesysteem voor het begrijpen 
van virale hepatitis-epidemieën, uitbreiding van de dekking van testen en 
behandeling door de gezondheidszorg, levering van hepatitis diensten via een 
pakket voor de volksgezondheid, financiering van duurzaamheid voor de dekking 
van de universele gezondheidszorg en versnelde innovaties. In reactie op de 
oproep tot actie van de WHO moet Ethiopië ook het nationale beleid en de 
nationale strategieën voorbereiden op gebieden als surveillance, identificatie van 
risicogroepen, diagnose, behandeling, mobilisatie van middelen, bewustmaking 
van het publiek en pleitbezorging. Dergelijke inspanningen vereisen een sterke 
politieke betrokkenheid en een hoge mate van aandacht die gelijk is aan hiv, 
tuberculose en malaria. Omdat de standaard serologische methode geen occulte 
hepatitis-B-infectie kan detecteren - HBsAg-negatief  maar viraal DNA-positief  
- moet Ethiopië beginnen met het opnemen van nucleïnezuuronderzoek in 
bloeddonorscreening bij nationale en regionale bloedbanken. Bovendien zijn 
genotypes en bepaling van genetische varianten bij chronische HBV- en HCV-
infectie belangrijk bij het schatten van ziekte progressie en het plannen van 
optimale antivirale behandelingen, vooral met de huidige direct werkende antivirale 
middelen en pan-genotypische geneesmiddelen. In Ethiopië, zoals aangetoond 
in deze studie, vertonen zowel HBV als HCV een breed scala aan genotypische 
diversiteit. Daarom moeten richtlijnen voor de preventie, zorg en behandeling 
van HBV- en HCV-infectie rekening houden met de genotypes die in het land 
circuleren. Bovendien moet de klinische impact van HBV- en HCV-genotypen in 
Ethiopië verder worden onderzocht.
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